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SUMMARY.
The feto-placental unit synthesises a variety of proteins and hormones which are 
secreted into the maternal circulation and amniotic fluid from early pregnancy. In 
pregnancies where the fetus has an autosomal trisomy, the normal concentration 
profiles of these markers in maternal serum and amniotic fiuld are disturbed. These 
marker changes can be used to estimate the risk that a pregnancy is affected by 
Down’s syndrome (or Trisomy 18) and thus allow the parents to make an informed 
decision regarding prenatal diagnosis by invasive testing. However, the factors which 
give rise to the varying patterns of marker concentrations in chromosomally abnormal 
pregnancies are poorly understood. The aim of this project was to investigate the 
underlying causes of abnormal marker concentrations in Down’s syndrome. Trisomy 
13 and Trisomy 18 pregnancies. Endogenous levels of a series of products of the feto­
placental unit were measured in fetal tissues and in corresponding maternal serum 
and amniotic fluid samples from affected pregnancies, and compared with the results 
obtained in the same tissues from unaffected pregnancies.
Samples of fetal liver, fetal ileum and placental tissue were collected from 71 
chromosomally abnormal pregnancies (67 Down’s syndrome, one Trisomy 13, three 
Trisomy 18) following prenatal diagnosis by chorionic villous sampling (CVS) or 
amniocentesis and termination of pregnancy at 10 to 24 weeks gestation. 
Corresponding tissues for use as controls were obtained from 75 putatively normal 
pregnancies terminated for psycho-social reasons at 12 to 22 weeks gestation,
Alphafetoprotein (AFP), intact human chorionic gonadotropin (hCG), free beta human 
chorionic gonadotropin (FphCG), pregnancy associated plasma protein-A (PAPP-A), 
pregnancy specific beta-1 glycoprotein (SP1), total and placental alkaline phosphatase 
(ALP) and gamma glutamyl transferase (GGT) were measured in placental tissue, AFP 
and GGT in fetal liver and GGT in fetal ileum from affected and unaffected 
pregnancies. Specific immunoassay methods were used to measure AFP, intact hCG,
30
FphCG, PAPP-A and SP1. Fluoromethc and spectrophotometric kinetic assays were 
used to measure ALP isoenzymes and GGT respectively. Marker levels in the fetal 
tissues were expressed as units per mg of total protein and converted to multiples of 
the control median (MOM) at the appropriate week of gestation.
FphCG, PAPP-A, SP1, total ALP and placental ALP levels were measured in maternal 
serum previously collected from 58 of the Down’s syndrome pregnancies and two of 
the Trisomy 18 pregnancies. AFP and intact hCG concentrations (expressed as MOM) 
in maternal serum from 62 of the Down’s syndrome pregnancies and two of the 
Trisomy 18 pregnancies were obtained from the West of Scotland routine screening 
database. Normal medians for SP1, total ALP and placental ALP were established by 
analysis of 114 randomly selected maternal serum samples at 15-20 weeks gestation. 
Weekly maternal serum FphCG and PAPP-A medians were available from previous 
studies in this laboratory. Marker levels in maternal serum from affected and 
unaffected pregnancies were converted to MOM.
Thirty four of the Down’s syndrome pregnancies and one of the Trisomy 18 
pregnancies from which fetal tissues were collected were prenatally diagnosed 
following amniocentesis. Amniotic fluid AFP levels were measured prospectively in 
these cases as part of the routine analysis of AFP in all amniotic fluid specimens. 
Amniotic fluid samples from 33 Down’s syndrome and one Trisomy 18 pregnancy were 
available from frozen storage for further marker analysis. Normal medians for intact 
hCG, FphCG, PAPP-A, SP1, total ALP, placental ALP and GGT levels were 
established by analysis of 132 randomly selected amniotic fluid samples at 15-21 
weeks gestation. Marker levels in amniotic fluid from affected and unaffected 
pregnancies were converted to MOM.
Placental localisation of AFP, hCG, PAPP-A, SP1 and placental ALP was investigated 
by immunohistochemistry in placental tissue from 16 Down’s syndrome and 16 
unaffected pregnancies, arranged into pairs matched for gestational age (14-20
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weeks). Frozen tissue sections were prepared for light microscopy by a two-step 
indirect immunoperoxidase staining technique.
AFP levels in fetal liver from Down’s syndrome pregnancies were not significantly 
different from the controls (Down’s syndrome median MOM = 0.97; control median 
MOM = 1.01; p=0.259). AFP levels were significantly elevated in placental tissue from 
Down’s syndrome pregnancies (2.43 MOM; p<0.001), while maternal serum and 
amniotic fluid AFP levels were reduced to 0.69 MOM and 0.87 MOM respectively. 
There was no correlation between tissue, maternal serum and amniotic fluid 
concentrations of AFP in Down’s syndrome pregnancies. AFP was localised to the 
syncytiotrophoblast in placental tissue from both Down’s syndrome and unaffected 
pregnancies. Synthesis of AFP by the fetal liver in Down’s syndrome pregnancies 
does not appear to be altered in the first half of pregnancy. Elevated placental levels 
of AFP in Down’s syndrome pregnancies suggest that AFP is accumulating in the 
syncytiotrophoblast and therefore reduced maternal serum levels of AFP may be 
caused by defective placental transport of AFP from the fetal circulation to the 
maternal circulation. Low amniotic fluid AFP levels in Down’s syndrome pregnancies 
may result from impaired excretion of AFP by the fetal kidneys.
Intact hCG levels were elevated in placenta! tissue (4.06 MOM; p<Q.001), maternal 
serum (2.72 MOM) and amniotic fluid (1.39 MOM; p=0.017) with significant correlation 
(p<Q.02) between the three compartments in the Down’s syndrome pregnancies. 
FphCG levels were also elevated in placental tissue (3.40 MOM; p<Q.001), maternal 
serum (3.06 MOM) and amniotic fluid (1.33 MOM; p=0.017) from Down’s syndrome 
pregnancies. There was also a significant correlation (p<0.002) between placental and 
maternal serum levels of FphCG, and between maternal serum and amniotic fluid 
FphCG levels. HCG was localised to the syncytiotrophoblast in placental tissue from 
both Down’s syndrome and unaffected pregnancies. The similarity in the change in 
levels of intact hCG and FphCG between placenta, maternal serum and amniotic fluid 
suggests that in Down’s syndrome pregnancies secretion of intact hCG and FphCG
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from the syncytiotrophoblast into the maternal circulation is not altered, and that higher 
maternal serum levels may be the result of increased placental synthesis of hCG 
subunits.
PAPP-A levels in placental tissue, maternal serum and amniotic fluid from Down’s 
syndrome pregnancies were not significantly different from controls (placental median 
MOM = 0.96, p=0.304; maternal serum median MOM = 0.92; amniotic fluid median 
MOM = 0.95, p=0.126). Despite the similarity in the median MOM levels of PAPP-A in 
the different feto-maternal compartments, there was no significant correlation between 
placental, maternal serum and amniotic fluid PAPP-A levels. Placental synthesis and 
secretion of PAPP-A does not appear to be disturbed in Down’s syndrome 
pregnancies in the second trimester.
SP1 levels in placental tissue (1.79 MOM) and maternal serum (1.33 MOM) from
Down’s syndrome pregnancies were significantly higher (p<0.001) than in unaffected 
pregnancies. However, amniotic fluid SP1 levels in Down’s syndrome pregnancies
(0.91 MOM) were not significantly different from normal (p=0.749). In contrast to intact 
hCG and FphCG , there was no correlation between placental levels of SP1 and either 
maternal serum or amniotic fluid SP1 levels in Down’s syndrome pregnancies. 
However, maternal serum and amniotic fluid SP1 levels in Down’s syndrome 
pregnancies were significantly correlated (p<0.001). SP1 was localised to the 
syncytiotrophoblast in placental tissue from both Down’s syndrome and unaffected 
pregnancies.
There was no difference in the activity of the placental isoenzyme of ALP in placental 
tissue from Down’s syndrome pregnancies (0.91 MOM) compared to controls 
(p=G.318). In maternal serum from Down’s syndrome pregnancies, total ALP activity 
was reduced to 0.83 MOM (p=0.002) of the unaffected pregnancies but placental ALP 
activity (1.04 MOM) was not significantly different from normal (p=0.505). In amniotic 
fluid from Down’s syndrome pregnancies, placental ALP (0.75 MOM) was reduced but
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to a much smaller extent than total ALP activity (0.39 MOM). There was some degree 
of correlation between placental ALP activity in placental tissue and In corresponding 
maternal serum and amniotic fluid samples from Down’s syndrome pregnancies, 
however this was not statistically significant. Placental ALP was localised to the 
syncytiotrophoblast in placental tissue from both Down’s syndrome and unaffected 
pregnancies. This suggests that placental synthesis and transport of placental ALP 
from the microviltar membrane of the syncytiotrophoblast is not disturbed in Down’s 
syndrome pregnancies. However, low amniotic fluid placental ALP activity may 
indicate a reduction in the rate of transfer of the enzyme from the maternal circulation 
to the amniotic fluid or reduced synthesis of placental ALP from an alternative source. 
The substantial reduction in total amniotic fluid ALP activity in Down’s syndrome 
pregnancies indicates a possible reduction in the tissue non-specific and/ or intestinal 
isoenzymes.
GGT activity was significantly elevated in extracts of fetal liver (2.01 MOM; p<0.D01) 
and placental tissue (1.29 MOM; p<0.01), and significantly reduced in extracts of fetal 
ileum (0.43 MOM; p<0.001) from Down’s syndrome pregnancies. In amniotic fluid from 
Down’s syndrome pregnancies, GGT activity was significantly reduced to 0.46 MOM 
(p<0.001) of the unaffected pregnancies. There was no significant correlation between 
GGT activity in fetal tissues and amniotic fluid from the Down’ syndrome pregnancies. 
However, the similarity between the median MOM levels of GGT activity in fetal ileum 
and amniotic fluid from the Down’s syndrome pregnancies suggests that GGT activity 
in amniotic fluid is of fetal intestinal origin. There appears to be tissue-specific 
differences in the expression of GGT in Down’s syndrome pregnancies.
Due to the small numbers of Trisomy 13 and Trisomy 18 pregnancies included in this 
study, it was not possible to identify likely causes of the marker variations associated 
with fetal Trisomy 13 and Trisomy 18. However, the variation in fetal tissue, maternal 
serum and amniotic fluid marker concentrations between Down’s syndrome, Trisomy 
13 and Trisomy 18 pregnancies suggests that the mechanisms giving rise to the
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abnormal marker levels associated with the different autosomal trisomies are not the 
same.
The results of this investigation indicate that in Down’s syndrome pregnancies, 
maternal serum levels of placental products reflect those found in the placenta: intact 
hCG, FphCG and SP1 levels were elevated while PAPP-A and placental ALP levels 
were little changed. This suggests that transport of these proteins from the placenta 
into the maternal circulation is not affected but there is altered synthesis of hCG 
subunits and SP1. Hepatic synthesis of AFP does not appear to be altered in Down’s 
syndrome pregnancies, but increased placental and reduced maternal serum levels of 
AFP point to a possible placental transport defect specific to AFP. Similarly reduced 
GGT levels in fetal intestine and in corresponding amniotic fluid from Down’s 
syndrome pregnancies suggest that amniotic fluid GGT activity is of fetal intestinal 
origin since GGT activity was elevated in fetal liver and placental from the same series 
of Down’s syndrome pregnancies.
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CHAPTER 1. 
INTRODUCTION
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1.1 CHROMOSOME ABNORMALITIES.
1.1.1 DOWN’S SYNDROME (TRISOMY 21).
Down’s Syndrome is the most common autosomal chromosome abnormality with an 
overali birth incidence of 1/700 live births. The incidence of Down’s syndrome is 
increased at advanced maternal age. The main complication associated with Down’s 
syndrome is mental handicap. Presenile dementia is common in Down’s syndrome 
individuals after 40 years of age, apparently caused by Alzheimers-like lesions in the 
brain. Other features of Down’s syndrome include heart defects. Increased 
susceptibility to infection, respiratory ailments and leukaemia, duodenal atresia and 
hypotonia. Individuals with Down’s syndrome have characteristic physical features 
such as shorter than average height, flat facial profile, small low set ears, small nose, 
upwards slanting eyes, slightly protuberant tongue and single palmar creases (Cooper 
and Hall 1988, Serra and Neri 1990, Connor and Ferguson-Smith 1991).
In 95% of cases, trisomy 21 arises from meiotic non-disjunction mainly occurring at the 
first meiotic division but sometimes at the second. Mosaicism, the presence of normal 
and trisomie cell lines, occurs in approximately 1% of Down’s syndrome individuals and 
in such cases the clinical features tend to be less severe. Approximately 4% of Down’s 
syndrome cases are caused by a translocation involving chromosome 21, either 
inherited or de-novo.
It is not fully understood how the Down’s syndrome phenotype arises from the 
presence of an extra copy of chromosome 21. The occurrence of Down’s syndrome as 
a result of translocations involving chromosome 21 led to the realisation that an extra 
copy of the entire chromosome 21 is not required to cause Down’s syndrome. 
Triplication of a region of the long arm of chromosome 21 (Down’s syndrome ‘critical 
region’) at 21q22, is thought to be sufficient for the expression of the Down’s 
syndrome phenotype. However, this does not exclude the possibility that regions of
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chromosome 21 outside the critical region may be involved in the pathogenesis of 
Down’s syndrome.
1.1.2 EDWARDS’ SYNDROME (TRISOMY 18).
Edwards’ syndrome is the second most common aneuploidy at term with an incidence 
of 1/3000 live births (Connor and Ferguson-Smith 1991). Clinical features associated 
with Trisomy 18 include low birth weight, heart defects, small chin, low set malformed 
ears, short sternum, clenched hands and single palmar creases. Only 10% of infants 
with Trisomy 18 survive beyond one year. The majority of trisomy 18 cases result from 
parental non-disjunction at meiosis either during the first or second meiotic divisions. 
Trisomy 18 rarely results from a translocation and mosaicism Is occasionally observed. 
The incidence of trisomy 18 is increased at advanced maternal age.
1.1.3 PATAU’S SYNDROME (TRISOMY 13).
The incidence of Patau’s syndrome (Trisomy 13) is 1/5000 live births (Connor and 
Ferguson-Smith 1991). In the majority of cases Trisomy 13 is caused by meiotic non- 
disjunction at either the first or second meiotic divisions. Around 20% of cases result 
from parental translocation and mosaicism is present in 5% of patients. The incidence 
of Trisomy 13 is increased at advanced maternal age. Clinical features associated with 
Trisomy 13 include heart defects, hypotelorism, cleft lip and palate, redundant skin 
around the nape of the neck, abnormal ears, clenched fists and single palmar creases. 
Only 10% of affected babies survive beyond one year.
1.2 PRENATAL DIAGNOSIS OF CHROMOSOME ABNORMALITIES.
Autosomal trisomies and other serious chromosome abnormalities can be diagnosed 
prenatally by fetal chromosome analysis of cultured amniotic fluid, chorionic villous or 
fetal blood cells. The diagnosis of such chromosome abnormalities in utero provides
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the option of selective termination of affected pregnancies or can allow adequate 
preparation for the birth of a disabled child. However, amniocentesis, chorionic villous 
sampling and fetal blood sampling are invasive techniques and all carry defined risks 
for the pregnancy (MacLachlan 1992, Silverman and Wapner 1992, Nicolini and 
Rodeck 1992). These techniques are also time consuming and expensive, and for 
these reasons it is not desirable for all women to have such a diagnostic test. Prenatal 
screening for chromosome abnormalities, in particular Down’s syndrome, provides a 
means of identification of women with a risk of carrying an affected fetus high enough 
to justify diagnostic testing.
1.3 PRENATAL SCREENING.
Various steroids and proteins produced in the feto-placental unit and secreted into the 
maternal circulation have been demonstrated to be of potential clinical importance in 
the identification of pregnancies in which there is a fetal disorder. The concentration of 
certain pregnancy markers in the maternal circulation and amniotic fluid has been 
shown to vary in pregnancies associated with fetal abnormalities compared to the level 
detected in normal pregnancies. Although such variation is not diagnostic of a fetal 
abnormality, analysis of certain markers in the maternal serum may be used to identify 
those pregnancies which are at increased risk of being associated with a particular 
fetal disorder. By identifying which pregnancies are at risk by this process of prenatal 
screening, a diagnostic test can be offered to confirm or exclude the presence of a 
fetal abnormality.
Biochemical analysis of markers in maternal serum requires only that a venous blood 
sample be taken from the mother and therefore does not hazard the pregnancy. As 
prenatal screening and diagnosis is intended only to identify pregnancies associated 
with a fetal disorder and cannot offer a cure, the only preventative measure is 
termination of the pregnancy.
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1.3.1 PRENATAL SCREENING FOR CHROMOSOME ABNORMALITIES.
The risk of a pregnancy being associated with an autosomal trisomy Increases with 
advancing maternal age. For this reason, advanced maternal age was originally the i-j %
most important criterion on which women were offered fetal chromosome analysis for 
the diagnosis of autosomal trisomies. Women aged 35 years and over (around 7% of 
the pregnant population) were considered to be at high risk and were offered a 
diagnostic test. This form of screening however, proved to be less than successful 
(Stone et al 1989) as only about 30% of autosomal trisomies occur in women of that 
age group. Thus, maternal age screening has a major disadvantage in that it misses 
70% of all autosomal trisomy cases. ;
The discovery that Down’s syndrome and other autosomal trisomy pregnancies were 
associated with reduced levels of maternal serum AFP (Cuckle et al 1984, Merkatz et 
al 1984) raised the potential for improving screening for chromosome abnormalities. 
Several studies have shown that maternal serum AFP levels are reduced to around 
70% of normal in Down's syndrome pregnancies and by using the risks derived from 
AFP levels and maternal age, it was estimated that screening performance could be 
improved to a detection rate of 37% of all autosomal pregnancies for no increase in 
the follow up rate accepted for maternal age screening (Cuckle et al 1987, Zeitune et 
al 1991).
It has also been shown that there are variations in the levels of other maternal serum 
markers in autosomal trisomy pregnancies. The main Down's syndrome markers are 
AFP, human chorionic gonadotropin (hCG) and unconjugated oestriol (UE3), and 
screening for Down's syndrome by measurement of some or all of these markers is 
well established in the United Kingdom. In such screening programmes, a woman's 
risk of having a pregnancy associated with Down's syndrome is estimated by 
combining her maternal age risk and a risk derived from the levels of the markers in 
the maternal serum. If a woman has a risk greater than a particular cut-off point,
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diagnostic testing is advised. There is also interest in extending this type of multiple 
marker screening to detect trisomy 18 pregnancies.
At present, if a woman is diagnosed as having an autosomal trisomy pregnancy, the 
only options available are to continue the pregnancy to term or to terminate the 
pregnancy. In practice, most women with affected pregnancies choose to avoid the 
birth of a disabled child. Selective termination of affected pregnancies in the first 
trimester is medically safer than at later gestations and may also help to reduce the 
emotional stress of the parents. It would therefore be desirable if screening 
procedures could be moved to the first trimester of pregnancy enabling termination of 
pregnancy to be carried out at an earlier stage. For this reason, the variation in the 
levels of many maternal serum markers in the first trimester of autosomal trisomy 
pregnancies has also been investigated (Macintosh and Chard 1992, Macintosh and 
Chard 1993). For many markers, the concentration changes seen in trisomie 
pregnancies are of a different magnitude at different stages of pregnancy.
1.4 BIOCHEMICAL MARKERS.
As a result of the immense amount of interest that biochemical screening for 
chromosome abnormalities has generated, numerous pregnancy markers have been 
investigated in maternal serum, amniotic fluid and fetal tissues from pregnancies 
affected by fetal Down's syndrome or other chromosome abnormalities. Complex 
patterns of variation of these markers have emerged, although little is known about the 
mechanisms which modulate the levels of these markers.
1.4.1 ALPHAFETOPROTEIN.
Alphafetoprotein (AFP) is a fetal-specific and cancer-associated glycoprotein and as 
such is of considerable clinical value as an indicator of fetal well-being and as a 
tumour marker.
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AFP is a 67-74 kDa protein which belongs to a superfamily of proteins which also 
includes Vitamin-D binding protein and albumin (Smith and Kelleher 1980, Deutsch
1991). There is considerable structural and sequence homology between the three 
proteins (Deutsch 1991). The genes for Vitamin-D binding protein, albumin and AFP 
have been mapped to the long arm of chromosome 4 and are thought to be derived 
from a common ancestral gene via gene duplication and subsequent divergence. 
(Weitkamp et al 1966, Harper and Dugaiczyk 1983).
During fetal development AFP is synthesised initially by the yolk sac and then by the 
fetal liver, although its presence has been detected in other fetal tissues including the 
gastrointestinal tract and occasionally in the kidney and placenta (van Firth and Adinolf 
1969, Gitlin et al 1972, Hustin et al 1980). Only trace amounts of AFP (2-25ng/m!) are 
detectable in normal adult serum (Gitlin 1975, Rouslahti and Hirai 1978). AFP exists in 
two distinct forms which can be distinguished by their ability to bind to Concanavalin-A 
(Con-A) (Ruoslahti et al 1978, Smith and Kelleher 1980). The Con-A reactive form of 
AFP is derived mainly from the fetal liver and the Con-A non-reactive form is derived 
from the yolk sac (Ruoslahti et al 1978, Smith and Kelleher 1980).
Abnormal levels of AFP in non-pregnant adult human serum can be caused by a 
variety of conditions including hereditary persistence of AFP, primary liver cancer, 
germ cell tumours, hepatitis, liver cirrhosis and tumours of the gastrointestinal tract 
(Rouslahti and Hirai 1978, Deutsch 1991, McVey et al 1993).
The physiological role of AFP has not yet been defined. AFP binds to a variety of 
molecules (oestrogens, fatty acids, bilirubin, drugs, metals) and may be involved in a 
number of physiological processes depending on the ligand to which it is bound 
(Deutsch 1991). Functions ascribed to AFP include binding and transport, 
immunoregulation and growth regulation (Ruoslahti and Hirai 1978, Deutsch 1991).
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1.4.1.1 AFP in Normal Pregnancy.
The principle sources of AFP in the fetal circulation during early development are the 
yolk sac and the fetal liver, with the fetal liver becoming the major source as gestation 
advances (Gitlin et al 1972, Gitlin 1975). AFP levels in the fetal circulation increase to 
a peak of approximately 3mg/ml at around 13 weeks gestation and then decrease to 
term (Gitlin and Boesman 1966). Circulating AFP levels decline rapidly after 32 weeks 
gestation and continue to decline after birth until adult levels are reached by around 
two years of age (Gitlin and Boesman 1966, Gitlin 1975).
In amniotic fluid, AFP levels increase from 11 weeks gestation to a peak at 13 weeks 
followed by a decrease to term (Seppala and Rouslahti 1972, Crandall et al 1989, 
Palomaki et al 1993), similar to the concentration profile of AFP in fetal serum. Wathen 
et al (1991, 1993) found that amniotic fluid AFP levels were high at 8 weeks gestation 
with a rapid decline to 11 weeks, after which the concentration profile was identical to 
that previously described. Amniotic fluid AFP is derived from the fetal circulation 
through the unkeratinised skin of the fetus in early pregnancy and from the fetal urine 
once the fetal kidney starts to function (Seppaia and Rouslahti 1972, Gitlin and 
Boesman 1966, Gitlin 1975). The relative concentrations of Con-A reactive and Con-A 
non-reactive AFP in amniotic fluid changes as gestation advances. The contribution of 
Con-A non-reactive AFP to total amniotic fluid AFP levels decreases as gestation 
advances, possibly due to the decline of the yolk sac at the end of the first trimester 
(Rouslahti et al 1979, Toftager-Larsen 1980, Mackiewicz et al 1984, Jauniaux and 
Moscoso 1992).
In the maternal circulation AFP levels rise steadily above non-pregnant adult base line 
levels at 6 to 7 weeks gestation to approximately 45Qng/ml at 32 weeks gestation,
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after which levels gradually decrease to term (Gitlin 1975, Rouslahti and Hirai 1978). 
Maternal serum AFP is derived from the fetal serum via the placenta and from the 
amniotic fluid through the fetal membranes (Gitlin 1975, Los et a! 1985).
1.4.1.2 AFP in Complications of Pregnancy.
,33:
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In twin pregnancies, maternal serum AFP levels are approximately double those found 
in normal singleton pregnancies (Wald et a! 1975, UK Collaborative study 1977).
Brock and Sutcliffe (1972) observed that the concentration of AFP in the amniotic fluid 
from pregnancies affected by neural tube defects (NTD) was significantly higher than 
in normal pregnancies. This provided a method for the prenatal diagnosis of NTD (UK 
Collaborative Study 1979). The discovery that AFP levels are also elevated in the 
maternal circulation of NTD pregnancies (Brock et al 1974) led to the development of a 
prenatal screening test for NTD (UK Collaborative Study 1977).
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In adult human serum, AFP is normally only present in small amounts. Hereditary 
persistence of AFP is an autosomal dominant trait in which affected individuals have 
markedly elevated serum AFP levels (McVey et al 1993). This condition does not 
appear to be associated with any clinical disability, but during pregnancy can give rise 
to abnormally high maternal serum AFP levels in cases where the fetus is not affected 
by a NTD.
Abnormal levels of AFP during pregnancy have also been reported in association with 
anterior abdominal wall defects, congenital nephrosis, fetal exomphalos, fetal 
esphogeal atresia, Meckel’s syndrome, or threatened abortion and intrauterine fetal 
death (Ruoslahti and Hirai 1978, Westergaard et al 1985b, Morrow et al 1993).
Maternal serum AFP concentrations have been reported to be low in women with
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anembryonic pregnancies (Bennett et a! 1978), although Stabile et al (1989) were 
unable to confirm these findings. Second trimester maternal serum AFP levels have 
been reported to be normal or reduced in women with insulin-dependent diabetes 
(Wald et al 1979, Reece et al 1987, Canick et al 1990b, Wald et al 1992a).
1.4.1.3 AFP in Chromosomally Abnormal Pregnancies.
The association between reduced maternal serum AFP levels and fetal chromosome 
abnormalities was first reported by Merkatz et al (1984). AFP levels were significantly 
reduced in second trimester maternal serum from Down’s syndrome. Trisomy 18 and 
Trisomy 13 pregnancies. Subsequent studies have confirmed this observation, 
particularly in association with Down’s syndrome (Fuhrmann et al 1984, Cuckle et al 
1987, Tabor et al 1987, Waller et al 1990, Zeitune et al 1991, Spencer et al 1992a). In 
a meta-analysis of 24 published studies, including a total of 823 Down’s syndrome 
cases, the overall second trimester maternal serum AFP level in Down’s syndrome 
pregnancies was found to be 0.74 multiples of the median (MOM) (Wald and Cuckle
1992). A similar reduction has also been found in the first trimester of Down’s 
syndrome pregnancies (Cuckle et al 1988, Brock et al 1990, Aitken et al 1993a, 
Fuhrmann et al 1993, Crandall et al 1993). The association between reduced second 
trimester maternal serum AFP levels and fetal Trisomy 13 and Trisomy 18 has also 
been confirmed (Lindenbaum et al 1987, Canick et al 1990a, Miller et al 1991, Zeitune 
et al 1991, Barkai et al 1993). Reduced maternai serum levels of AFP have also been 
reported in the first trimester of Trisomy 18 pregnancies (Johnson et al 1991, Aitken et 
al 1993a, Fuhrmann et al 1993).
Although Merkatz et al (1984) found apparently normal amniotic fluid AFP levels 
associated with fetal trisomy, other groups have reported that amniotic fluid AFP levels
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in Down’s syndrome pregnancies are reduced to approximately 70% of normal levels 
(Cowchock and Ruch 1984, Davis et ai 1985, Jones et al 1986, Crandall et at 1988, 
Kaffe et al 1988, Zeitune et ai 1989). Combining the results 10 published studies, 
including a total of 546 Down’s syndrome pregnancies, amniotic fluid AFP levels were 
below the control group median in 85.3% of affected cases (Zeitune et al 1989). No 
such association has been found in pregnancies affected by Trisomy 18 or Trisomy 13 
(Davis et al 1985, Doran et al 1986, Ashwood et al 1987, Lindenbaum et al 1987, 
Kaffe et at 1988, Crandall et al 1988, Zeitune et al 1989).
The concentration of AFP in serum from Down’s syndrome fetuses has been reported 
to be normal before 20 weeks gestation, but declines more rapidly than in fetal serum 
from unaffected pregnancies after 20 weeks (Nicolini et al 1988, Scioscia et al 1988, 
Seller et al 1990). Cuckle and Wald (1986) reported that AFP levels were significantly 
reduced to 0.45 (MOM) in cord sera from Down’s syndrome babies compared to 
normal.
1.4.2 HUMAN CHORIONIC GONADOTROPIN.
Human chorionic gonadotropin (hCG) is a glycoprotein hormone which is closely 
related to the pituitary hormones luteinising hormone (LH), follicle-stimulating hormone 
(FSH) and thyroid-stimulating hormone (TSH) (Pierce and Parsons 1981). HCG is 
composed of two non-identicai subunits non-covalently linked to form a heterodimer 
and contains approximately 30% carbohydrate by weight. The a-subunit (15kDa) is 
identical to that of the other glycoprotein hormones, while the (3-subunit (23kDa) Is 
non-identical and confers specific biological activity. Due to the structural homology 
between hCG and LH the two hormones bind to the same receptors which are present 
in gonadal tissues and in a number of other tissues including the placenta, uterus.
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fetal membranes and decidua (Reshef et ai 1990, Lei and Rao 1992). The a-subunit of 
hCG is coded by a single gene on chromosome 6 (Fiddes and Goodman 1981) and 
the (3-subunit by a cluster of six genes on chromosome 19 (Policastro et al 1986, 
Graham et al 1987). Talmadge et al (1984) reported that only two of the (3-genes were 
expressed in the placenta, however more recent studies suggest that at least five p- 
genes are transcribed in vivo (Bo and Boime 1992).
In the placenta mononucleated cytotrophoblast cells continuously differentiate and 
fuse to form multinucleated syncytiotrophoblast cells. Hoshina et al (1982,1983) 
reported that ahCG and phCG subunit genes were expressed predominantly in the 
syncytiotrophoblast and in some cytotrophoblast cells. Subsequent studies have 
shown that the ahCG subunit is localised primarily in the cytotrophoblast, while the 
phCG subunit is localised almost exclusively to the syncytiotrophoblast (Hay et ai 
1988, Kelly et al 1991). Synthesis of intact hCG Is linked primarily to the 
syncytiotrophoblast and multinucleated intermediate cells (Gosseye and Fox 1984, 
Hay 1988), although hCG may be expressed in cytotrophoblast cells in placentae at 4- 
5 weeks gestation (Marou et al 1992).
The principle physiological role of hCG is the maintenance of the corpus luteum during 
the initial stages of pregnancy. The corpus luteum is essential for the production of 
hormones during the first seven weeks of pregnancy, until placental production of 
hormones takes over around the 8th week of pregnancy. Apart from its luteotrophic 
function, the role of hCG throughout the remainder of pregnancy is largely unknown. 
HCG may be involved in a number of processes including placental glycogen 
metabolism (Demers et al 1973), trophoblast differentiation (Shi et al 1993), steroid 
biosynthesis and regulation of placental function (Lei and Rao 1992).
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1.4.2.1 HCG in Normal Pregnancy.
HCG synthesis begins in the blastocyst and can be detected in the maternal circulation 
around the time of implantation (Grudzinskas et al 1977). The concentration of 
heterodimeric HCG (intact hCG) in the maternal circulation rises rapidly to a peak at 8- 
10 weeks gestation and then declines to a plateau at 18-20 weeks gestation after 
which the concentration remains relatively constant to term (Braunstein et al 1976, 
Kletzky et al 1985, Ozturk et al 1987). HCG is also present in the maternal circulation 
in the form of its free ahCG (FahCG) and phCG (FphCG) subunits. Maternal serum 
FahCG increases from low levels in early pregnancy to around 30-40% of total hCG 
levels at term (Cole et al 1984, Ozturk et al 1987). FphCG accounts for less than 5% of 
total hCG in maternal serum and levels increase to a peak at 8-9 weeks gestation and 
decline thereafter (Cole et al 1984, Ozturk et al 1987). The concentration of hCG in the 
maternal circulation is influenced by the sex of the fetus. From approximately 18 
weeks gestation, maternal serum levels of hCG have been reported to be higher in 
women carrying a female fetus (Crosignani et ai 1972, Boroditsky et al 1975, Obiekwe 
and Chard 1982, Leporrier et al 1992, Muller et al 1993).
The concentration of intact hCG in amniotic fluid is lower than in the maternal 
circulation (Ozturk et al 1988, Iles et al 1992). Amniotic fluid intact hCG levels increase 
from nine weeks gestation to a peak at 11-14 weeks followed by a marked decrease to 
low levels which are maintained to term (Clements et al 1976, Ozturk et al 1988). In 
fetal serum, hCG levels are lower than in amniotic fluid and maternal serum and show 
a changing profile similar to that in the maternal circulation (Crosignani et al 1972, 
Clements et al 1976). The relative concentrations of intact hCG in maternal serum, 
amniotic fluid and fetal serum suggest that hCG is secreted from the
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syncytiotrophoblast directly into the maternal circulation and from there into the 
amniotic fluid across the fetal membranes. Amniotic fluid FahCG and FphCG levels 
decrease from around 15 weeks gestation until 23 weeks gestation (Ozturk et al 
1988). In contrast to intact hCG, the concentration of FahCG and FphCG in the 
amniotic fluid is approximately 10 times higher than in the maternal circulation, 
although there is no evidence of increased breakdown of hCG into its subunits in 
amniotic fluid (Ozturk et al 1988, Iles et ai 1992). This suggests that, unlike intact hCG, 
the free subunits of hCG may reach the amniotic fluid via an alternative route or the 
there are other sources hCG subunits in the amniotic fluid.
1.4.2.2 HCG in Complications of Pregnancy.
HCG is a product of the trophoblast and as such is an indicator of the presence of 
viable trophoblastic tissue. The measurement of hCG in serum or urine is used as an 
indicator of pregnancy. Abnormal levels of hCG are associated with a number of 
pregnancy complications. Low maternal serum levels of hCG have been reported in 
association with ectopic pregnancy, threatened abortion and fetal death (Bischof et al 
1983d, Salem et al 1984, Grudzinskas et al 1986, Muller et al 1993a). In women with 
insulin-dependent diabetes mellitus intact hCG levels are normal or slightly reduced 
(Canick et al 1990b, Wald et al 1992a). In twin pregnancies, maternal serum intact 
hCG levels are elevated to approximately two times the levels in singleton pregnancies 
(Canick et al 1990b, Neibolo et al 1991). Elevated maternal serum levels of hCG have 
also been reported in association with gestational trophoblastic disease, intrauterine 
growth retardation and fetal death (Grudzinskas et al 1986, Tanaka et al 1993, Muller 
et al 1993a). Henderson et al (1992) reported a significant reduction in the expression 
of free a- and p-subunits in trophoblast tissue from pregnancies with early embryonic 
failure.
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1.4.2.3 Intact hCG in Chromosomally Abnormal Pregnancies.
Maternal serum levels of intact hCG are elevated to approximately twice normal levels 
in the second trimester of pregnancies with a Down’s syndrome fetus (Bogart et al 
1987, Wald et al 1988a, Norgaard-Pedersen et al 1990, Crossley et al 1991a, Haddow 
et al 1992, Ryall et al 1992, Spencer et al 1992a, Stone et al 1993). A meta-analysis 
of 18 published studies, including a total of 559 Down’s syndrome pregnancies, 
revealed an overall second trimester maternal intact hCG level of 2.05 MOM (Wald 
and Cuckle 1992). In the first trimester, although intact hCG levels are marginally 
raised in association with Down’s syndrome, the magnitude of the change is much less 
than that observed in the second trimester (Cuckle et al 1988, Bogart et al 1989, Brock 
et al 1990, Johnson et al 1991, Kratzer et al 1991b, van Lith et al 1992, Aitken et al 
1993a, Crandall et al 1993).
In contrast to Down’s syndrome, second trimester intact hCG levels are markedly 
reduced in pregnancies associated with Trisomy 18 (Arab et al 1988, Canick et al 
1990a, Crossley et al 1991b, Miller et al 1991, Barkai et al 1993). Kratzer et al (1991b) 
and Aitken et al (1993a) reported that maternal serum intact hCG levels were 
significantly reduced in the first trimester of Trisomy 18 pregnancies, while Van Lith et 
al (1992) reported that levels were not significantly different from normal. In Trisomy 
13 pregnancies, second trimester maternal serum hCG levels have been reported as 
normal (Crossley et al 1991b), elevated (Muller et al 1993a) and reduced (Suchy and 
Yeager 1990). In the first trimester, maternal serum intact hCG levels have been 
reported to be low in association with fetal Trisomy 13 (Kratzer et al 1991b).
In amniotic fluid from Down’s syndrome pregnancies, intact hCG levels are 
significantly higher than in unaffected pregnancies (Cuckle et al 1991, Wolf et al 1992, 
Spencer et al 1993a),
50
1.4.2.4 Free ahCG and phCG Subunits in Chromosomally Abnormal
Pregnancies.
FphCG levels are elevated to more than twice normal levels in second trimester 
maternal serum from Down’s syndrome pregnancies (Maori et al 1990, Crossley et al 
1991a, Spencer 1991a, Ryall et al 1992, Spencer et al 1992a, Stone et al 1993). 
Maternal serum FphCG levels are also increased in the first trimester of Down’s 
syndrome pregnancies, the magnitude of increase being similar to that in the second 
trimester (Ozturk et al 1990, Spencer et al 1992b, Aitken et al 1993a, Maori et al 
1993a).
Some studies have shown that FahCG levels in maternal serum are significantly 
elevated in the second trimester of Down’s syndrome pregnancies (Bogart et al 1987, 
Bogart et al 1989, Kratzer et al 1991b, Ryall et al 1992). However, in a study of 36 
Down’s syndrome cases, Spencer (1993) was unable to confirm this observation. 
Bogart et al (1989) reported that FahCG levels in the first trimester of Down’s 
syndrome pregnancies were not significantly different from normal. In contrast, data 
from Ozturk et al (1990) suggest that FahCG levels are slightly elevated, while Kratzer 
et al (1991b) found that FahCG levels to be significantly reduced in the first trimester 
of Down’s syndrome pregnancies
Reduced maternal serum levels of FphCG (0.37 MOM) have been reported in 
association with Trisomy 18 in the second trimester of pregnancy (Spencer et al 
1993b), and with Trisomy 18 and Trisomy 13 in the first trimester (Ozturk et al 1990, 
Spencer et al 1992b, Aitken et al 1993a, Maori et al 1993a). Kratzer et al (1991b) 
reported that first trimester maternal serum FahCG levels were reduced in Trisomy 13 
pregnancies but normal in Trisomy 18 pregnancies. In contrast, Ozturk et al (1990)
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found that FahCG levels were elevated In Trisomy 18 pregnancies in the first trimester. 
Bogart et al (1989) found that second trimester serum levels of FahCG were normal in 
two cases of Trisomy 18 and elevated in one of two cases of Trisomy 13.
Both FphCG and FahCG levels have been found to be elevated in amniotic fluid from 
Down’s syndrome pregnancies (Wolf et al 1992, Spencer et al 1993a).
1.4.3 PREGNANCY ASSOCIATED PLASMA PROTEIN-A.
Pregnancy associated plasma protein-A (PAPP-A) is a glycoprotein with a molecular 
weight of approximately 750-820kDa and is composed of two identical subunits of 
equal molecular weight (Bischof 1979). The gene encoding PAPP-A has been mapped 
to chromosome 9q33.1 (Silahtaroglu et al 1993). The syncytiotrophoblast of the 
placenta is believed to be the principle source of circulating PAPP-A. 
Immunohistochemical studies demonstrating that PAPP-A is localised to the 
syncytiotrophoblast support this theory (Lin and Halbert 1976, Wahlstrom et al 1981, 
Gosseye and Fox 1984, Tornehave et al 1984). However, PAPP-A has also been 
shown to be present in other tissues including the villous cytotrophoblast and decidua 
(DuBerg et al 1982, Dobashi et al 1984, Schindler et al 1984), and in non-pregnant 
females and in male seminal plasma (Bischof et al 1983b, Bersinger and Klopper 
1984). Schindler and Bischof (1984) demonstrated the histochemical localisation of 
PAPP-A in the decidua, fetal adrenal cells, fetal renal tubules, fetal intestinal mucosa, 
adult proliferative endometrial cells and red cell precursors. However, they found that 
the use of different preparations of PAPP-A antibody revealed significant differences 
in immunohistochemical staining.
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In a recent study, Oxvig et al (1993) proposed that circulating PAPP-A was present in 
the form of a disulphide-bridged complex between PAPP-A and the pro-form of 
eosinophil major basic protein (proMBP). Eosinophil major basic protein (MBP) Is 
found in the core of the eosinophil granule. During pregnancy, a protein 
immunologically identical to MBP is found in placenta, amniotic fluid and maternal 
serum (Maddox et al 1983, Maddox et al 1984, Vernof et al 1984). Levels of the 
pregnancy associated MBP in the maternal circulation increase in a sigmiodal fashion 
with advancing gestation (Wagner et al 1993). Oxvig et al (1993) reported that certain 
commercial preparations of anti-PAPP-A polyclonal antibody used in the analysis of 
PAPP-A levels in pregnancy and in immunohistochemical studies were poly-specific, 
binding to both MBP and its pro-form. Bueler and Bersinger (1989) have also 
demonstrated the cross-reactivity of some batches of commercially available anti- 
PAPP-A antibodies, in that antiserum marketed by Dakopatts was capable of binding 
to human haptoglobin. Cross-reactivity of commercial PAPP-A antibodies may partly 
be responsible for the controversy surrounding the site of synthesis of PAPP-A.
The physiological role of PAPP-A during pregnancy is not known. PAPP-A has been 
reported to exert inhibitory effects on immune and coagulation systems and it has 
been proposed that PAPP-A may play a role in the protection of the fetal allograft 
(Bischof et al 1979, Bischof et al 1982b, Bischof et al 1983a/c, Bischof et al 1984, 
Stabile et al 1988)
1.4.3.1 PAPP-A in Normal Pregnancy.
PAPP-A is synthesised in the syncytiotrophoblast of the placenta and secreted directly 
into the maternal circulation where levels increase in a sigmoidal fashion to term 
(Sutcliffe et al 1980, Folkersen et al 1981, Bischof et al 1982a). The rate of production
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of PAPP-A may be a direct reflection of the total mass of the trophoblast and the blood 
flow in the intervillous space (Gordon and Chard 1979, Chard 1986).
The concentration of PAPP-A in the amniotic fluid is lower than that in the maternal 
circulation and the change in amniotic fluid PAPP-A levels with gestation reflects the 
concentration profile of PAPP-A in the maternal circulation (Bischof et al 1982a). This 
suggests that amniotic fluid PAPP-A is derived primarily from the maternal circulation 
across the fetal membranes.
1.4.3.2 PAPP-A In Complications of Pregnancy.
PAPP-A is of potential value in the prenatal diagnosis of a rare condition known as 
Cornelia de Lange (CdL) syndrome. Westergaard et al (1983a) reported the apparent 
absence of PAPP-A from the maternal circulation and from trophoblast tissue in 
pregnancies which resulted in the birth of a child with CdL syndrome. Support for this 
observation is provided in a subsequent study by Graham et al (1988).
Reduced levels of PAPP-A in the maternal circulation have also been associated with 
threatened abortion, early pregnancy failure, ectopic pregnancy, insulin dependent 
diabetes and trophoblastic disease (Sutcliffe et al 1982, Masson et al 1983, 
Westergaard et al 1983b, Westergaard et al 1985b, Grudzinskas et al 1986, Stabile et 
al 1988). Elevated maternai serum levels of PAPP-A have been reported in 
association with twin pregnancy, pre-eclampsia and ante-partum haemorrhage 
(Klopper and Hughes 1980, Westergaard et al 1985a, Grudzinskas et al 1986).
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1.4.3.3 PAPP-A In Chromosomally Abnormal Pregnancies.
Maternal serum levels of PAPP-A are significantly reduced in Down’s syndrome 
pregnancies In the first trimester, with median PAPP-A levels reported in the range of 
0.23 to 0.63 MOM (Wald et al 1992b, Aitken et al 1993b, Brambati et al 1993, Hurley 
et al 1993, Muller et al 1993b). Maternai serum PAPP-A levels in the second trimester 
of Down’s syndrome pregnancies are not significantly different from normal (Cuckle et 
al 1992, Wald and Voiler 1992, Knight et al 1993). There are no published studies on 
amniotic fluid levels of PAPP-A in Down’s syndrome pregnancies.
1.4.4 PREGNANCY SPECIFIC BETA 1 GLYCOPROTEIN.
Pregnancy specific beta 1 glycoprotein (SP1) Is a 90kDa glycoprotein which is 
synthesised by the syncytiotrophoblast and secreted into the maternal circulation 
during pregnancy (Bohn 1979). SP1 belongs to the immunoglobulin superfamily and 
exhibits strong homology with carcinoembryonic antigen and neurone-cellular 
adhesion molecule (Streydio et al 1988, Barnett et al 1990, Leslie et al 1990, Zheng et 
al 1990). A family of genes encoding SP1 has been mapped to chromosome 19 
(Streydio et al 1990). Immunohistochemical studies have shown that SP1 is localised 
to the syncytiotrophoblast of the placenta and synthesis of SP1 has been 
demonstrated in trophoblast cultures (Lin and Halbert 1976, Gosseye and Fox 1984, 
Chou and Zilberstein 1990). Differential expression of SP1 genes has also been 
demonstrated in the chorionic and amniotic membranes as well as in the trophoblast 
(Plouzek et al 1993). SP1 may be present at extremely low concentrations in the 
serum of healthy non-pregnant individuals (Grudzinskas et al 1979, Sorensen 1984). 
Elevated levels of SP1 can be detected in the serum of individuals with trophoblastic
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tumours and other malignant non-trophoblastic tumours (Searle et al 1978, 
Grudzinskas et al 1979, Sorensen 1984).
The physiological role of SP1 is not known. Considering the structural homology 
between SP1 and cellular adhesion molecules, SP1 may act as placental cellular
adhesion molecule important in the maintenance of placental structural integrity. SP1
may also be Involved in immunosuppression, carbohydrate metabolism and play a role 
as a carrier protein (Grudzinskas et al 1979, Sorensen 1984).
1.4.4.1 SRI in Normal Pregnancy.
SP1 can be detected in the maternal circulation soon after conception (18-23 days) 
(Grudzinskas et al 1977). SP1 is secreted from the syncytiotrophoblast into the 
maternal circulation where levels increase in a sigmiodal fashion to term (Schultz- 
Larsen 1978, Guibai et al 1980, Braunstein et al 1980). The concentration of SP1 in 
the maternal circulation at term is approximately 100-290mg/l which Is considerably 
higher than the levels of other placental proteins (Bohn 1979, Sorensen 1984). It is 
thought that the concentration of SP1 in the maternal circulation throughout gestation 
reflects the growth of the placenta and trophoblastic mass (Gordon and Chard 1979, 
Braunstein et al 1980). The concentration of SP1 in the amniotic fluid is approximately 
1% of that in the maternal serum, while fetal serum levels are approximately 0.1% of 
maternal serum levels (Grudzinskas et al 1978). SP1 is present in maternal urine at 
approximately 1% of maternal serum levels (Grudzinskas et al 1978). The increase in 
amniotic fluid SP1 levels with gestation reflects the concentration profile of SP1 in the 
maternal circulation, suggesting that amniotic fluid SP1 may be derived from the 
maternal circulation across the fetal membranes.
56
1.4.4.2 SP1 in Complications of Pregnancy.
Low levels of SP1 in the maternal circulation in early pregnancy are predictive of 
pregnancy failure following threatened abortion (Schultz-Larson and Herz 1978, Ho 
and Jones 1980, Masson et al 1983, Sterzik et al 1986). Lower than normal serum 
SP1 levels have also been reported associated with ectopic pregnancy, fetal hypoxia, 
intrauterine growth retardation, anembryonic pregnancy and pre-eclampsia (Gordon et 
al 1977, Bennett et al 1978, Ho and Jones 1980, MacDonald et al 1983, Sterzik et al
1989, Silver et al 1993). Elevated maternal serum SP1 levels are associated with twin 
pregnancy and choriocarcinoma (Searle et al 1978, Westergaard et al 1985a).
1.4.4.3 SP1 in Chromosomally Abnormal Pregnancies.
Maternal serum concentrations of SP1 were first investigated in relation to Down’s 
syndrome by Bartels and Lindemann (1988). SP1 levels were found to be elevated to 
approximately twice normal levels (2.10 MOM) in Down’s syndrome pregnancies in the 
second trimester. Subsequent studies have confirmed that SP1 levels are elevated in 
Down’s syndrome pregnancies (Wald et al 1989, Bartels et al 1990, Petrocik et al
1990, Graham et al 1992, Aitken et al 1994), however the degree of elevation appears 
to be less than in the initial study by Bartels and Lindemann (1988). A meta-analysis of 
five published studies, including a total of 213 Down’s syndrome pregnancies, 
revealed an overall second trimester maternal serum SP1 level of 1.54 MOM in the 
affected cases (Wald and Cuckle et al 1992). In the first trimester, maternal serum 
SP1 levels are significantly reduced in association with Down’s syndrome. Brock et al 
(1990) reported a median maternal serum level of 0.79 MOM in 21 Down’s syndrome 
pregnancies at 7-14 weeks gestation, while Macintosh et al (1993) found maternal 
serum SP1 levels to be reduced to 0.40 MOM in 14 Down’s syndrome pregnancies at 
6-12 weeks gestation.
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Bartels and Lindemann (1988) reported that in three out of four Trisomy 18 cases, 
maternal serum SP1 levels were elevated compared to controls. Subsequent studies 
suggest that maternal serum SP1 levels are not significantly different from normal in 
Trisomy 18 pregnancies in either the first or second trimesters (Bartels et al 1990, 
Graham et al 1992, Macintosh et al 1993). Bartels et al (1990) reported maternal 
serum SP1 levels of 1.07 MOM and 0.36 MOM in two Trisomy 13 pregnancies, while 
Graham et al (1992) found that maternal serum SP1 levels in four Trisomy 13 cases 
were not significantly different from controls.
Bartels and Lindemann (1988) also reported that amniotic fluid levels of SP1 in Down’s 
syndrome pregnancies were significantly elevated at 16 and 17 weeks gestation and 
normal at 18 and 19 weeks gestation. Previous studies have shown amniotic fluid SP1 
levels to be normal or slightly reduced in association with fetal trisomy (Wurz et al 
1981, Helkinheimo et al 1984).
1.4.5 ALKALINE PHOSPHATASE.
The alkaline phosphatases (ALP) are a group of isoenzymes which are present on the 
microvillar membranes of a number of tissues. The enzymes are attached to the outer 
surface of the microvillar membrane by means of a glycosyl-phosphatidylinositol 
anchor (GPl) that is covalently attached to the C-terminus of the peptide (Low 1988). 
Four structural genes encoding the alkaline phosphatase isoenzymes have now been 
identified. The gene encoding the tissue non-specific isoenzyme, which is expressed 
In bone, liver, kidney and other cells, has been mapped to chromosome 1 (Swallow et 
al 1984). The adult intestinal ALP gene has been mapped to chromosome 2 (q34-37), 
where the genes encoding the placental and germ-cell (placental-like ALP) 
isoenzymes are also located (Kam et al 1985, Henthorn et al 1987, Martin et al 1987). 
The germ-cell isoenzyme is expressed at low levels in lung, cervix, testes and thymus
58
(Goldstein et al 1982). The placental ALP gene exhibits considerable allelic variation 
which gives rise to a number of electrophoretically distinct phenotypes of placental 
ALP (Robson and Harris 1967, Donald and Robson 1974). There is considerable 
homology between the amino acid sequences of the placental and germ-cell 
isoenzymes (98%), and between the placental and adult intestinal isoenzymes 
(86.5%). Adult intestinal ALP and tissue non-specific ALP exhibit 56.6% sequence 
homology (Henthorn et al 1987, De Broe and Moss 1992).
The different isoenyzmes exhibit considerable heterogeneity with respect to 
electrophoretic mobility, inhibition characteristics and susceptibility to heat. These 
differences can be exploited to distinguish between the isoenzymes. Mulivor et ai 
(1978c) demonstrated that the isoenzymes can be separated into three distinct 
categories of tissue non-specific, placental and adult intestinal ALP using the 
appropriate combination of the inhibitors L-homoarginine, L-phenylalanine, L-leucine, 
L-leucylglycylglycine and L-phenylalanylglycyiglycine. There is no difference in the 
inhibition characteristics of the tissue non-specific isoenzymes and differences in the 
electrophoretic mobilities of these isoenzymes are probably due to tissue specific 
variation in post-translational modifications. The placental isoenzyme can be 
distinguished on the basis of its resistance to heating at 65°C, a temperature at which 
the other isoenzymes are inactivated (Moss 1982). Placental ALP isoenzyme is also 
immunologically distinct from the other isoenzymes (Moss 1982).
Circulating ALP in normal adult serum is thought to be mainly of the tissue non-specific 
type, although a small amount of the intestinal isoenzyme is also present (Moss 1982, 
Mulivor et al 1985). ALP activity in body fluids may originate from the breakdown and 
desquamation of microvillar membranes or from the differential release of the enzyme 
from microvillar membranes by specific phospholipases, present in various tissues and
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body fluids, which cleave the GPl anchor (Davitz et al 1987, Davitz et al 1989, 
Hamilton et al 1989, Raymond et al 1991, De Broe and Moss 1992, Deng et al 1992).
The ALP isoenzymes hydrolyse a variety of monophosphate esters at a high optimum 
pH, although the physiological significance of this role in vivo is not clear. ALP may 
have an important role in bone mineralisation due the association between reduced 
levels of tissue non-specific ALP and abnormal bone mineralisation in the disease 
hypophosphatasia (Mulivor et al 1978b). Makiya and Stigbrand (1992) proposed that 
due to its affinity for immunoglobulin G (IgG) molecules, placental ALP may be 
involved in the transport of IgG across the placenta to the fetus. ALP may also be 
involved in the binding and transport of substances across microvillar membranes.
1.4.5.1 ALP In Normal Pregnancy.
Mulivor et al (1978a) identified the existence of a fetal form of the intestinal ALP 
isoenzyme which is electrophoretically distinct from the adult intestinal form. There 
was no evidence for the existence of fetal forms of the tissue non-specific and liver 
isoenzymes. The major difference between the fetal and adult intestinal ALP was their 
carbohydrate content, although differences in their electrophoretic mobility after 
treatment with neuraminidase suggested possible differences in the protein structure. 
Behrens et al (1983) proposed that the fetal isoenzyme was composed of two non­
identical subunits, one similar to that of the placental isoenzyme and the other, a 
glycosylated form of the adult intestinal ALP. This suggests that expression of fetal 
Intestinal ALP does not arise from the existence of a separate genetic loci, but from 
the co-expression of the placental and adult intestinal genes during fetal development.
ALP levels in the maternal circulation during pregnancy are increased due to the 
contribution of the placental isoenzyme (Mulivor et al 1985). Synthesis of the placental
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isoenzyme in the syncytiotrophoblast occurs from around the 7th week of gestation 
(Okamoto et al 1990). Low levels of placental ALP activity have been detected in 
maternal circulation from 8 weeks gestation and activity increases throughout 
pregnancy, with a marked increase after the second trimester (Okamoto et al 1990).
Muller et al (1988) reported that total ALP activity in amniotic fluid was extremely low 
until 13 weeks gestation at which stage ALP activity increased corresponding to the 
disappearance of the anal membrane. Amniotic fluid ALP activity increases to a peak 
at around 18 weeks gestation followed by a decline in activity to a plateau at around 
24 weeks, with a further increase in activity after 28 weeks gestation (Seelen 1978, 
Mulivor et al 1979, Muller et al 1988, Campbell et al 1992b). Mulivor et al (1979) 
demonstrated that the relative contributions of the ALP isoenzymes to total ALP 
activity in the amniotic fluid changed considerably as pregnancy progressed. At 14-22 
weeks gestation the major isoenzyme in the amniotic fluid was the intestinal 
isoenzyme of fetal origin (81%), with a small contribution from the tissue non-specific 
(15%) and placental (4%) isoenzymes. Later in pregnancy (25-44 weeks gestation) the 
intestinal isoenzyme was found to contribute to only 5% of total ALP activity, while the 
proportions of placental and tissue non-specific activity had increased (placental - 
27%, tissue non-specific - 69%). High levels of ALP are present in the fetal intestine 
and in meconium (Dahlquist and Lindberg 1966). Intestinal ALP in the amniotic fluid 
may be derived from the fetal intestine as a result of desquamation of intestinal 
epithelia. The demonstration that a proportion of ALP activity in the amniotic fluid is 
bound to microvillar membrane fragments, thought to originate primarily from the fetal 
intestine, supports this theory (Jalanko et al 1985, Potier et al 1986). Mulivor et al 
(1979) proposed that in early pregnancy some placental ALP may enter the amniotic 
fluid directly from the placenta and that the increase in placental ALP levels with
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gestation can be attributed to an increased contribution of placental ALP from the 
maternal circulation.
1.4.6.2 ALP in Complications of Pregnancy.
The activity of total ALP in the amniotic fluid is significantly reduced in pregnancies 
with a fetus affected by cystic fibrosis (Brock et al 1984, Aitken et al 1985, Mulivor et al
1987). Elevated amniotic fluid ALP activity has been reported In association with a 
number of fetal abnormalities including intra-uteri ne fetal death, abdominal wall 
defects, hydrops fetalis syndrome and Meckel’s syndrome (Jalanko et al 1983a), while 
low amniotic fluid ALP activity has been reported in cases of fetal intestinal 
obstructions (Morin et al 1987). Brock and Barron (1988) reported that maternal 
plasma placental ALP activity was significantly elevated in pregnancies with 
subsequent low birth weight outcome.
1.4.5.3 ALP in Chromosomally Abnormal Pregnancies.
The activity of total ALP in amniotic fluid has been reported to be reduced in 
association with Down’s syndrome and Trisomy 18 (Jalanko et al 1983a, Morin et al
1987). Brock et al (1984) reported that the ratio of phenylalanine-resistant ALP (tissue- 
non-specific ALP) and homoarginine-resistant ALP (placental and intestinal) was 
abnormal in amniotic fluid from a small proportion of Down’s syndrome (11%) and 
Trisomy 18 (21%) pregnancies. In contrast. Giddy et al (1989) found that the activities 
of phenylalanine-resistant ALP and homoarginine-resistant ALP in amniotic fluid from 
Down’s syndrome pregnancies were not significantly different from normal. Ind et al 
(1993) investigated the activity of the placental isoenzyme in amniotic fluid from
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Down’s syndrome pregnancies and found that placental ALP activity was significantly 
lower than normal.
Brock et al (1990) reported that the activity of placental ALP in first trimester maternal 
serum from Down’s syndrome pregnancies was not significantly different form normal.
Urea-resistant neutrophil alkaline phosphatase (URNAP) is present in normal human 
polymorphonuclear leukocytes. Grozdea et al (1984) reported a significant increase in 
URNAP activity in women who had previously given birth to a Down’s syndrome child. 
Cuckle et al (1990b) investigated maternal URNAP activity in 72 women with Down’s 
syndrome pregnancies prior to therapeutic termination, and in 156 unaffected 
pregnancies. Maternal blood films were stained for URNAP activity and a semi- 
quantitative technique was used to estimate enzyme activity. The median URNAP 
activity the Down’s syndrome pregnancies was 1.65 times higher than in the controls.
1.4.6 GAMMA GLUTAMYL TRANSFERASE.
Gamma glutamyl transferase (GGT) is an enzyme found on the external surface of 
cells which exhibit a high secretory or absorptive capacity. GGT activity is most 
prominent in the kidney, but Is also present in the liver, pancreas, intestine, lung, 
testes, epididymis, spleen and placenta (Rosalki 1975). GGT in tissues is present 
primarily as a membrane bound form. It is made up of two subunits of unequal size 
(22kDa and 62kDa) and is bound to the microvillar membrane via a single hydrophobic 
anchoring sequence located at the N-terminus of the large subunit. The smaller 
hydrophilic subunit, on which the catalytically active site is located, extends into the 
extracellular compartment (Semenza 1986). GGT in tissues also exists in a soluble 
form which contributes to around 10% of tissue GGT activity (Szewozuk 1966). High
63
levels of GGT activity have been reported in bile and seminal plasma (Rosalki and 
Rowe 1973, Wenham et al 1982). GGT activity is also present in serum, urine and at 
very low levels in cerebrospinal fluid (Swinnen 1967, Beck 1978).
A number of isoenzymes of GGT have been identified which exhibit marked 
heterogeneity with respect to lectin affinity and electrophoretic mobility. These 
differences are evident between isoenzymes from different tissues and are probably 
due to variations in post-translational modifications (Shaw et al 1980, Huseby 1981).
The liver is likely to be the main source of GGT activity in serum due to the 
demonstration of similarities In electrophoretic mobility, lectin affinity and kinetic 
properties of the liver and serum isoenzymes (Naftalin et al 1969, Shaw et al 1980, 
Huseby 1981). GGT activity present in body fluids is thought to arise directly from the 
cells of the liver and kidney by a process of cell breakdown and desquamation 
(Rosalki 1975).
A cluster of genes coding for GGT has been mapped to the long arm of chromosome 
22 (Bulle et al 1987). Figlewicz et al (1993) not only identified three GGT genetic loci 
on chromosome 22, but also GGT related sequences on chromosomes 18,19 and 20.
As a key enzyme in the gamma glutamyl cycle, GGT is involved in the metabolism of 
glutathione. GGT catalyses the transfer of the gamma glutamyl moiety from 
glutathione (and other gamma glutamyl peptides) to other peptides, amino acids, water 
and to glutathione itself. The gamma amino acids formed by GGT are transported into 
cells where they are converted into the corresponding amino acids for réutilisation. 
Glutathione itself is reformed in the gamma glutamyl cycle and is involved, either 
directly or indirectly, in a number of biological processes including DNA and protein
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synthesis, metabolism, enzyme activity, transport and cellular protection (Meister and 
Anderson 1983).
1.4.6.1 GGT in Normal Pregnancy.
Levels of GGT in the maternal circulation during pregnancy have been reported as 
normal (Lum and Gambino 1972) and reduced (Rosalki et al 1970). Rosalki (1975) 
reported that plasma levels of GGT decrease with advancing gestation with levels in 
the third trimester being almost half that of non-pregnant female controls. Other 
studies have shown that there is no significant change in GGT activity with gestation 
(Jalanko et al 1983b, Moniz et al 1984).
GGT activity in the fetal serum is approximately 10 times greater than in maternal 
serum and there is no significant change in activity with advancing gestation (Moniz et 
al 1984).
Kottegen et al (1976) demonstrated that GGT exists in two forms in the liver and small 
intestine depending on the stage of development. A sialic acid rich fetal GGT, which 
does not bind to Concanavalin-A (Con-A), was found in the fetal liver and small 
intestine and in undifferentiated cryptal cells of the adult small intestine. A sialic acid 
poor adult GGT, which bind Con-A, was present in the adult liver and small intestine.
In the amniotic fluid, GGT activity is extremely low until the 13th week of gestation 
when there is a sharp increase in the levels of enzyme activity (Muller et al 1988). 
GGT activity reaches a maximum around 15-16 weeks gestation, after which activity 
decreases to a plateau which is maintained to term (Jalanko et al 1983b, Moniz et al 
1984, Muller et al 1988). Moniz et al (1984) reported that amniotic fluid contained at 
least two isoenzymes of GGT, the main isoenzyme having the same electrophoretic
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mobility as that of the fetal serum. The contribution of the adult form of GGT to the 
total GGT activity decreased as gestation advanced. In the amniotic fluid, a high 
proportion of GGT activity was shown to be bound to a particulate fraction containing 
microvillar membrane fragments thought to originate primarily from the fetal intestinal 
epithelia (Jalanko et al 1985, Potier et al 1986). This indicates that the fetal intestine 
may be a major source of amniotic fluid GGT activity through cell breakdown and 
desquamation of the intestinal epithelia. Jalanko et ai (1983b) demonstrated that 
considerable GGT activity was present in a number of fetal tissues including the 
intestine, kidney, liver, placenta and fetal membranes. Second trimester bile and 
meconium contained the highest GGT activities. All of these sources may contribute to 
amniotic fluid GGT activity.
1.4.6.2 GGT in Complications of Pregnancy.
GGT levels are significantly reduced in amniotic fluid from pregnancies with a fetus 
affected by cystic fibrosis (Carbarns et ai 1983, Brock et al 1984, Aitken et al 1985, 
Mulivor et al 1987). Abnormal amniotic fluid GGT activity has also been associated 
with a number of other fetal abnormalities including Meckel’s syndrome, abdominal 
wall defects, neural tube defects, intestinal and biliary atresia and congenital nephrosis 
(Carbarns et al 1983, Jalanko et al 1983b, Buamah et al 1984, Morin et al 1987, Muller 
et al 1988).
1.4.6.3 GGT in Chromosomally Abnormal Pregnancies.
GGT activity in amniotic fluid from Down’s syndrome, Trisomy 18 and Trisomy 13 
pregnancies is significantly lower than the levels found in unaffected pregnancies 
(Jalanko and Aula 1982, Brock et al 1984, Buamah et al 1984, Morin et al 1987, 
Macek et al 1987, Jones ad Evans, Giddy et al 1988, Zeitune et al 1989). Combining
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the results of eight published studies, amniotic fluid GGT activity was below the control 
group median in 91% of Down’s syndrome pregnancies (n-234), 96.4 % of Trisomy 18 
pregnancies (n=56) and 94.1% of Trisomy 18 pregnancies (n=17) (Zeitune et al 1989).
1.5 OTHER MARKERS IN CHROMOSOMALLY ABNORMAL
PREGNANCIES.
1.5.1 UNCONJUGATED OESTRIOL.
Oestriol, the major oestrogen produced during pregnancy, is synthesised in the 
placenta from the fetal precursor 16a-hydroxy-dehydroepiandrosterone-sulphate. The 
concentration of oestriol in maternal serum and amniotic fluid increases throughout 
pregnancy (Belisie and Tulchinsky 1988, Russell 1989). Oestriol undergoes sulphate 
or glucuronide conjugation in the maternal liver, however, a small proportion ( - 10%) of 
oestriol remains unconjugated (UE3).
The concentration of ÜE3 is reduced in maternal serum from Down’s syndrome 
pregnancies in second trimester (Canick et al 1988, Wald et al 1988b, Del Junco et al 
1989, Osanthanondh et al 1989, Hey I et al 1990, Norgaard-Pedersen et al 1990, 
MacDonald et al 1991, Haddow et al 1992, Mancini et al 1992, Phillips et al 1992, 
Ryall et al 1992, Spencer et al 1992a, Crossley et al 1993). In a meta analysis of 11 
published studies, including a total of 363 Down’s syndrome pregnancies, the overall 
median second trimester maternal serum UE3 level was 0.73 MOM in the affected 
cases (Wald and Cuckle 1992). Maternal serum UE3 levels are also reduced in the first 
trimester of Down’s s syndrome pregnancies, with median levels in the range of 0.35-
0.73 MOM (Cuckle et al 1988, Brock et al 1990, Crandall et al 1991, Aitken et al 
1993a, Crandall et al 1993). In Trisomy 18 pregnancies, maternal serum UE3 levels
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are reduced in both the first and second trimesters (Canick et a! 1990, Aitken et a! 
1993a, Barkai et a! 1993, Crandall et al 1993, Crossley et al 1993).
Cuckle et al (1991) reported that the concentration of UEa in second trimester amniotic 
fluid from Down’s syndrome pregnancies was reduced to 0.50 MOM.
1.5.2 INHIBIN.
inhibin is produced by the testes and the ovary and suppresses the secretion of
follicle-stimulating hormone (FSH) from the pituitary. Inhibin is a 32kDa dimeric protein 
composed of two non-identical subunits, an a-subunit and one of two p-subunits (pA 
and pB). Thus two forms of inhibin exist; inhibin-A (a-pA) and inhibin-B (a-pB) (Mather 
et al 1992). The placenta is the most likely source of circulating inhibin during 
pregnancy (Petraglia et al 1987, Mather et al 1992). The concentration of inhibin in the 
maternal circulation increases to a peak at 8-10 weeks gestation, followed by a 
decrease to a plateau between 14 and 30 weeks, with a subsequent increase so that 
the highest levels are reached at term (Abe et al 1990, Tabei et al 1991). Maternal 
serum concentrations of inhibin are elevated in the second trimester of Down's 
syndrome pregnancies (Van Lith et al 1992, Spencer et al 1993c).
1.5.3 CANCER ANTIGEN 125.
Cancer antigen 125 (CA125) is a tumour associated protein which can be detected in 
maternal serum and amniotic fluid during pregnancy (Niloff et al 1984, O’Brien et al 
1986, Campbell et al 1992). The concentration of CA125 in maternal serum is high 
during the first trimester and then decreases during the second trimester to low levels 
at term (Niloff et al 1984). Amniotic fluid CA125 levels are high in early pregnancy and
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decrease towards term (Niloff et al 1984, Kobayashi et al 1989). The decidua contains 
high concentrations of CA125 and is the most likely source of CA125 during 
pregnancy (O’Brien et al 1986, Kobayashi et al 1989, Jacobs and Bast 1989). CA125 
Is also present at high concentrations in the amnion and chorion (O’Brien et al 1986, 
Kobayashi et al 1989)
The data on maternal serum CA125 concentrations in Down’s syndrome pregnancies 
are variable. Van Lith et al (1991b) reported that first trimester maternal serum CA125 
levels were reduced in Down’s syndrome pregnancies. However, other studies 
reported that maternal serum CA125 levels were not significantly different from normal 
in either the first or second trimesters of Down’s syndrome pregnancies (Spencer 
1991b, Norton and Golbus 1992, Van Blerk et al 1992, Van Lith et al 1993). In 
contrast, Hogdall et al (1992) reported that CA125 levels were increased in first and 
second trimester maternal serum from Down’s syndrome pregnancies. Van Blerk et al 
(1992) reported that amniotic fluid CA125 levels in Down’s syndrome pregnancies 
were not significantly different from normal. In contrast, Borri et al (1993) reported that 
amniotic fluid CA125 levels were significantly increased in Down’s syndrome 
pregnancies.
1.5.4 PROGESTERONE.
Progesterone is a steroid hormone which is secreted by the corpus luteum and by the 
placenta. Maternal serum concentrations of progesterone increase in a sigmoidal 
fashion throughout pregnancy. In amniotic fluid, the highest concentrations of 
progesterone are reached between 10 and 20 weeks gestation, with a gradual decline 
thereafter (Belisie and Tulchinsky 1988).
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Cuckle et ai (1990a) reported that progesterone levels were significantly increased to 
1.20 MOM in second trimester maternal serum from 77 Down’ syndrome pregnancies. 
Two other studies have also reported that maternal serum progesterone levels are 
elevated in the second trimester of Down’s syndrome pregnancies (Knight et al 1989, 
Kratzer et al 1991b). In contrast, Ryall et al (1992) reported that second trimester 
maternal serum progesterone levels in Down’s syndrome pregnancies were not 
significantly different from in unaffected pregnancies. Kratzer et al (1991b) reported 
that first trimester maternal serum progesterone levels in Down’s syndrome 
pregnancies were not significantly different from normal, whereas in Trisomy 18 and 
Trisomy 13 pregnancies, progesterone levels were significantly reduced.
1.5.5 HUMAN PLACENTAL LACTOGEN.
Human placental lactogen (hPL) is a glycoprotein hormone which is made in the 
syncytiotrophoblast of the placenta. The concentration of hPL in the maternal 
circulation increases in a sigmoidal fashion throughout pregnancy (Guibai et al 1980, 
Kilman and Feinberg 1992). The concentration of hPL in amniotic fluid is lower than in 
maternal serum and increases gradually throughout pregnancy (Belisie and Tulchinsky
1988). Maternal serum concentrations of hPL have been reported to be elevated in 
Down’s syndrome pregnancies (Knight et al 1989, Ryall et al 1992).
1.6 POSSIBLE CAUSES OF MARKER CHANGES IN CHROMOSOMALLY
ABNORMAL PREGNANCIES.
From the above it is clear that a complex pattern of variation in the concentration of 
biochemical markers exists in maternal serum and amniotic fluid from trisomie
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pregnancies. However, the mechanisms which give rise to these changes in Down’s 
syndrome, Trisomy 18 and Trisomy 13 pregnancies are poorly understood.
It was proposed initially that fetal and placental immaturity was the cause of the 
abnormal levels of AFP, UE3 and hCG in the second trimester of Down’s syndrome 
pregnancies, reduced AFP and UE3, and elevated hCG levels being characteristic of 
fetal and placental production at an earlier gestation (Canick et al 1988, Wald et al
1988). However, the elevation of SP-1 levels in the second trimester of Down’s 
syndrome pregnancies contradicts this theory. Librach et al (1988) reported that there 
was no difference In the weights of Down’s syndrome fetuses compared to unaffected 
fetuses in the second trimester. Kucera (1971) measured the prenatal growth of 563 
Down’s syndrome fetuses from 29 weeks of gestation to term. There was no evidence 
of abnormal growth of Down’s syndrome fetuses compared to normal until the last few 
weeks of term. Shepard et a! (1989) found no evidence of reduced placental weight in 
association with Down’s syndrome pregnancies. Waller et al (1992) investigated levels 
of AFP in maternal serum from 54 women who subsequently gave birth to a Down’s 
syndrome child. They found no significant association between maternal serum AFP 
levels and birth weight in Down’s syndrome pregnancies.
In Trisomy 18 pregnancies the size of the placenta is generally smaller than in normal 
pregnancies (Shepard et al 1989) and placental insufficiency may be a cause of low 
serum AFP and hCG levels in Trisomy 18 pregnancies. However, normal serum SP-1 
levels in both the first and second trimesters of Trisomy 18 pregnancies suggest the 
explanation may be more complex.
Merkatz et al (1984) postulated that altered trophoblast production or reduced 
clearance by the placenta, rather than reduced fetal synthesis, may be responsible for 
low maternal serum AFP levels in Down’s syndrome pregnancies. However, this was
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based on their finding that amniotic fluid AFP levels were normal. As described 
previously, subsequent studies have shown that amniotic fluid AFP levels are reduced 
in Down’s syndrome pregnancies. Voitlander and Vogel (1986) proposed that due to 
the reduction in serum albumin levels in Down’s syndrome patients and the close 
proximity of the AFP and albumin genes on chromosome 4, the reduction of AFP and 
albumin in Down’s syndrome (both prenatally and postnatally) are caused by 
disruption of a common regulatory mechanism. Some authors have suggested that low 
maternal serum and amniotic fluid AFP levels in Down’s syndrome pregnancies may 
be due to reduced or delayed synthesis of AFP by the fetal liver (Cuckle et al 1984, 
Davis et al 1986, Crandall et al 1988). Some support for this theory was obtained from 
the results of a study by Cuckle and Wald (1986), which showed that AFP levels were 
significantly reduced in cord blood at term from 22 babies with Down’s syndrome. 
However, Nicolini et al (1988) and Scioscia et al (1988) both reported that second 
trimester fetal serum AFP levels were normal in cases of Down’s syndrome. Seller 
(1990) also measured serum levels of AFP in Down’s syndrome fetuses and found 
that levels were normal prior to 20 weeks gestation, after which serum AFP levels 
declined more rapidly in Down syndrome fetuses than in normal fetuses. Kronquist et 
al (1990a) examined fetal hepatic AFP in a total of 28 cases of Down’s syndrome and 
47 unaffected controls. There was no difference in the structure of the mRNA 
transcript or in the average mass or charge of the AFP polypetide in the Down’s 
syndrome and unaffected cases. This suggests that mRNA processing and post- 
translational modifications of the AFP polypeptide are not altered in Down’s syndrome. 
The mean level of AFP per mg of protein in fetal liver homogenates was significantly 
reduced in cases of fetal Down’s syndrome at 17-23 weeks gestation. However, 
further Investigation, including affected cases at 12.7-14.9 weeks gestation, revealed 
that this reduction was significant only at 17-19 weeks gestation (Kronquist et al 1994). 
Jones et al (1988) found that there was no significant difference in the percentage 
contributions of Con-A binding (fetal liver origin) and Con-A non-binding (yolk sac
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origin) AFP in amniotic fluid from normal and Down’s syndrome pregnancies. These 
results suggest that it is unlikely that reduced fetal synthesis of AFP is the fundamental 
cause of low maternal serum and amniotic fluid levels of AFP In Down’s syndrome 
pregnancies noted in the first and second trimesters. Other mechanisms have been 
proposed including impaired kidney function and abnormal membrane or placental 
passage (Nicolini et al 1988, Scioscia et al 1998, Seller 1990, van Lith et al 1991).
Nicolini et al (1988) reported that AFP levels In fetal serum may be reduced in 
association with Trisomy 18 (0.78 MOM), suggesting that reduced hepatic synthesis of 
AFP may be the underlying cause of lower than normal maternal serum AFP levels in 
Trisomy 18 pregnancies. AFP levels in the amniotic fluid of Trisomy 18 pregnancies 
may be restored to normal by a lack of fetal swallowing giving rise to reduced turnover 
of AFP (Zeitune et al 1989).
HCG, PAPP-A, SP1 and placental ALP are all products of the placenta and It is 
possible that there may be a common mechanism which may affect the levels of these 
markers in Down’s syndrome pregnancies. Chard (1991) proposed that in Down’s 
syndrome pregnancies there is a general reduction in the levels of products of fetal 
origin and a general increase in products of placental origin. However, subsequent 
studies have shown that there is considerable variation in the changes in the maternal 
serum concentrations of placental markers in Down’s syndrome pregnancies. Intact 
hCG is elevated in the second trimester of Down’s syndrome pregnancies but only 
slightly increased in the first trimester, while FphCG is elevated in both the first and 
second trimesters. Maternal serum PAPP-A and SP1 levels are reduced in the first 
trimester Down’s syndrome pregnancies, however, in the second trimester SP1 levels 
are elevated while PAPP-A levels are unchanged. Maternal serum placental ALP does 
not appear to be altered in the first trimester of Down’s syndrome pregnancies. Lack of 
appropriate decline of Intact hCG levels after 10 weeks gestation may be the cause of
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GGT activity is substantially decreased in amniotic fluid from pregnancies with a fetus 
affected by autosomal trisomy or CF. Heeley and Fagan (1984) proposed that the 
abnormalities associated with OF and Trisomy 18 were caused by a common defect 
due to the elevated levels of blood immunoreactive trypsin in OF and Trisomy 18 
infants and the presence of common pathohistological lesions, Gosden and Gosden 
(1984) investigated the possibility that the reduction in microvillar enzyme activity 
association with autosomal trisomy and OF was further evidence for a common defect. 
They proposed that a common defect was unlikely and that in OF and Trisomy 13 
pregnancies reduced amniotic fluid microvillar enzyme activity was caused by 
disruptions in the pathways by which the enzymes reach the amniotic fluid. In Trisomy 
18 fetuses there was a deficiency of microvilli in the epithelial cells of the intestine, 
trachea and proximal renal tubules. Brock et al (1984) proposed that renal 
abnormalities, which occur in 70% of Trisomy 18 cases, may be partially responsible
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elevated levels in the second trimester (Bogart et al 1989). Kratzer et al (1990a) 
investigated the bioactivity of hCG in maternal serum from Down’s syndrome and 
unaffected pregnancies. There was no significant difference in the bioactivity of hCG 
in maternal serum from the control and Down’s syndrome pregnancies in either the 
first or second trimesters. This suggests that abnormal regulation of hCG synthesis, 
rather than the production of an abnormal hCG molecule, is more likely to be the 
cause of altered hCG levels in Down’s syndrome pregnancies. Other possible 
mechanisms for the variation of placental markers in trisomie pregnancies include 
abnormal synthesis, altered metabolic clearance, altered trophoblastic mass and 
morphological changes giving rise to changes in the secretory and synthetic capacity 
of the placenta (Bartels et al 1990, Graham et al 1992). Abnormal placental 
morphology has been described in association with fetal trisomy, in particular 
maturation of placental villi appears to be impaired in trisomie placentae (Honore et al 
1976, Rochelson et al 1990, Oberweis et al 1993).
1
Thus, no clear understanding has emerged of the mechanisms which give rise to the
for the reduction in amniotic fluid microvillar enzyme activity in Trisomy 18 
pregnancies. However, such defects are uncommon in Down’s syndrome fetuses. 
Morin et al (1987) reported that intestinal abnormalities were present in the majority of 
Down’s syndrome and Trisomy 18 cases which had low amniotic fluid microvillar 
enzyme activity.
various changes observed in maternal serum and amniotic fluid marker levels in 
Down’s syndrome and other chromosomally abnormal pregnancies.
:
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1.7 AIMS.
The aim of this study was to investigate the physiological basis of the changes in 
marker concentrations associated with chromosomally abnormal pregnancies by:
1. Measurement of endogenous levels of AFP, intact hCG, FphCG, PAPP-A,
SP1, total and placental ALP and GGT in placenta! tissue from Down’s 
syndrome, Trisomy 18 and Trisomy 13 pregnancies.
2 . Measurement of endogenous levels of AFP and GGT in fetal liver and GGT in 
fetal ileum from Down’s syndrome, Trisomy 18 and Trisomy 13 pregnancies.
3. Measurement of each of these markers in corresponding tissues from 
unaffected pregnancies to allow a comparison of the variation in marker levels 
between affected and unaffected pregnancies.
4. Investigation of the localisation of AFP, hOG, PAPP-A, SP1 and placental ALP 
in placental tissue from Down’s syndrome and unaffected pregnancies by 
immunohistochemical methods.
5. Analysis of AFP, intact hCG, FphCG, PAPP-A, SP1, total and placental ALP 
levels in corresponding second trimester maternal serum samples from Down’s 
syndrome. Trisomy 18 and Trisomy 13 pregnancies from which fetal tissues 
were obtained.
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6 . Analysis of AFP, intact hCG, FphCG, PAPP-A, SP1, total ALP, placental ALP 
and GGT levels in corresponding second trimester amniotic fluid samples from 
Down’s syndrome. Trisomy 18 and Trisomy 13 pregnancies from which fetal 
tissues were obtained.
7. Investigation of the relationship between the levels of these markers in fetal 
tissues and in corresponding maternal serum and amniotic fluid from the 
affected pregnancies.
8 . Relating the biochemical results to the pathology of the affected cases.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 BIOCHEMICAL MARKERS IN FETAL TISSUES.
2.1.1 FETAL TISSUES.
2.1.1.1 Down’s Syndrome.
Between May 1992 and March 1996 samples of fetal liver, fetal ileum and placenta 
were obtained following the therapeutic termination of 67 pregnancies in which 
prenatal diagnosis by fetal chromosome analysis had confirmed the presence of 
Down’s syndrome. Parental consent was obtained in all cases and the use of fetal 
material in this study was approved by the Yorkhill NHS Trust Ethics Committee. The 
indication for amniocentesis or chorionic villous sampling in 62 cases was a high risk 
on serum screening, in one case the indication was advanced maternal age alone and 
in 3 cases fetal abnormalities were detected on ultrasound scan (US). Reports of post 
mortem examinations were available for 55 of the Down’s syndrome fetuses and 
confirmation of the prenatal diagnosis was obtained by chromosome analysis of 
cultured fetal cells (rib, pericardium or facia lata). Of the 67 Down’s syndrome cases, 
25 had a 47,XX,+21 karyotype and 37 had a 47,XY,+21 karyotype. Five of the cases 
had chromosome translocations (47,XY,inv(5)(q13.1,q35),+21; 46,XX,-21,+t(21q,21q); 
46,XY, der(14:21)(q10,q10),+21; 46,XY,-14,t(14q,21q); 47,XX,+21, t(4q,10q). Where 
possible, the gestation of the fetus at termination of pregnancy was determined from 
the date of last menstrual period (LMP). If the LMP was uncertain or absent, or if the 
gestation by US was more than one week over or two weeks under the gestation by 
LMP, the gestation at termination was calculated from the gestation at the time of 
screening (or diagnostic testing) as determined by US. The gestation of the Down’s 
syndrome cases ranged from 10-24 weeks. A summary of the fetal tissues available at 
each gestation is given in Table 2.1.1.
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Table 2.1.1 Summary of fetal tissues available for study from Down’s syndrome and 
control tissues at each week of gestation.
Gestation Unaffected controls
Placenta Liver Ileum
Down’s syndrome 
Placenta Liver Ileum
10 - - - 1 «
11 - - - - -
12 2 2 2 “
13 5 6 5 - 1 1
14 9 12 8 2 2 2
15 4 7 8 - - -
16 12 16 15 3 4 3
17 7 7 7 2 2 1
18 5 6 6 5 7 6
19 6 9 9 8 7 6
20 2 1 1 14 13 12
21 " - - 6 10 10
22 - 2 2 5 5 4
23 - - “ 4 2 1
24 - - - 1 1 1
Total 52 65 63 51 54 47
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2.1.1.2 Trisomy 13 and Trisomy 18.
During this study fetal tissues were also collected from one Trisomy 13 and four 
Trisomy 18 pregnancies following prenatal diagnosis and subsequent termination of 
pregnancy. A summary of the fetal tissues available for study from these trisomie 
pregnancies is given in Table 2.1.2.
2.1.1.3 Unaffected Controls,
Samples of fetal liver, fetal ileum and placenta were obtained following termination of 
apparently normal pregnancies for psycho-social reasons. The fetuses were sexed 
and the gestation at termination was determined from the average foot measurement. 
The gestational age of the control fetuses ranged from 12-22 weeks gestation. A 
summary of the control fetal tissues available at each gestation is given in Table 2.1.1.
2.1.1.4 Termination of Pregnancy.
Fetal tissues were obtained from trisomie and apparently normal pregnancies following 
induction of labour by administration of Gemeprost (Cervigem) vaginal pessaries either 
alone or in combination with Mifepristone (RU486).
2.1.2 COLLECTION AND STORAGE OF FETAL MATERIAL.
Fetal tissues were obtained with minimum delay, within 24 hours if possible, after
termination of pregnancy. Three sections of placenta, one section of liver and one 
section of ileum were obtained from the majority of cases. In some cases only
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Table 2.1.2 Summary of fetal tissues available for study from Trisomy 13 and 
Trisomy 18 pregnancies.
Case no. Gestation Placenta Liver Ileum
T13/1 23 + +
T18/1 23 + + +
T18/2 22 + + "f
T18/3 21 + + +
T18/4 19 - + +
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placental tissue or only liver and ileum could be obtained. The tissues were wrapped in 
aluminium foil, snap frozen in liquid nitrogen and stored frozen at -70°C.
2.1.3 PREPARATION OF FETAL MATERIAL FOR MARKER ANALYSIS.
2.1.3.1 Placenta.
Placental tissue was removed from frozen storage (-70°C) and allowed to thaw at 
room temperature. The tissue was washed in phosphate buffered saline (PBS) (pH 
7.2) to remove excess blood. A cross-section of placenta (0.2g) was removed and 
homogenised in 1ml of extraction buffer (lOmM sodium phosphate buffer containing 
120mM sodium chloride, 2.7mM potassium chloride and 0.1% Triton X-100, pH 7.4) 
using a Potter- Elvehjem homogeniser. The homogenate was sonicated on ice at an 
amplitude of 4pm (2 x 30s), centrifuged at lOOOOg for 15 minutes and the resulting 
supernatant was used for analysis.
2.1.3.2 Liver.
Fetal liver was recovered from frozen storage (-70°C) and allowed to thaw at room 
temperature. A portion of tissue (0.2g) was removed and homogenised in 1ml of 
extraction buffer. The extraction procedure was the same as described for placental 
tissue except that the liver homogenate was not sonicated as this was found to 
inactivate the enzymes in the sample.
2.1.3.3 Ileum.
Fetal ileum was recovered from frozen storage (-70°C) and allowed to thaw at room 
temperature. A portion of tissue (50mg) was removed and any meconium was gently
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squeezed out. The tissue was homogenised in 1ml of extraction buffer using the same 
procedure as described for placental tissue.
2.1.4 MARKER ANALYSIS IN FETAL TISSUES.
2.1.4.1 Total Protein Estimation.
Total protein in the tissue extracts was measured using the method of Lowry et al 
(1951). This method is based on the reaction of certain amino acids (principally 
tyrosine, tryptophan and to a lesser extent cysteine and histidine) with a mixture 
sodium molybdate, tungstate and phosphoric acid with a copper catalyst. The 
chelation of copper to the amino acid backbone facilitates the reduction of the mixed 
metalloacids (Folin-Ciocalteu Phenol Reagent) producing a blue coloured solution 
which absorbs light strongly at 750nm.
2.1.4.1.1 Total Protein Assay Protocol.
Stock solutions A (2% sodium carbonate in 0.1M sodium hydroxide), B1 (2% copper 
sulphate in distilled water) and B2 (2% sodium potassium tartrate in distilled water) 
were prepared and stored at 4°C until required. A solution (A/B1/B2) consisting of 98% 
solution A, 1% solution B1 and 1% solution B2 was prepared fresh for each assay. 
From a stock solution of 500pg/ml bovine serum albumin (BSA) in distilled water, serial 
dilutions of 500-0|xg/ml BSA were prepared. Tissue extracts were diluted (placenta 
x50, liver x50 and ileum xIO) in distilled water. All test samples and standards were 
assayed in duplicate. In appropriately labelled tubes, 80^1 of samples and standards 
were added to 800pl of A/B1/B2 solution. The tubes were vortex mixed and incubated 
at room temperature for 10 minutes. Folin-Ciocalteu Phenol Reagent (80p.l, diluted 1:1
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with distilled water) was added with thorough mixing and the samples placed in the 
dark for a minimum of 45 minutes to allow for colour development. The absorbance of 
the samples at 750nm was measured against a reagent blank using a Pye-Unicam 
8820 UVA/IS spectrophotometer. The absorbance of the standards at 750nm was 
plotted against BSA concentration (fxg/ml) to provide the standard curve from which 
the total protein content (mg/ml) of the tissue extracts was determined.
2.1.4.2 Alphafetoprotein.
AFP was measured in placental and liver extracts using an immunoradiometric assay 
(Stevenson et al 1987). The assay has been in use for routine pre-natal screening in 
the West of Scotland since 1985. This assay employs a monoclonal anti-human AFP 
antibody radiolabelled with iodine-125 and a polyclonal anti-human AFP antibody 
bound to a Sepharose solid phase. Separation of the bound and unbound fractions 
was by sucrose density sedimentation. The assay was later modified to include an 
anti-human AFP antibody coupled to magnétisable particles so that isolation of the 
bound and unbound fractions was by magnetic separation. The assay was 
standardised using the British Standard preparation 72/227.
2.1.4.2.1 AFP Assay Protocol (Sucrose Density Sedimentation).
Before assay, placental extracts were diluted xlOO in bovine serum (SAPU) and liver 
extracts were diluted x500 in bovine serum. Test samples, standards and quality 
controls were assayed in duplicate. Using a Kemble 1000 automatic sample 
processor, 25pl of sample was diluted with 200pl of assay buffer (0.1M EPPS buffer, 
pH 8.0, containing 0.1% v/v Tween 20 and 0.1% w/v sodium azide). To this was added 
200pl of assay buffer containing 2.2% v/v sheep serum (SAPU), 25pg/l '’^ ^l-labelled
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monoclonal anti-AFP (Immunodiagnostics Group, Medical Physics, Ninewells Hospital, 
Dundee) and 5g/l polyclonal sheep anti-human AFP linked to Sepharose CL-4B 
(SAPU). The samples were incubated on an orbital shaker (400rpm) for 2 1/2 hours at 
room temperature. After adding 1ml of wash solution (9g/l sodium chloride and 0.1% 
v/v Tween 20) to each tube, 3ml of density sedimentation reagent (30g/l sucrose, 0.1% 
Tween 20) was pumped into the bottom of each tube using a peristaltic pump. After 
15-30 minutes incubation, the supernatant containing the unbound fraction was 
aspirated. The bound fraction was then resuspended in 3ml of density sedimentation 
reagent and the process was repeated. Radioactivity in the bound fraction was 
measured using a Packard Cobra 5010 Gamma counter. The data was then 
processed using a four-parameter curve fitting routine (SASPRO calculation package, 
Edward and Ekins 1983). Results were expressed as KU/I.
2.1.4.2.2 AFP Assay Protocol (Magnetic Separation).
Using a Kemble 1000 automatic sample processor, 25pl of sample was diluted with 
lOOpI of assay buffer (0.1M EPPS buffer, pH 8.0, containing 0.2% v/v Tween 20 and 
Ig/I sodium azide). To this was added lOOpI of EPPS buffer containing 5% sheep 
serum, 5% bovine serum, 0.5% mouse serum and 10pg/l ^^^l-labelled monoclonal anti- 
AFP (Immunodiagnostics Group, Medical Physics, Ninewells Hospital, Dundee). The 
samples were incubated on an orbital shaker (400rpm) for 2 hours at room 
temperature, after which lOOpI of magnetic anti-AFP was added. The samples were 
then incubated for a further 30 minutes at room temperature. The tubes were washed 
with 0.5ml of wash buffer (9g/l sodium chloride and 0.1% v/v Tween 20) and placed on 
a magnetic separator for 5 minutes. The supernatant was then dumped and the 
process was repeated. Radioactivity in the bound fraction was measured using a 
Packard Cobra 5010 Gamma counter. The data was then processed using a four-
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parameter curve fitting routine (SASPRO calculation package, Edward and Ekins 
1983). Results were expressed as KU/I,
2.1.4.2.3 AFP Data Analysis.
The sucrose density sedimentation AFP assay had an inter-assay coefficient of
variation (CV) of 6.0% and an intra-assay CV of 2.5% within the working range of 5-
500KU/I. The magnetic separation assay had an inter and intra-assay CVs of less than 
10% within the working range of 2-490KU/I. AFP levels in the tissue extracts were 
converted to units per mg of protein. Median placental and liver AFP levels at each 
gestation were calculated using linear regression of logarithmically transformed data. 
AFP levels in the unaffected and Down’s syndrome tissues were converted to MOM at 
each gestation.
2.1.4.3 Human Chorionic Gonadotropin.
HCG was measured in placental tissue extracts using the Serono hCG MAIAclone kit 
(Serono Diagnostics). This assay is used for routine pre-natal screening in the West of 
Scotland and measures predominantly intact hCG (i.e. dimeric hCG) with only minimal 
recognition of the free p-subunit. The assay incorporates two monoclonal antibodies 
labelled with ^^ 1^ which bind to the intact hCG molecule and its p-subunit and one 
flourescein labelled monoclonal antibody which binds to a discrete site on the p- 
subunit forming a ‘sandwich’. The hCG-antibody complex is then bound by a sheep 
serum monoclonal anti-flourescein antibody coupled to a magnetic solid phase, 
allowing rapid sedimentation in a magnetic field.
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2.1.4.3.1 HCG Assay Protocol.
Placental homogenates and quality control samples were diluted x500 in horse serum 
containing 0.2% sodium azide. In addition to the negative (horse serum and 0.2% w/v 
sodium azide) and positive controls (horse serum with hCG and 0.2% w/v sodium 
azide) supplied with the kit, quality controls made up of pooled maternal serum (15-20 
weeks gestation) were included in the assays. The pooled sera was aliquoted and 
stored frozen (-20°C) until use. The volumes of samples, standards and reagents used 
in the assay were half those given in the manufacturers protocol.
Using a Kemble 1000 automatic sample processor, 25pl of samples, standards or 
quality controls were added to appropriately labelled tubes along with 250pl of ^^ 1^ anti- 
hCG Reagent (flourescein and ^^®l labelled mouse monoclonal anti-hCG antibodies in 
Tris buffer containing normal sheep serum, bovine serum albumin (BSA), inert dye and 
0.2% w/v sodium azide). The tubes were vortex mixed and incubated at 37°C for 15 
minutes. MAIAclone Separation Reagent (sheep antiserum to flourescein bound to 
magnetic particles in Tris buffer containing BSA and 0.1% w/v sodium azide) was 
mixed thoroughly and lOOpI was added to each tube. The tubes were mixed gently 
and incubated for 5 minutes at room temperature. The rack of tubes was placed on the 
MAIA Magnetic Separator and the particles allowed to sediment for 2 minutes. The 
supernatant was decanted from the tubes by inversion of the MAIA Magnetic 
Separator. To reduce non-specific binding, 250pl of Wash Buffer (Tris buffer 
containing 0.8% w/v sodium azide, diluted x8 in distilled water) was added and each 
tube was mixed thoroughly by vortexing. The tubes were returned to the MAIA 
Magnetic Separator and the particles were allowed to sediment for a further 2 minutes, 
after which the supernatant was decanted from the tubes. Radioactivity in the bound
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fraction was measured using a Packard Cobra 5010 Gamma counter. The data was 
then processed using the SASPRO calculation package (Edward and Ekins 1983). 
Results were expressed as lU/ml standardised against the International Reference 
preparation for hCG (75/537).
2.1.4.3.2 HCG Data Analysis.
The hCG assay had an inter-assay CV of 7.5% and an intra-assay CV of 3% within the 
range of 5-100IU/I. HCG levels In the tissue extracts were converted to lU per mg of 
protein. Median hCG levels at each gestation in unaffected placental tissue were 
calculated using an exponential regression model. HCG levels in the unaffected and 
Down’s syndrome tissues were converted to MOM at each gestation.
2.1.4.4 Free Beta Human Chorionic Gonadotropin.
FphCG was measured in placental tissue extracts using an ELISA kit provided by NTD 
Laboratories. This assay is specific for the free beta subunit and both non-competetlve 
and competetive cross-reactivity studies have demonstrated minimal cross-reactivity 
with the intact molecule (0.05% wt/wt) and with other glycoprotein hormones or their p- 
subunits (Macri eta! 1993b).
2.1.4.4.1 FphCG Assay Protocol.
Placental tissue extracts were diluted x20 in assay buffer before assay. Before 
beginning the assay all placental extracts, calibrators and controls were arranged in a 
preparation tray according to the layout of the assay plate to allow quick and efficient 
transfer of samples. Assay reagents were prepared fresh for each assay.
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To 25ml of assay buffer, 50pl Heterophilic Blocking Reagent (HBR) was added and 
mixed thoroughly. Using an eight-channel multi-pipette 100p.l of the assay buffer/ HBR 
mixture was transferred to all assay plate wells and 20pl of tissue extract, standards or 
controls were added to the appropriate wells in duplicate. The assay plate was 
covered with an adhesive plate sealer and placed on a platform rotator for 30 minutes 
(+/- 5 minutes) at 200rpm. After incubation the adhesive seal was removed, the 
contents of the assay plate discarded and the assay plate was inverted and tapped 3 
times on absorbent paper towels. Wash solution (PBS pH7.2, containing 0.05% Tween 
20) was then added to all wells, discarded and the plate tapped 3 times on absorbent 
paper tissues. This procedure was repeated until the assay plate had been washed 5 
times. After the final wash the plate was tapped 10 times on the paper towels to 
remove all residual wash solution. To each well of the assay plate, lOOpI of Reagent 1 
(20fxl Stock Biotin Conjugate in 25ml assay buffer) was added. The plate was covered 
with an adhesive seal and incubated on a platform rotator for 30 minutes (+/- 5 
minutes) at 200rpm. During this incubation, the substrate was prepared by adding 10 
ortho-phenylenediamine (OPD) tablets to 25ml of Substrate Solution. The OPD/ 
Substrate Solution was mixed thoroughly and stored in the dark until required. After 30 
minutes incubation, the assay plate was washed 5 times as described previously and 
lOOpI of Reagent 2 (Streptavidin-Horseradish Peroxidase Conjugate) was added to 
each well. The plate was covered with an adhesive sealer and Incubated for 4.5 
minutes (+/- 15 seconds) at 200rpm. The assay plate was then washed 5 times (as 
described previously) and lOOpI of OPD/Substrate Solution added to all wells. The 
assay plate was covered with an adhesive sealer and incubated on platform rotator for 
8 minutes (+/- 0.5 minutes) at 200rpm. The reaction was stopped by the addition of 
100(xl of stop solution (1.0M sulphuric acid) to all wells. The absorbance at 492nm was 
measured using a Labsystems Multiscan microtitre plate reader and data analysis was 
carried out using the Genesis calculation package (Labsystems). Results were
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expressed in ng/ml. Purified FphCG (UCB Bioproducts, Belgium) was used as a 
standard.
2.1.4.4.2 FphCG Data Analysis.
The FphCG assay had an inter-assay CV of 7.0% at 6ng/ml and 6.0% at 40ng/ml, The 
concentration of FphCG in placental tissue extracts was expressed as ng per mg of 
total protein. Median FphCG levels at each gestation in unaffected placental tissue 
were calculated using linear regression of logarithmically transformed data. FphCG 
levels in the unaffected and Down’s syndrome tissues were converted to MOM at each 
gestation.
2.1.4.5 PREGNANCY ASSOCIATED PLASMA PROTEIN A.
PAPP-A was measured in placental tissue extracts using an ELISA kit provided by 
NTD Laboratories (Spencer at al 1994). The anti-PAPP-A antibody (DAKO, A230, Lot 
No. 082) used in the assay showed no significany cross-reactivity when tested against 
non-pregnant normal human plasma (DAKO specification sheet) and does not 
significantly cross react with haptoglobin or MBP (personal communication, Dr JN 
Macri).
2.1.4.5.1 PAPP-A Assay Protocol.
Placental tissue extracts were diluted x5 in assay buffer. Before beginning the assay 
all placental extracts, calibrators and controls were arranged in a preparation tray 
according to the layout of the assay plate to allow quick and efficient transfer of 
samples. Assay reagents were prepared fresh for each assay.
Using an eight-channel multi-pipette, lOOpj of assay buffer was transferred to all assay 
plate wells and 20pl of tissue extract, standards or controls were then added to the 
appropriate wells in duplicate. The assay plate was covered with an adhesive plate
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sealer and placed on platform rotator for 30 minutes (+/- 5 minutes) at 200rpm. After 
incubation the adhesive seal was removed, the contents of the assay plate discarded 
and the assay plate was inverted and tapped 3 times on absorbent paper towels. 
Wash solution (PBS pH7.2, containing 0.05% Tween 20) was then added to all wells, 
discarded and the plate tapped 3 times on absorbent paper tissues. This procedure 
was repeated until the assay plate had been washed 5 times. After the final wash the 
plate was tapped 10 times on the paper towels to remove all residual wash solution. 
To each well of the assay plate, lOOpI of Reagent 1 (lOpI Stock Reagent 1 in 12.5ml 
assay buffer) was added. The plate was covered with an adhesive seal and incubated 
on a platform rotator for 30 minutes (+/- 5 minutes) at 200rpm. Working Substrate/ 
Chromogen Solution was prepared by adding 7ml of 3,3 ,5,5' tetramethylbenzidine 
(TMB)/ Peroxidase Substrate Solution A to 7ml of Peroxidase Solution B. The Working 
Substrate/ Chromogen Solution was mixed thoroughly and lOOpI added to all wells. 
The plate was covered with an adhesive sealer and incubated for 12 minutes at 
200rpm. After incubation lOOpI of Stop Solution (1M sulphuric acid) was added to all 
wells. The absorbance at 450nm was measured using a Labsystems Multiscan plate 
reader and data analysis was carried out using the Genesis calculation package 
(Labsystems). A third trimester pregnancy sera pool standardised against PAPP-A in 
the World Health Organisation 78/610 reference preparation for pregnancy associated 
proteins was used as a standard. Results were expressed as lU/l.
2.1.4.5.2 PAPP-A Data Analysis.
The PAPP-A assay had an inter-assay CV of 6.9% at 0.28IU/I and 6.5% at 1.08IU/I. 
The concentration of PAPP-A in placental tissue extracts was expressed as mlU per 
mg of total protein. Median PAPP-A levels at each gestation in unaffected placenta!
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tissue were calculated using logarithmic regression. PAPP-A levels in the unaffected 
and Down’s syndrome tissues were converted to MOM at each gestation.
2.1.4.6 PREGNANCY SPECIFIC BETA 1 GLYCOPROTEIN.
SP1 was measured in undiluted placental extracts by ‘Rocket’ Immunoelectrophoresis 
(Teisner et al 1978). This assay is based on the electrophoretic separation of samples 
in an agarose gel which has a central strip containing a specific antibody. During 
electrophoresis the sample migrates into the antiserum strip, becoming more dilute the 
further it travels. When the concentration of antigen in the sample reaches the 
equivalent concentration of specific antibody, an insoluble antlgen-antibody complex is 
formed. After staining, this is visualised as a ‘rocket’ peak, the area of which is 
proportional to the concentration of antigen in the test sample.
2.1.4.6.1 SP1 Assay Protocol.
The assays were standardised using a secondary standard consisting of pooled 
maternal serum samples collected routinely at 15-20 weeks gestation. The secondary 
standard was calibrated against an International reference preparation of SP1 
(Statens Seruminstitut, WHO Laboratory for Biological Standards) and had a 
concentration of 0.0281 U/ml. The internal quality control consisted of pooled sera from 
pregnant women between 15-20 weeks gestation. Both the secondary standard and 
internal quality control were aliquoted and stored at -20°C until use,
Immunoelectrophoresis plates were prepared using 1% (w/v) agarose diluted in a 1:1 
solution of gel buffer (7.5mM barbitone, 42.5mM sodium barbitone and 1.6mM calcium 
lactate in distilled water, pH 8.6) and distilled water. The agarose solution was heated
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to boiling and 10ml of the molten solution was poured onto a glass plate (8 x 8cm). 
When the agarose had solidified, a central strip representing 1/4 of the area of the 
plate was removed and replaced with 2.5ml of molten agarose containing 25pl of 
rabbit anti-human SP1 polyclonal antibody (DAKO). Using a pasteur pipette, 14 wells 
were punched in the agarose in a row directly below the antibody strip following a 
template. A second row of adjoining wells was made directly below and overlapping 
the first row, each double well being large enough to accommodate 4|nl of sample. 
Placental extracts, SP1 standard and internal quality control were applied to the wells 
in the agarose using a SGE microsyringe.
SP1 standard and internal quality control were applied in duplicate on each plate, 
while placental extracts were assayed in duplicate on separate plates. In order to 
minimise possible effects caused by fluctuation in experimental conditions, such as 
uneven distribution of antibody in the antibody strip, duplicate samples were placed in 
different positions on each plate.
A flat-bed electrophoresis tank was filled with tank buffer (3mM barbitone, 1.7mM 
sodium barbitone and 2.0mM calcium lactate in distilled water, pH 8.6) and 
electrophoresis was carried out overnight at 4°C at 2.0 volts/cm across the plate. After 
electrophoresis, the agarose was overlaid with moist filter paper and dried in a warm 
air stream. The plates were then immersed in coomassie brilliant blue stain (2g 
coomassie brilliant blue in II destain solution consisting of 100ml acetic acid, 450ml 
methanol and 450ml distilled water) until peaks could be observed in the antiserum 
strip.
The area under a peak is proportional to the concentration of SP1 in the sample 
applied to that well, but with narrow rocket' peaks, peak height may be used with little
94
error. The concentration of SP1 was calculated using the following equation. Results
were expressed as lU/ml.
SP1 conc. = test peak height (mm) x standard conc. 
standard peak height (mm)
2.1.4.6.2 SP1 Data Analysis.
The SP1 assay had an inter-assay CV of 6.6% and an intra-assay CV of 7.6% at a 
concentration of 0.026IU/ml. The concentration of SP1 in placental tissue extracts was 
expressed as lU per mg of total protein. Median SP1 levels at each gestation in 
unaffected placental tissue were calculated using linear regression. SP1 levels in the 
unaffected and Down’s syndrome tissues were converted to MOM at each gestation.
2.1.4.7 ALKALINE PHOSPHATASE.
Total and placental ALP were measured in placental tissue extracts using a 
fluorometric end point assay with 4-methylumbelliferyl phosphate (4-MUP) as a 
substrate. Placental ALP is resistant to heating at 65°C for at least 30 minutes, a 
temperature at which other ALP isoenzymes are rapidly inactivated. Placental ALP can 
be determined by measuring the residual ALP activity following heat inactivation at 
60°C for 1 hour (Aitken et al 1996).
2.1.4.7.1 Preparation of 4-Methylumbelliferone Standard Curve.
A solution of 200).iM 4-methylumbelliferone (4-MU, Sigma) was prepared by dissolving 
7.05mg of 4-MU in approximately 200^1 of acetone and then making up this solution to
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200ml with AMPD buffer (0.1M 2-amino-2-methyl-1,3-propandiol buffer containing 
0.28M sodium chloride and 0.5mM magnesium chloride, pH 9.8). A stock standard 
concentration of 4000nM 4-MU was prepared by diluting 4ml of the 200pM 4-MU 
solution in 196ml 0.4M glycine sodium hydroxide buffer (pH 10.4). A series of 
standards from 4000nM-500nM 4-MU were then prepared with 0.4M glycine sodium 
hydroxide buffer. The standards were aliquoted and stored frozen (-20°C) until use. At 
the beginning of each assay, the 4-MU standards were recovered from frozen storage, 
allowed to thaw at room temperature and mixed thoroughly. The lOOOnM 4-MU 
standard was used to standardise a Perkin Elmer MPF-44B fluorescence 
spectrophotometer to 90% of full scale deflection on the chart recorder at signal gain 1 
(excitation 365nm and emission 448nm). The fluorescence of the standards was 
measured against a glycine sodium hydroxide buffer blank and a standard curve of 
fluorescence against 4-MU concentration was prepared.
2.1.4.7.2 Measurement of Total and Placental Alkaline Phosphatase.
Placental extracts were diluted xIO in extraction buffer before assay. A pool of 
supernatant from 25 unaffected control placental homogenates was collected, 
aliquoted and stored at -20°C for use as an internal quality control. All samples were 
assayed in duplicate. Each test sample was divided into two aliquots and one aliquot 
was incubated at 60°C for 1 hour. ALP activity In both the heated (placental ALP) and 
unheated samples (total ALP) was then determined. A reaction mixture containing lOpI 
test sample, 90pl PBS (pH 7.2) and lOOpI of substrate solution (5mM 4-MUP in 0.1M 
AMPD buffer) was incubated at 37°C for 1 hour. A reagent blank containing lOpI 
extraction buffer instead of test sample was included in all assays. After incubation the 
reaction was stopped by adding 2.3ml of 0.4M glycine sodium hydroxide buffer (pH
10.4) and the fluorescence was measured using a Perkin Elmer MPF-44B
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fluorescence spectrophotometer standardised to 90% of full scale deflection on the 
chart recorder at signal gain 1 (excitation 365nm, emission 448nm and slit width 7). 
The concentration of 4-MU liberated in the reaction was determined using the 4-MU 
standard curve and the ALP activity (nmoles/hr/ml) calculated using the following 
equation.
ALP activity = 4-MU liberated (nM) x dilution factor 
incubation time (hr) x 1000
Where;
Dilution factor = 250.
Incubation time = 1 hour.
1000 = conversion from litres to ml.
2.1.4.7.3 ALP Data Analysis.
ALP activity in placental extracts was expressed as nmoles per hour per mg of total 
protein. The total ALP assay had an inter-assay CV of 7.1% and an intra-assay CV of 
6.0% at 933nmoles/hr/mg, while the placental ALP assay had an inter-assay CV of 
3.4% and an intra-assay CV of 3.3% at 1045nmoles/hr/mg. The Wilcoxon Signed- 
Rank Test was used to compare total and placental ALP levels in the placental 
homogenates. Median placental ALP levels at each gestation in unaffected placental 
tissue was calculated using linear regression of logarithmically transformed data. 
Placenta! ALP levels in the unaffected and Down’s syndrome tissues were converted 
to MOM at each gestation.
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2.1.4.8 GAMMA GLUTAMYL TRANSFERASE.
GGT was measured in extracts of placental, fetal liver and fetal ileum by kinetic 
enzyme assay using y-GT Reagent from Sigma Diagnostics. The reconstituted y-GT 
Reagent contains L-y-glutamyl-3-carboxy-4-nitroanilide (4.56mM) and glycylglycine 
(60mM). GGT catalyses the transfer of the glutamyl group from L-y-glutamyl-3- 
carboxy-4-nitroanilide to glycylglycine to produce L-y-glutamylglycylglycine and 5- 
amino-2-nitrobenzoate which absorbs light at 405nm.
2.1.4.8.1 GGT Assay Protocol.
ACCUTROL™ Normal Control Serum (Sigma Diagnostics) was used as a quality 
control for the GGT assay. This is a lyophilised human serum preparation which, when 
reconstituted in 5ml of distilled water, has a known range of GGT activity. The 
ACCUTROL™ Normal Control Serum was assayed in the same manner as the tissue 
extracts and all samples were assayed in duplicate.
y-GT Reagent was reconstituted In the appropriate volume of distilled water. A glass 
cuvette containing 1ml of y-GT Reagent was placed in the temperature controlled 
chamber of a Pye Unicam 8820 Spectrophotometer set at 37°C for a minimum of 5 
minutes to ensure that the y-GT Reagent is warmed to assay temperature. After 
appropriate dilution in distilled water (placenta-neat, liver x10, ileum x2), 40|nl of tissue 
extract was added and mixed thoroughly. The absorbance reading at 405nm was set 
to zero and the reagent mixture was incubated for 5 minutes at 37°C to allow for the 
initial lag phase of the reaction. The absorbance at 405nm was then recorded at 30 
second intervals for 5 minutes. GGT activity is directly proportional to the rate of
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increase of absorbance at 405nm and was be calculated using the following equation.
Results were expressed as U/l.
GGT activity (U/l) AA per min x TV x 1000 
9.6 X SV X LP
Where:
AA per min
TV = 
SV = 
LP = 
9.5 =
1000 =
Change in absorbance per minute at 405nm. 
Total reaction mixture volume.
Sample volume.
Lightpath (1cm).
Millimolar absorptivity of 5-amino-2- 
nitrobenzoate at 405nm.
Converts units per ml to units per litre.
2.1.4.8.2 GGT Data Analysis.
The GGT assay had an inter-assay CV of 9.9% and an intra-assay CV of 4.3% at a 
concentration of 32U/I. GGT activity in the tissue homogenates was expressed as 
units per mg of total protein. In unaffected placental tissue, median GGT levels at each 
gestation were calculated using linear regression. Median GGT levels were calculated 
using the S regression model for fetal liver extracts and by linear regression of 
logarithmically transformed data for fetal ileum extracts. GGT levels in Down’s 
syndrome and unaffected tissues were converted to MOM at each gestation.
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2.2 BIOCHEMICAL MARKERS IN MATERNAL SERUM.
2.2.1 MATERNAL SERUM SAMPLES.
The Duncan Guthrie Institute of Medical Genetics (Yorkhill NHS Trust, Glasgow) 
provides routine second trimester maternal serum screening for neural tube defects 
and Down’s syndrome in the West of Scotland. Blood samples are collected from 
pregnant women at 15 to 20 weeks gestation on attendance at antenatal clinics. The 
blood is allowed to clot and after centrifugation, the serum is aliquoted. One aliquot is 
used for the analysis of screening markers (AFP and Intact hCG) and the other aliquot 
is stored frozen at -20°C.
2.2.1.1 Down’s syndrome.
Sixty-two of the Down’s syndrome pregnancies from which fetal tissues were collected 
were identified as ‘high risk’ through routine maternal serum screening. The number of 
serum samples at each week of gestation from 15 to 20 weeks gestation is shown in 
Table 2.2.1. Maternal serum samples from 58 of the Down’s syndrome pregnancies 
were available from frozen storage for further marker analysis.
2.2.1.2 Trisomy 18.
Maternal serum, collected for routine maternal serum screening, was available for two 
of the Trisomy 18 pregnancies (T18/3 - 16 weeks gestation, T18/4 - 15 weeks 
gestation) from which fetal tissues were obtained post termination.
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Table 2.2.1 Summary of Down’s syndrome and unaffected control maternal serum 
samples at each week of gestation.
Gestation Maternal serum 
Down’s syndrome Unaffected controls
15 18 20
16 22 20
17 17 20
18 3 20
19 - 16
20 2 18
Total 62 114
■y
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2.2.1.3 Unaffected Controls.
Serum samples randomly selected from 114 presumably chromosomally normal 
pregnancies (collected routinely from 1993 to 1996) at 15 to 20 weeks gestation were 
recovered from frozen storage for use as controls. The number of serum samples at 
each week of gestation from 15 to 20 weeks gestation Is shown in Table 2.2.1.
2.2.2 MARKER ANALYSIS IN MATERNAL SERUM.
2.2.2.1 Alphafetoprotein.
Serum AFP was measured prospectively using an immunoradlometric assay 
(described in Section 2.1.4.2) as part of the routine screening programme. Maternal 
serum AFP levels, expressed as MOM, were available from the Departmental maternal 
serum screening records for 62 of the Down’s syndrome pregnancies.
2.2.2 2 Human Chorionic Gonadotropin.
Serum hCG levels were measured prospectively the Serono hCG MAIAclone kit 
(described in Section 2.1.4.3) as part of the routine screening programme. Maternal 
serum hCG levels, expressed as MOM, were available from the Departmental maternal 
serum screening records for 62 of the Down’s syndrome pregnancies.
2.2 2.3 Free Beta Human Chorionic Gonadotropin.
Maternal serum FphCG levels were measured using an ELISA provided by NTD 
Laboratories (described in Section 2.1.4.4). Control median FphCG levels (ng/ml) at
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each week of gestation from 15-20 weeks were established by the analysis of 1000 
second trimester serum samples from unaffected pregnancies in a previous study by 
Berry et al (1997). FphCG was measured in maternal serum from 58 of the Down’s 
syndrome pregnancies and results were converted to MOM using the appropriate 
gestational medians.
2 2.2.4 Pregnancy Associated Plasma Protein A.
Maternal serum PAPP-A levels were measured using an ELISA provided by NTD 
Laboratories (described in Section 2.1.4.5) following a xIO dilution in assay buffer. 
PAPP-A levels (IU/l) in maternal serum from 58 of the Down’s syndrome cases were 
converted to MOM using second trimester control medians (15-20 weeks) established 
in a study by Berry et al (1997).
2.2.2 5 Pregnancy Specific Beta 1 Glycoprotein.
Maternal serum levels of SP-1 in Down’s syndrome and unaffected pregnancies were 
measured using Rocket Immunoelectrophoresis. The technique used was identical to 
that described in Section 2.1.4.6, except that 30|il of anti-human SP-1 antibody were 
used In the antiserum strip and only 2|nl of test samples, standards and quality controls 
were loaded into single wells beneath the antiserum strip.
2.2.2.5.1 SP-1 Data Analysis.
The maternal serum SP-1 assay had an inter-assay CV of 7.8% and an intra-assay CV 
of 6.4% at a concentration of 27.2IU/I. Median serum SP-1 levels (IU/l) in the 
unaffected pregnancies were calculated for each week of gestation from 15 to 20
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weeks. Linear regression of the logarithmically transformed medians, weighted for the 
number of samples at each week of gestation, provided the regression equation from 
which smoothed gestational medians were calculated. SP-1 levels in the affected and 
unaffected samples were converted to MOM.
2.2.2 6 Alkaline Phosphatase. Î
, • 3
Total and placental ALP levels were measured in maternal serum using a modified 
version of the technique described in Section 2.1.4.7.
2.2.2.6.1 Measurement of Total and Placental ALP.
A pool of second trimester maternal serum was aliquoted and stored at -20°C for use 
as an internal quality control. Affected, unaffected and quality control samples were 
recovered from frozen storage and allowed to thaw. Each sample was divided into two 
aliquots and one aliquot was heat inactivated at 60°C for 90 minutes. Total ALP was 
measured by adding lOpI of unheated sample to 90pl PBS (pH 7.2) and lOOpI of 
substrate solution. The reaction mixture was incubated at 37°C for 30 minutes after 
which the reaction was stopped by the addition of 2.3ml of glycine sodium hydroxide 
buffer (pH 10.4). Placental ALP activity was measured by adding 20)j.l of heated 
sample to 80pl PBS (pH 7.2) and 100^1 of substrate solution. The reaction mixture was 
incubated at 37°C for one hour after which the reaction was stopped as described 
above. A reagent blank containing lOOjil PBS and lOOjil of substrate solution was 
included in both the total and placental ALP assays. Fluorescence was measured 
using a Perkin Elmer MPF-44B fluorescence spectrophotometer and the concentration 
of 4-MU liberated was determined using a 4-MU standard curve, as described in
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Section 2.1.4.7. ALP activity (nmoles/hr/ml) was calculated using the following 
equation.
ALP activity =
Where:
Dilution factor
Incubation time (hr)
1000
4-MU liberated (nM) x dilution factor 
incubation time (hr) x 1000
= 250 for unheated samples.
125 for heated samples.
= 0.5 for unheated samples.
1 for heated samples.
= conversion from litres to ml.
2.2 2.6.2 ALP Data Analysis.
The total ALP assay had an inter-assay CV of 10.3% and an intra-assay CV of 3.6% at 
1046nmoles/hr/ml, while the placental ALP assay had an inter-assay CV of 34.2% and 
an intra-assay CV of 18.8% at 36.3nmoles/hr/ml. Median total and placental ALP 
levels (nmoles/hr/ml) in the unaffected pregnancies were calculated for each week of 
gestation from 15 to 20 weeks. Linear regression of the logarithmically transformed 
medians, weighted for the number of samples at each week of gestation, provided the 
regression equation from which smoothed gestational medians were calculated. Total 
and placental ALP levels in the affected and unaffected samples were converted to 
MOM.
il
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2.3 BIOCHEMICAL MARKERS IN AMNIOTIC FLUID.
2.3.1 AMNIOTIC FLUID SAMPLES.
The Duncan Guthrie Institute of Medical Genetics receives amniotic fluid samples 
collected from women who are potential carriers of chromosomally abnormal fetuses. 
The amniotic fluid samples are centrifuged and the pelleted fetal cells are used for 
fetal chromosome analysis. The supernatant is stored frozen at -20°C.
2.3.1.1 Down’s Syndrome.
Thirty-four of the Down’s syndrome pregnancies from which fetal tissues were 
collected were prenatally diagnosed following amniocentesis. The number of amniotic 
fluid samples at each week of gestation from 15 to 21 weeks gestation is shown in 
Table 2.3.1. Amniotic fluid samples from 33 of these pregnancies were available for 
further marker analysis.
2.3.1.2 Trisomy 18.
One of the Trisomy 18 pregnancies (T18/4) from which fetal tissues were collected 
was prenatally diagnosed following amniocentesis at 17 weeks gestation. Amniotic 
fluid from this pregnancy was available for further marker analysis.
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Table 2.3.1 Summary of Down’s syndrome and unaffected control amniotic fluid 
samples at each week of gestation.
Gestation Maternal serum
Down’s syndrome Unaffected controls
15 2 20
16 5 20
17 9 20
18 11 18
19 5 20
20 1 20
21 1 14
Total 34 132
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2.3.1.3 Unaffected Controls.
Amniotic fluid samples from 132 chromosomally normal pregnancies at 15 to 20 weeks 
gestation were randomly selected from stored samples collected from 1992 to 1996 
and used as controls. The number of amniotic fluid samples at each week of gestation 
is shown in Table 2.3.1.
2.3.2 MARKER ANALYSIS IN AMNIOTIC FLUID.
2.3.2.1 Alphafetoprotein.
Amniotic fluid AFP levels were measured using Rocket Immunoelectrophoresis as part 
of the routine analysis of amniotic fluid samples for the detection of neural tube 
defects.
2.3.2.1.1 AFP Assay Protocol.
The technique used to measure AFP in amniotic fluid was similar to the described for 
that measurement of SP1 in placental homogenate (Section 2.1.4.6). The assays were 
standardised using a commercial AFP standard (Behring). The working standard had a 
concentration 28.4MU/1. An amniotic fluid pool was used as an internal quality control. 
Lyophylised anti-human AFP antibody, supplied by SARU, was reconstituted in 2ml of 
distilled water. Immunoelectrophoresis plates were prepared as described in Section 
2.1.4.6.1, except that the antiserum strip was prepared using 2.5ml of molten agarose 
containing ISpil anti-human AFP polyclonal antibody. A series of single wells, each 
accommodating 2|o,l of sample, were punched in the agarose beneath the antiserum 
strip. AFP standard, quality control and amniotic fluid test samples were applied in
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duplicate on two separate plates. Electrophoresis and staining of plates was carried 
out as described in Section 2.1.4.6.1. The concentration of AFP in the amniotic fluid 
was determined using the following equation and the average of the quadruplicate 
results was calculated. Results were expressed as MU/I.
AFP conc. = test peak height (mm) x standard conc.
standard peak height (mm)
2.3.21.2 AFP Data Analysis.
The amniotic fluid AFP assay typically has an inter-assay CV of 8.9% and intra-assay 
CV of 10.4% at a concentration of 25.4MU/I. The concentration of AFP in the amniotic 
fluid was expressed in MU/I. AFP levels in amniotic fluid from 34 Down’s syndrome 
pregnancies were converted to MOM using control gestational medians established 
from the routine analysis of several hundred amniotic fluid specimens at each 
gestation.
2.3.2.2 Human Chorionic Gonadotropin.
HCG levels in amniotic fluid from Down’s syndrome and unaffected pregnancies were 
measured using the Serono hCG MAIAclone kit (described in Section 2.1.4.3) 
following a x50 dilution in horse serum.
2.3.2.2.1 HCG Data Analysis,
Median amniotic fluid hCG levels (lU/ml) in the unaffected pregnancies were 
calculated for each week of gestation from 15 to 21 weeks. Linear regression of the
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logarithmically transformed medians, weighted for the number of samples at each 
week of gestation, provided the regression equation from which smoothed gestational 
medians were calculated. HCG levels in the affected and unaffected samples were 
converted to MOM.
2 3.2.3 Free Beta Human Chorionic Gonadotropin.
Levels of FphCG in amniotic fluid from Down’s syndrome and unaffected pregnancies 
were measured using an ELISA provided by NTD Laboratories (described in Section
2.1.4.4) following a xIO dilution in assay buffer.
2.3.2.3.1 FphCG Data Analysis.
Median amniotic fluid FphCG levels (ng/ml) in the unaffected pregnancies were 
calculated for each week of gestation from 15 to 21 weeks. Linear regression of the 
logarithmically transformed medians, weighted for the number of samples at each 
week of gestation, provided the regression equation from which smoothed gestational 
medians were calculated. FphCG levels in the affected and unaffected samples were 
converted to MOM.
2.3.2.4 Pregnancy Associated Plasma Protein A.
Levels of PAPP-A in amniotic fluid from Down’s syndrome and unaffected pregnancies 
were measured using an ELISA provided by NTD Laboratories (described in Section
2.1.4.5).
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2.3.2.4.1 PAPP-A Data Analysis.
a
Median amniotic fluid PAPP-A levels (IU/l) in the unaffected pregnancies were 
calculated for each week of gestation from 15 to 21 weeks. Linear regression of the 
logarithmically transformed medians, weighted for the number of samples at each 
week of gestation, provided the regression equation from which smoothed gestational 
medians were calculated. PAPP-A levels in the affected and unaffected samples were
The concentration of SP1 was measured in amniotic fluid from trisomie and unaffected 
pregnancies was measured by a time resolved immunofluoromethc assay (Qin et al 
1997) using a rabbit anti-SPI antibody (A131, DA KO, Denmark) labelled with Eu^ "^ - 
chelate (Wallac GY, Finland). Analysis of amniotic fluid SP1 concentration was carried 
out in the Department of Clinical Biochemistry, Statens Seruminstitut, Denmark.
2.3.2.5.1 SP1 Data Analysis.
The amniotic fluid SP1 intra-assay CV of less than 10% and inter-assay CV of 12.4% 
at 2.7mlU/l, 9.3% at 7.5mlU/l and 7.2% at 12.8mlU/l. Median amniotic fluid SP1 levels 
(mlU/l) in the unaffected pregnancies were calculated for each week of gestation from 
15 to 21 weeks. Linear regression of the logarithmically transformed medians, 
weighted for the number of samples at each week of gestation, provided the 
regression equation from which smoothed gestational medians were calculated. SP1 
levels in the affected and unaffected samples were converted to MOM.
I l l
converted to MOM.
2.3.2 5 Pregnancy Specific Beta 1 Glycoprotein.
2.3.2 6 Alkaline Posphatase.
Total and placental ALP was measured in amniotic fluid from Down’s syndrome and 
unaffected pregnancies using a modified version of the enzyme assay described in 
Section 2.1.4.7.
2.3.2.6.1 Measurement of Total and Placental ALP.
A pool of amniotic fluid samples was aliquoted and stored at -20°C for use as an 
internal quality control. Affected, unaffected and quality control samples were 
recovered from frozen storage and allowed to thaw. Each sample was divided into two 
aliquots and one aliquot was heat inactivated at 60°C for 1 hour. Total ALP was 
measured by adding 10|il of unheated sample to 90 |liI PBS (pH 7.2) and IOOp.1 of 
substrate solution. The reaction mixture was incubated at 37°C for 1 hour after which 
the reaction was stopped by the addition of 2.3ml of glycine sodium hydroxide buffer 
(pH 10.4). Placental ALP activity was measured by adding 40|al of heated sample to 
GOpI PBS (pH 7.2) and 100|il of substrate solution. The reaction mixture was incubated 
at 37°C for one hour after which the reaction was stopped as described above. A 
reagent blank containing lOOpI PBS and lOOjul of substrate solution was included in 
both the total and placental ALP assays. Fluorescence was measured using a Perkin 
Elmer MPF-44B fluorescence spectrophotometer and the concentration of 4-MU 
liberated was determined using a 4-MU standard curve, as described in Section 
2.1.4.7. ALP activity was calculated using the following equation.
ALP activity = 4-MU liberated fnM) x dilution factor
incubation time (hr) x 1000
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Where:
Dilution factor = 250 for unheated samples.
62.5 for heated samples.
Incubation time = 1 hour.
1000 = conversion from litres to ml.
2.3.2 6.2 ALP Data Analysis.
The total ALP assay had an inter-assay CV of 8.9% and an intra-assay CV of 7.5% at 
267nmoles/hr/ml, while the placental ALP assay had an Inter-assay CV of 26.9% and 
an intra-assay CV of 16.1% at 14.0nmoles/hr/ml. Median total and placental ALP 
levels (nmoles/hr/ml) in the unaffected pregnancies were calculated for each week of 
gestation from 15 to 20 weeks. Linear regression of the logarithmically transformed 
medians, weighted for the number of samples at each week of gestation, provided the 
regression equation from which smoothed gestational medians were calculated. Total 
and placental ALP levels in the affected and unaffected samples were converted to 
MOM.
2.3.2 7 Gamma Glutamyl Transferase.
GGT was measured in amniotic fluid from Down’s syndrome and unaffected 
pregnancies using the y-GT Reagent from Sigma Diagnostics (described in Section 
2.1.4.8). ACCUTROL^"^ Normal Control Serum (Sigma Diagnostics) was used as a 
quality control. For the measurement of GGT in amniotic fluid the sample volume was 
reduced to 20pl in 1ml of y-GT Reagent.
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2.3.2.7.1 GGT Data Analysis.
The amniotic fluid GGT assay had an inter-assay CV of 7.7% and an intra-assay CV of 
4.9% at 29.4U/I. GGT levels (U/l) in the unaffected pregnancies were calculated for 
each week of gestation from 15 to 20 weeks. Linear regression of the logarithmically 
transformed medians, weighted for the number of samples at each week of gestation, 
provided the regression equation from which smoothed gestational medians were 
calculated. GGT levels in the affected and unaffected samples were converted to 
MOM.
2.4 IMMUNOHISTOCHEMISTRY.
Placental tissue from 16 Down’s syndrome and 16 unaffected control pregnancies was 
selected for immunohistochemical analysis. Placental tissue from each of the Down’s 
syndrome pregnancies was matched to an unaffected control sample of the same 
gestational age and approximate length of time in frozen storage. The placental 
localisations of AFP, intact hCG, PAPP-A, placental ALP and SP-1 were investigated 
using a two-step indirect immunoperoxidase technique. In this technique, a specific 
unlabelled primary antibody is bound to antigen present in the tissue. A Horseradish 
Peroxidase (HRP) conjugated secondary antibody, directed against the 
immunoglobulin of the animal species in which the primary antibody has been raised is 
then applied. The peroxidase can then be visualised by development with the 
chromogen diaminobenzidine (DAB) and urea hydrogen peroxide to produce a brown 
product which is insoluble in alcohol, xylene and other inorganic solvents.
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2.4.1 PREPARATION OF FROZEN SECTIONS FOR IMMUNOSTAINING.
Placental tissue was recovered from frozen storage at -70^0. Frozen sections were cut 
at 4pm using a cryostat at -25^0 and picked up on Polysine slides (BDH) and air dried 
at room temperature for a minimum of 1 hour. At this stage sections can be wrapped in 
aluminium foil and stored at -20°C for a maximum of 7 days. Sections were fixed in 
acetone for 20 minutes and then air dried at room temperature.
2.4.2 INDIRECT IMMUNOPEROXIDASE TECHNIQUE FOR FROZEN 
SECTIONS.
All of the antibodies used in this study were obtained from DA KO. The primary 
antibodies were diluted to the appropriate working concentration in 0.0IM  PBS 
containing 1% normal human serum (NHS); rabbit anti-human AFP polyclonal - 1:50, 
rabbit anti-human hCG (p chain) polyclonal - 1:2000, rabbit anti-human PAPP-A 
polyclonal - 1:500, rabbit anti-human SP-1 polyclonal - 1:2000 or mouse anti-human 
placental ALP monoclonal - 1:5. The specificity of each of the antibodies has been 
ascertained by crossed-immunoelectrophoresis and/ or ELISA against non-pregnant 
human plasma and no significant cross-reaction was observed (DAKO specification 
sheet). The anti-human chorionic gonadotropin antibody shows a slight cross-reaction 
(approximately 3%) with LH. The matched Down’s syndrome and unaffected sections 
were stained in the same batch to minimise possible variations due to any differences 
in experimental conditions and to allow comparison of the stained sections. Negative 
case controls, obtained by omitting primary antibody from the staining procedure, were 
included for each case to allow monitoring of non-specific staining. A positive control 
slide of normal mid-trimester placenta, and in some cases term placenta, was also 
included in each batch.
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Fixed sections were washed in 0.01M PBS (pH 7.4) containing 0.3% Triton X-100 for 5 
minutes. Appropriately diluted primary antibody was applied to the sections and 
incubated for 30 minutes at room temperature. The sections were washed in 0.01 M 
PBS/ Triton X-100 for 5 minutes. A normal goat serum protein block (BioGenex) was 
applied to the section and incubated for 15 minutes. The slides were then drained and 
HRP-conjugated secondary antibody diluted 1/50 in 0.01 M PBS (pH 7.4) containing 
10% normal human serum was applied and incubated for 30 minutes. If the primary 
antibody was a rabbit anti-human polyclonal antibody, goat anti-rabbit immunoglobulin 
polyclonal/ HRP was used and if the primary antibody was a mouse anti-human 
monoclonal antibody, goat anti-mouse immunoglobulin polyclonal/ HRP was used. 
Slides were washed in 0.01 M PBS/ Triton X-100 for 5 minutes and then in water for 5 
minutes. The Sigma FAST DAB peroxidase substrate was prepared during the wash 
steps. Peroxidase substrate was applied to the sections and the colour was developed 
for approximately 3-5 minutes. The sections were washed in water for 5 minutes and 
then counterstained with Mayer’s haematoxylin. The sections were placed in acid 
alcohol (0.25% concentrated hydrochloric acid in methylated spirit), in water and then 
in Scott’s tap water (0.04M sodium bicarbonate, 0.16M anhydrous magnesium 
sulphate in distilled water) before being rinsed finally in water.
2.4.3 DEHYDRATION AND MOUNTING OF STAINED SECTIONS.
Sections were dehydrated through 3 changes of methylated spirits ( 3 x 5  minutes) and 
two changes of xylene ( 2 x 5  minutes). The sections were then mounted using Acrytol 
mounting medium (Surgipath).
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2.4.4 QUALITATIVE AND SEMI-QUANTITATIVE ANALYSIS OF STAINED
SECTIONS.
Stained sections were examined using an Olympus light microscope at x20 and x40 
magnification to compare the localisation of each marker in the Down’s syndrome and 
control placental sections. Semi-quantitative analysis of the stained sections was 
carried out by scoring the intensity of staining to determine if there was any difference 
between the Down’s syndrome and unaffected control placental sections. The slides 
were coded and examined using an Olympus light microscope (x20 and x40 
magnification). The staining intensity was scored blind by two people independently 
using the guidelines described in Table 2.4.1. and the results were pooled. The slides 
were then decoded and any differences in staining intensities between matched 
Down’s syndrome and unaffected placental sections were investigated using the Sign 
test.
2.5 STATISTICAL METHODS.
Statistical analysis was carried out using SPSS for Windows.
2.5.1 COEFFICIENT OF VARIATION.
The coefficient of variation (CV) is the standard deviation (SD) expressed as a
percentage of the mean (X). The inter-assay CV and intra-assay CV for each of the
assays was calculated using the following equation.
CV = (100xSD/X)%
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Table 2.4.1 Guidelines for scoring intensity of staining of placental sections.
Score Degree of staining
No staining present.
+/- Light staining but patchy and not on all villi.
+ Light staining on all villi and around circumference of villi.
++ Medium to strong staining on all villi..
+++ Strong to very strong staining on all villi and around circumference of villi.
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2.5.2 KOLMOGOROV-SMIRNOV TEST.
The Kolmogorov-Smirnov (K-S) test is used to determine how well a random sample 
of data fits a specific theoretical distribution. The test is based on a comparison of the 
sample cumulative distribution function with the hypothetical distribution function. The 
K-S test was used to determine whether the distributions of marker levels, both raw 
data and logarithmically transformed data, in unaffected tissues fitted a normal 
distribution.
2.5.3 MEDIANS.
The median is defined as the middle value of a group of observations when the data 
are arranged in order of increasing magnitude. When there is an even number of 
observations, the median is the average of the two middle observations. The position 
of the median is defined as (n+1)/2.
2.5.4 DETERMINATION OF MEDIANS BY REGRESSION ANALYSIS.
Due to the limited number of unaffected control tissues at each gestation, median 
marker levels were calculated using regression analysis. Regression analysis is a way 
of summarising the relationship between two quantitative variables by means of an 
equation. A regression equation allows that, for variables X and Y, a value of Y can be 
calculated for any given value of X. The equations for the regression models used in 
the analysis of the control data are described below. Median marker levels in the 
unaffected controls at each gestational week were calculated using the appropriate 
regression equation. Regression analysis, weighted according to the number of
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samples at each week of gestation, was also used to calculate smoothed gestational 
medians for the control maternal serum and amniotic fluid data.
Linear: Y = a + bX
Logarithmic: Y = a + bln(X)
Exponential: Y = a(e'^^)
S-curve: Y = e^  ^^
2.5.5 MULTIPLES OF THE MEDIAN.
Marker levels in both Down’s syndrome and unaffected control tissues were converted 
to multiples of the control median (MOM) of the appropriate gestational group.
MOM = marker level/ median
2.5.6 THE MANN-WHITNEY TEST.
The Mann-Whitney test is used to compare two independent samples. It is a non- 
parametric test which is valid no matter what the form of the population distributions. It 
tests the hypothesis that the population distributions of the two independent samples 
is the same. The observations from both samples are combined and ranked from 
smallest to largest. If the groups have the same distributions then the sample 
distribution of ranks should be similar. If one of the groups has a higher proportion of 
high or low ranks, there is reason to suspect that the two underlying distributions are
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different. If the significance level (p-value) is greater then 0.05, the hypothesis that the 
samples have the same distribution is not rejected.
2.5.7 THE WILCOXON SIGNED RANK TEST.
The Wilcoxon Signed-Rank test is a non-parametric test used with two related 
samples to test the hypothesis that the distributions of the two variables are the same. 
No assumptions are made about the shape of the distributions. The test was used to 
compare the levels of total and placental ALP in each of the placental homogenates. 
The differences between the pairs are ranked without considering the signs of the 
differences. Average ranks are assigned in the case of ties. The sums of the ranks for 
the positive and negative differences are then calculated. If the distributions of the two 
variable are the same, the number and magnitude of the positive and negative 
differences should be similar. If the observed significance level is greater than 0.05, 
the hypothesis that the distributions are the same is not rejected.
2.5.8 CORRELATION.
The degree of association between two variables can be quantified using the Pearson 
correlation coefficient (r). It can be calculated from the equation below, where Sx and 
Sy are the standard deviations of the x and y variables respectively.
r = Z(x-x)(v-v)
(n-1)SxSy
The value of r (+1 -> -1) indicates the strength of the relationship between the two 
variables. The largest absolute value of ‘r’ is 1, which occurs when all of the points on
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a scatter plot lie on a straight line. A value of zero indicates that there is no linear 
relationship. When 'r' is positive, there is a positive correlation between the two 
variables and when ‘r’ is negative, there is a negative correlation between the two 
variables. Significance testing is based on the hypothesis that the correlation 
coefficient is zero i.e. there is no correlation between the two variables. If the observed 
significance level is greater than 0.05, the hypothesis that there is no correlation 
between the two variables is not rejected.
2.5.9 THE SIGN TEST.
The sign test is a non-parametric test used with two related samples to test the 
hypothesis that the distributions of the two variables are the same. No assumptions 
are made about the shape of the distributions. This test was used to compare the 
scores, given on the basis of staining intensity, for each of the matched pairs Down's 
syndrome and unaffected placental sections after immunohistochemical analysis. The 
differences between the scores are calculated for each matched pair. The number of 
positive and negative differences is then determined. If the distributions of the two 
variables are the same, the numbers of positive and negative differences should be 
similar. If the observed significance level is greater than 0.05, the hypothesis that the 
distributions are the same is not rejected.
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CHAPTER 3.
RESULTS
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3.1 MARKER LEVELS IN FETAL TISSUES.
Marker levels in the fetal tissues were expressed relative to the amount of total protein 
in the tissue extract. Regression analysis was used to estimate median marker levels 
at each gestation in the unaffected control tissues for two reasons. Firstly, the 
gestational ranges of the unaffected control and Down’s syndrome pregnancies at 
termination are different. The majority of the unaffected pregnancies were terminated 
at 14-19 weeks gestation, while the majority of the Down’s syndrome pregnancies 
were terminated at 18-23 weeks gestation. Secondly, there is an insufficient number of 
control samples at each week of gestation to allow the calculation of gestation-specific 
medians as described in Section 2.5.3. Using regression analysis it is possible to fit a 
curve which best describes the relationship between marker levels and gestation and 
which can be extrapolated to cover the gestations for which there is little or no control 
data. Median marker levels at each week of gestation can be calculated from the 
equation of the regression line.
Raw control data and logarithmically transformed control data were each analysed 
using the K-S test to determine which best fitted a normal distribution. Then, using 
either the raw data or the logarithmically transformed data, the most suitable 
regression model for each of the markers in the control tissues was established. To 
allow for the change in marker concentrations with gestation, all analyte values were 
converted to multiples of the control group median at each gestation (MOM). The 
median MOM for each marker in the control tissues should be close to 1.0 MOM if the 
chosen regression model accurately describes the data.
124
3.1.1 AFP LEVELS IN PLACENTAL TISSUE.
3.1.1.1 Unaffected Controls.
The concentration profile of AFP with gestation in placental tissue from 52 unaffected 
control pregnancies at 12 to 20 weeks gestation is shown in Figure 3.1.1. Median AFP 
levels, determined by linear regression of logarithmically transformed data (AFP 
median = iQ(4 ')9-o i2xgestat,on)y are given in Table 3.1.1. Median AFP levels decrease by
an average of about 25% from week to week as gestation advances. The overall 
median AFP level, in MOM, in control placental tissue estimated using the regressed 
median values was 0.99 MOM.
3.1.1.2 Down’s Syndrome.
AFP levels, expressed as MOM, in placental tissue from 51 Down’s syndrome 
pregnancies at 10 to 24 weeks gestation are shown in Figure 3.1.2. In the majority of 
Down’s syndrome pregnancies AFP levels were greater than 1.0 MOM and there 
appeared to be a trend of rising levels with advancing gestation. The median AFP 
level in the affected pregnancies was 2.43 MOM. AFP levels in the Down’s syndrome 
and control pregnancies were compared using the Mann-Whitney test. AFP was 
significantly higher In placental tissue from Down’s syndrome pregnancies than in 
control placental tissue (p<0.001).
3.1.1.3 Trisomy 13 and Trisomy 18.
AFP levels (MOM) in placental tissue from one Trisomy 13 and three Trisomy 18
pregnancies are shown in Figure 3.1.2. The level of AFP in placental tissue from one
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Figure 3.1.1 AFP levels (U/mg) in placental tissue from 52 unaffected control
pregnancies at 12 to 20 weeks gestation. Smoothed medians across the gestational
range were calculated by linear regression of logarithmicaliy transformed data.
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Table 3.1.1 Regressed median levels of AFP in placental tissue (U/mg) and fetal 
liver (KU/mg) from unaffected control pregnancies at each week of gestation from 10 
to 24 weeks.
Gestation Median AFP levels
Placenta
(U/mg)
Liver
(KU/mg)
10 1756.31 7.77
11 1319.78 6.71
12 991.74 5.79
13 745.25 5.00
14 560.02 4.32
15 420.82 3.73
16 316.23 3.22
17 237.63 2.78
18 178.57 2.4
19 134.18 2.07
20 100.83 1.79
21 75.77 1.54
22 56.94 1.33
23 42.79 1.15
24 31.15 0.99
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Figure 3.1.2 AFP levels (MOM) in placental tissue from 51 Down's syndrome
pregnancies at 10 to 24 weeks gestation, and in one Trisomy 13 and three Trisomy 18
pregnancies.
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Trisomy 13 pregnancy was 3.25 MOM. In placental tissue from three Trisomy 18 
pregnancies AFP levels were 1.18 MOM, 3.18 MOM and 2.01 MOM.
3.1.2 AFP LEVELS IN FETAL LIVER.
3.1.2.1 Unaffected Controls.
The concentration profile of AFP in fetal liver from 68 unaffected pregnancies at 12 to 
22 weeks gestation is shown in Figure 3.1.3, Median AFP levels at each gestation 
were determined by linear regression of logarithmically transformed data (AFP median 
= '|Qh-53-o o638xgestation)j and are shown in Table 3.1.1. Median AFP levels decrease as
gestation advances from 12 to 22 weeks. Hepatic AFP levels are 10-20 times higher 
than placental AFP levels at the corresponding gestations between 15 and 20 weeks. 
The median AFP level in fetal liver from unaffected control pregnancies was 1.01 
MOM.
3.1.2.2 Down’s syndrome.
The concentrations of AFP, expressed as MOM, in fetal liver samples from 54 Down’s 
syndrome pregnancies at 13 to 24 weeks gestation are illustrated in Figure 3.1.4, AFP 
levels in the Down’s syndrome tissue extracts were distributed evenly above and 
below the control group median. The median level of AFP in the Down’s syndrome 
pregnancies was 0.97 MOM. There was no statistically significant difference in AFP 
levels in fetal liver from Down’s syndrome pregnancies compared with the normal 
control pregnancies (Mann-Whitney, p=0.26).
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Figure 3.1.3 AFP levels (KU/mg) in fetal liver from 68 unaffected control pregnancies
at 12 to 22 weeks gestation. Smoothed medians across the gestational range were
calculated by linear regression of logarithmically transformed data.
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Figure 3.1.4 AFP levels (MOM) in fetal liver from 54 Down’s syndrome pregnancies
at 13 to 24 weeks gestation, and in one Trisomy 13 and four Trisomy 18 pregnancies.
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3.1.2.3 Trisomy 13 and Trisomy 18.
AFP levels (MOM) in fetal liver from the Trisomy 13 and Trisomy 18 pregnancies are 
shown in Figure 3.1.4. The level of AFP in feta! liver from one Trisomy 13 pregnancy 
was 1.24 MOM. In fetal liver from four Trisomy 18 pregnancies AFP levels were 1.88 
MOM, 1.22 MOM, 1.83 MOM and 0.92 MOM.
3.1.3 INTACT HOG LEVELS IN PLACENTAL TISSUE.
3.1.3.1 Unaffected Controls.
The concentration profile of hCG in placental tissue from 52 unaffected control 
pregnancies at 12 to 20 weeks gestation is shown in Figure 3.1.5. Median hCG levels 
at each week of gestation, determined using an exponential regression model (intact 
hCG median = 221 ), are given in Table 3.1.2, intact hCG levels
decreased as gestation advances from 12 to 20 weeks. The overall median level of 
intact hCG in placental tissue from unaffected pregnancies was 1.19 MOM.
3.1.3.2 Down’s Syndrome.
Intact hOG levels, expressed as MOM, in placental tissue from 51 Down’s syndrome 
pregnancies at 10 to 24 weeks gestation are shown in Figure 3.1.6. In each of the 
Down’s syndrome pregnancies placental hOG levels were above the control group 
median. Intact hCG levels in placental tissue from Down’s syndrome pregnancies were 
significantly higher than in unaffected pregnancies (Mann-Whitney, p <0.001), with a 
median value of 4.06 MOM in the Down’s syndrome pregnancies.
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Figure 3.1.5 intact hCG levels (IU/mg) in placental tissue from 52 unaffected control
pregnancies at 12 to 20 weeks gestation. Smoothed medians across the gestational
range were calculated using an exponential regression model.
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Table 3.1.2 Regressed median levels of intact hCG (IU/mg) in placental tissue from 
unaffected control pregnancies at each week of gestation from 10 to 24 weeks.
Gestation Median intact hCG levels 
(IU/mg)
10 9.10
11 6.61
12 4.81
13 3.49
14 2.54
15 1.85
16 1.34
17 0.98
18 0.71
19 0.52
20 0.37
21 0.27
22 0.2
23 0.14
24 0.10
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Figure 3.1.6 Intact hCG levels (MOM) in placental tissue from 51 Down’s syndrome
pregnancies at 10 to 24 weeks gestation, and in one Trisomy 13 and three Trisomy 18
pregnancies.
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3.1.3.3 Trisomy 13 and Trisomy 18.
Intact hCG levels (MOM) in placental tissue from the Trisomy 13 and Trisomy 18 
pregnancies are shown in Figure 3.1.6. The level of intact hCG in placental tissue from 
one Trisomy 13 pregnancy was 4.20 MOM. In placental tissue from three Trisomy 18 
pregnancies intact hCG levels were 0.59 MOM, 2.97 MOM and 0.31 MOM.
3.1.4 PpHCG LEVELS IN PLACENTAL TISSUE.
3.1.4.1 Unaffected Controls.
The concentration profile of the free beta subunit of hCG in placental tissue from 52 
unaffected pregnancies Is illustrated In Figure 3.1.7. Gestational medians were 
calculated by linear regression of logarithmically transformed data (pphCG median
=  gestation)  ^ given in Table 3.1.3. Placental levels of FphCG
decreased with gestation from 12 to 20 weeks. The overall median level of FphCG in 
placental tissue from unaffected placental tissue Is 1.05 MOM.
3.1.4.2 Down’s Syndrome.
Placental levels of FphCG, expressed as MOM, in 51 Down’s syndrome pregnancies 
at 10 to 24 weeks gestation are shown in Figure 3.1.8. The majority of the Down’s 
syndrome cases had placental FphCG levels above the control group median. FphCG 
levels in placental tissue from Down’s syndrome pregnancies were significantly higher 
than in unaffected pregnancies (Mann-Whitney, p<0.001). The overall median level of 
FphCG in placental tissue from Down’s syndrome pregnancies was 3.40 MOM.
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Figure 3.1.7 FphCG levels (ng/mg) in placental tissue from 52 unaffected control
pregnancies at 12 to 20 weeks gestation. Smoothed medians across the gestational
range were calculated by linear regression of logarithmically transformed data.
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Table 3.1.3 Regressed median levels of FphCG (ng/mg) in placental tissue from 
unaffected control pregnancies at each week of gestation from 10 to 24 weeks.
Gestation Median FphCG levels 
(ng/mg)
10 285
11 210
12 154
13 114
14 83.6
15 61.6
16 45.3
17 33.4
18 24.6
19 18.1
20 13.3
21 9.80
22 7.22
23 5.31
24 3.91
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Figure 3.1.8 FphCG levels (MOM) in placental tissue from 51 Down’s syndrome
pregnancies at 10 to 24 gestation, and in one Trisomy 13 and three Trisomy 18
pregnancies.
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3.1.4.3 Trisomy 13 and Trisomy 18.
FphCG levels (MOM) in placental tissue from the Trisomy 13 and Trisomy 18 
pregnancies are shown in Figure 3.1.8. The level of FphCG in placental tissue from 
one Trisomy 13 pregnancy was 0.95 MOM. In placental tissue from three Trisomy 18 
pregnancies FphCG levels were 1.66 MOM and 0.04 MOM in cases T18/2 and T18/3 
respectively, and undetectable (below assay sensitivity) in case T18/1.
3.1.5 PAPP-A LEVELS IN PLACENTAL TISSUE.
3.1.5.1 Unaffected Controls.
The concentration profile of PAPP-A in placental tissue from 52 unaffected 
pregnancies at 12 to 20 weeks gestation is shown in Figure 3.1.9. Median PAPP-A 
levels at each gestation were determined using logarithmic regression (PAPP-A 
median = -0.142+0.114 In(gestation)) and are given in Table 3.1.4. Median levels of 
PAPP-A in unaffected placental tissue increased gradually from 12 to 20 weeks 
gestation. The overall median level of PAPP-A in placental tissue from unaffected 
pregnancies was 0.84 MOM.
3.1.5.2 Down’s Syndrome.
Placental levels of PAPP-A, expressed as MOM, in 51 Down’s syndrome pregnancies 
at 10 to 24 weeks gestation are shown in Figure 3.1.10. PAPP-A levels were evenly 
distributed above and below the control group median and were not significantly 
different from normal (Mann-Whitney, p=0.304). The overall median placental level of 
PAPP-A in the Down’s syndrome pregnancies was 0.96 MOM.
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Figure 3.1.9 PAPP-A levels (mlU/mg) in placental tissue from 52 unaffected control
pregnancies at 12 to 20 weeks gestation. Smoothed medians across the gestational
range were calculated by logarithmic regression.
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Table 3.1.4 Regressed median leveis of PAPP-A (mlU/mg) in placental tissue from 
unaffected control pregnancies at each week of gestation from 10 to 24 weeks.
Gestation Median PAPP-A levels
10 0.120
11 0.131
12 0.141
13 0.150
14 0.158
15 0.173
16 0.173
17 0.180
18 0.187
19 0.193
20 0.199
21 0.204
22 0.209
23 0.214
24 0.219
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Figure 3.1.10 PAPP-A levels (MOM) in placental tissue from 51 Down’s syndrome
pregnancies at 10 to 24 weeks gestation, and in one Trisomy 13 and three Trisomy 18
pregnancies.
143
ii
3.1.5.3 Trisomy 13 and Trisomy 18.
PAPP-A levels (MOM) in placental tissue from the Trisomy 13 and Trisomy 18 
pregnancies are shown in Figure 3.1.10. The levei of PAPP-A in placental tissue from 
one Trisomy 13 pregnancy was 0.39 MOM. In placental tissue from three Trisomy 18 
pregnancies PAPP-A levels are 0.39 MOM, 0.39 MOM and 0.45 MOM.
3.1.6 SRI LEVELS IN PLACENTAL TISSUE.
3.1.6.1 Unaffected Controls.
The concentration profile of SP1 in placental tissue from 52 unaffected pregnancies at 
12 to 20 weeks gestation is shown in Figure 3.1.11. Median SP1 levels at each 
gestation were calculated using linear regression (SP1 mediam = 0.002-8.00x10'^ x 
gestation) and are given in Tabie 3.1.5. Median SP1 levels decreased from 12 to 20 
weeks gestation. The overall median level of SRI in placental tissue from unaffected 
pregnancies was 0.91 MOM.
3.1.6.2 Down’s syndrome.
SP1 levels, expressed as MOM, in placental tissue from 51 Down’s syndrome 
pregnancies at 10 to 24 weeks gestation are shown in Figure 3.1.12. The median level 
of SP1 in Down’s syndrome placental tissue was 1.79 MOM with the majority of 
Down’s syndrome cases having SP1 levels greater than the control group median. 
SP1 levels in Down’s syndrome placental tissue were significantly higher than in 
unaffected controls (Mann-Whitney, p <0.01).
144
20
Sp1
Levels
(IU/mg
x10^)
IQ-
21201917 18161513 1411 12
Gestation (completed weeks)
Figure 3.1.11 SP-1 levels (IU/mg x 10''^ ) in placental tissue from 52 unaffected control
pregnancies at 12 to 20 weeks gestation. Smoothed medians across the gestational
range were calculated by linear regression.
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Table 3.1.5 Regressed median levels of SP-1 (IU/mg x 10''*) in placental tissue from 
unaffected control pregnancies at each week of gestation from 10 to 24 weeks.
Gestation Median SP-1 levels
(IU/mg X 10" )^
10 12.0
11 11.2
12 10.4
13 9.60
14 8.80
15 8.00
16 7.20
17 6.40
18 5.60
19 4.80
20 4.00
21 3.20
22 2.40
23 1.60
24 8.00
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Figure 3.1.12 SP-1 levels (MOM) in placental tissue from 51 Down’s syndrome
pregnancies at 10 to 24 weeks gestation, and in one Trisomy 13 and three Trisomy 18
pregnancies.
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3.1.6.3 Trisomy 13 and Trisomy 18.
SP1 levels (MOM) in placental tissue from the Trisomy 13 and Trisomy 18 pregnancies 
are shown in Figure 3.1.12. The level of SP1 in placental tissue from one Trisomy 13 
pregnany was 7.44 MOM. In placental tissue from three Trisomy 18 pregnancies SP-1 
levels were 1.41 MOM, 1.30 MOM and 1.85 MOM.
3.1.7 ALP LEVELS IN PLACENTAL TISSUE.
ALP activity was measured in unheated placental homogenates and in homogenates 
that were incubated at 60°C for 1 hour. ALP activity in the unheated samples 
represents total ALP activity which may be composed of bone/liver/kidney, intestinal 
and placenta! isoenzymes. Residual ALP activity in the placenta! homogenates after 
heating is due to the placental isoenzyme which is heat stable. There was little 
difference in ALP activity in the heated and unheated samples suggesting virtually 
exclusive expression of the placental isoenzyme in the placenta. The Wilcoxon 
Signed-Rank Test was used to compare total and placental ALP activities in each 
placental homogenate to determine if the distributions of the enzyme activities were 
the same. The results of the Wilcoxon Signed-Rank Test for the complete set of data 
(Down’s syndrome and control samples) and for the Down’s syndrome and control 
samples separately are presented in Table 3.1.6. There was no significant difference 
between total and placental ALP activities in the the placental samples from either the 
Down’s syndrome or the unaffected pregnancies confirming that only the placental 
isoenzyme is expressed in placental tissue.
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Table 3.1.6 Comparison of total and placental ALP levels in placental tissue from 
Down’s syndrome and unaffected pregnancies using the Wilcoxon Signed-Rank Test.
+ve differences -ve differences Ties p-value
All data 59 50 0 0.645
Controls only 29 23 0 0.387
Down’s syndrome only 26 25 0 0.603
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3.1.7.1 Unaffected Controls.
The concentration profile of the placental isoenzyme of ALP in placental tissue from 
52 unaffected control pregnancies at 12 to 20 weeks gestation is shown in Figure 
3.1.13. Gestational medians were determined using linear regression of logarithmically 
transformed data (placental ALP median = xgestation)^  and are given in Table
3.1.7. Median levels of placental ALP increased with advancing gestation from 12 to 
20 weeks. The overall median activity of placental ALP in placental tissue from 
unaffected pregnancies was 1.10 MOM.
3.1.7.2 Down’s Syndrome.
Placental ALP activity, expressed as MOM, in placental tissue from 51 Down’s 
syndrome pregnancies at 10 to 24 weeks gestation are shown in Figure 3.1.14. 
Placental ALP activity in the Down’s syndrome tissues was distributed around the 
control group median and were not significantly different from normal (Mann-Whitney, 
p=0.318). The overall median activity of placentai ALP in the affected tissues was 0.91 
MOM.
3.1.7.3 Trisomy 13 and Trisomy 18.
Placental ALP activity (MOM) in placental tissue from the Trisomy 13 and Trisomy 18 
pregnancies are shown in Figure 3.1.14. The activity of placental ALP in placental 
tissue from one Trisomy 13 pregnancy was 1.43 MOM. In placental tissue from three 
Trisomy 18 pregnancies PALP activity was 0.70 MOM, 1.07 MOM and 2.11 MOM.
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Figure 3.1.13 Placental ALP levels (nmoles/hr/mg) in placental tissue from 52 
unaffected control pregnancies at 12 to 20 weeks gestation. Smoothed medians 
across the gestational range were calculated by linear regression of logarithmically 
transformed data.
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Table 3.1.7 Regressed median levels of placental ALP (nmoles/hr/mg) in placental
tissue from unaffected control pregnancies at each week of gestation from 10 to 24
weeks.
Gestation Median placental ALP levels 
(nmoles/hr/mg)
10 98.4
11 115
12 135
13 158
14 184
15 216
16 252
17 295
18 345
19 404
20 472
21 552
22 646
23 756
24 884
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Figure 3.1.14 Placental ALP levels (MOM) in placental tissue from 51 Down’s
syndrome pregnancies at 10 to 24 weeks gestation, and in one Trisomy 13 and three
Trisomy 18 pregnancies.
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3.1.8 GGT LEVELS IN PLACENTAL TISSUE.
3.1.8.1 Unaffected Controls.
The activity profile of GGT in placental tissue from 52 unaffected control pregnancies 
at 12 to 20 weeks gestation is shown in Figure 3.1.15. Median levels at each week of 
gestation were calculated using linear regression (GGT median = 0.002-4.0x10'^ x 
gestation) and are given in Table 3.1.8. GGT activity decreased slightly with advancing 
gestation. The median level of GGT activity in placental tissue from unaffected 
pregnancies was 0.93 MOM.
3.1.8.2 Down’s Syndrome.
GGT activity, expressed as MOM, in placental tissue from 51 Down’s syndrome
pregnancies at 10 to 24 weeks gestation are shown in Figure 3.1.16. GGT activity in 
placental tissue from Down’s syndrome pregnancies was slightly higher than in 
unaffected pregnancies, with a median level of 1.29 MOM in the affected tissues. This 
increase was found to be statistically significant using the Mann-Whitney test (p 
< 0 .01).
3.1.8.3 Trisomy 13 and Trisomy 18.
GGT actvity (MOM) in placental tissue from the Trisomy 13 and Trisomy 18
pregnancies are shown in Figure 3.1.16. GGT activity in placental tissue from one 
Trisomy 13 pregnancy was 2.68 MOM. In placental tissue from three Trisomy 18 
pregnancies GGT activity was 1.20 MOM, 4.18 MOM and 2.75 MOM.
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Figure 3.1.15 GGT levels (U/mg x 10' )^ in placental tissue from 52 unaffected control
pregnancies at 12 to 20 weeks gestation. Smoothed medians across the gestational
range were calculated by linear regression.
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Table 3.1.8 Regressed median levels of GGT activity (U/mg x 10" )^ in placental 
tissue, fetal liver and fetal ileum from unaffected control pregnancies at each week of 
geststion from 10 to 24 weeks.
Gestation Median GGT levels
(U/mg X 10'^)
Placenta Liver Ileum '1
10 1.40 51.3 35.6
11 1.36 41.1 37.2 Î
12 1.32 34.1 38.8 1
13 1.28 29.2 40.5 I
14 1.24 25.6 42.3 1
15 1.20 22.8 44.1 i
'3-16 1.16 20.6 46.0
17 1.12 18.8 48.0 S:
.
18 1.08 17.4 50.1 1
19 1.04 16.2 52.3
20 1.00 15.2 54.6 ■
21 0.96 14.3 57.0
22 0.92 13.6 59.4
23 0.88 12.9 62.0
24 0.84 12.4 64.7 1
:'r
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Figure 3.1.16 GGT levels (MOM) in placental tissue from 51 Down’s syndrome
pregnancies at 10 to 24 weeks gestation, and in one Trisomy 13 and three Trisomy 18
pregnancies.
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3.1.9 GGT LEVELS IN FETAL LIVER.
3.1.9.1 Unaffected Controls.
GGT activity in fetal liver from 64 unaffected control pregnancies at 12 to 22 weeks 
gestation are shown in Figure 3.1.17. Median levels at each gestation, calculated 
using the S-phase regression model (GGT median = gestation)^  ^ are given in
Table 3,1.8. Median GGT levels decreased with advancing gestation from 12 to 22 
weeks. The median level of GGT activity in fetal liver from unaffected control 
pregnancies was 0.90 MOM.
3.1.9.2 Down’s Syndrome.
GGT levels, expressed as MOM, in fetal liver from 53 Down’s syndrome pregnancies 
at 13 to 24 weeks gestation are shown in Figure 3.1.18. In the majority of Down’s 
syndrome fetuses hepatic GGT activity was greater than the control group median. 
The median GGT level of GGT activity in the affected cases was 2.01 MOM . GGT 
activity in fetal liver from Down’s syndrome pregnancies was significantly higher than 
in unaffected pregnancies (Mann-Whitney, p <0.001).
3.1.9.3 Trisomy 13 and Trisomy 18.
GGT activity (MOM) in fetal liver from the Trisomy 13 and Trisomy 18 pregnancies are 
shown in Figure 3.1.18. GGT activity in fetal liver from one Trisomy 13 pregnancy was 
7.58 MOM. In fetal liver from four Trisomy 18 pregnancies GGT activity was 6.39 
MOM, 3.97 MOM, 3.15 MOM and 1.06 MOM.
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Figure 3.1.17 GGT levels (U/mg x 10’^ ) in fetal liver from 64 unaffected control 
pregnancies at 12 to 22 weeks gestation. Smoothed medians across the gestational 
range were calculated using the S-phase regression model. !v■à
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Figure 3.1.18 GGT levels (MOM) in fetal liver from 53 Down’s syndrome pregnancies
at 13 to 24 weeks gestation, and in one Trisomy 13 and four Trisomy 18 pregnancies.
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3.1.10 GGT LEVELS IN FETAL ILEUM.
3.1.10.1 Unaffected Controls.
GGT activity In extracts of fetal ileum from 63 unaffected control pregnancies at 12 to 
22 weeks gestation are shown in Figure 3.1.19. Gestational medians were determined 
by linear regression of logarithmically transformed data*"' (GGT median = 
.j q(-i .6330+0.0185 X gestation)^  shown in Table 3.1.8. Median GGT levels increased
with advancing gestation from 12 to 22 weeks. The overall median activity of GGT in 
fetal ileum from unaffected pregnancies was 1.02 MOM.
3.1.10.2 Down’s Syndrome.
GGT activity, expressed as MOM, in fetal iluem from 47 Down’s syndrome 
pregnancies at 13 to 24 weeks gestation are shown in Figure 3.1.20. Fetal intestinal 
GGT activity in Down’s syndrome pregnancies was lower than in unaffected 
pregnancies with a median level of 0.43 MOM. This reduction was found to be 
statistically significant using the Mann-Whitney test (p <0.001).
3.1.10.3 Trisomy 13 and Trisomy 18.
GGT activity (MOM) in fetal ileum from the Trisomy 13 and Trisomy 18 pregnancies 
are shown in Figure 3.1.20. The activity of GGT in fetal ileum from one Trisomy 13 
pregnancies was 0.35 MOM. In fetal ileum from four Trisomy 18 pregnancies GGT 
levels were 0.30 MOM, 0.81 MOM, 0.52 MOM and 0.33 MOM.
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Figure 3.1.19 GGT levels (U/mg x 10' )^ in fetal Ileum from 63 unaffected control
pregnancies at 12 to 22 weeks gestation. Smoothed medians across the gestational
range were calculated by linear regression of logarithmically transformed data.
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Figure 3.1.20 GGT levels (MOM) in fetal ileum from 47 Down’s syndrome pregnancies
at 13 to 24 weeks gestation, and in one Trisomy 13 and four Trisomy 18 pregnancies.
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3.1.11 SUMMARY OF MARKER LEVELS IN FETAL TISSUES.
Median AFP levels (MOM) in placental tissue and fetal liver from Down’s syndrome 
and unaffected control pregnancies are summarised in Table 3.1.9. AFP levels were 
strikingly elevated In placental tissue from Down’s syndrome pregnancies, while in the 
fetal liver, AFP levels did not differ significantly from normal. AFP levels (MOM) in fetal 
liver and placental tissue from Down’s syndrome, Trisomy 13 and Trisomy 18 
pregnancies are shown in Figure 3.1.21.
Median levels (MOM) of the placental markers intact hCG, FphCG, PAPP-A, SP-1 and 
PALP in placental tissue from Down’s syndrome and unaffected control pregnancies 
are presented in Table 3.1.10. Intact hCG, FphCG and SP-1 were significantly 
elevated in Down’s syndrome placental tissue, while PAPP-A and PALP were 
unchanged. Levels of intact hCG, FphCG, PAPP-A, SP-1 and PALP (MOM) in 
placental tissue from Down’s syndrome. Trisomy 13 and Trisomy 18 pregnancies are 
shown in Figure 3.1.22.
Median levels of GGT (MOM) in placenta, fetal liver and fetal ileum from Down’s 
syndrome and unaffected pregnancies are presented in Table 3.1.11. GGT was 
significantly elevated in placenta and in fetal liver from Down’s syndrome pregnancies. 
In fetal ileum from Down’s syndrome pregnancies GGT levels were significantly lower 
than normal. GGT levels (MOM) in placental tissue, fetal liver and fetal ileum from 
Down’s syndrome, Trisomy 13 and Trisomy 18 pregnancies are shown in Figure 
3.1.23.
Marker levels (MOM) in fetal tissues from the Trisomy 13 and Trisomy 18 pregnancies 
are presented in Table 3.1.12.
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Table 3.1.9 Median AFP levels (MOM) in placental tissue and fetal liver from
unaffected control and Down’s syndrome pregnancies, and results of significance
testing.
Tissue Median MOM Mann-Whitney
Unaffected controls Down’s syndrome p-value
Placenta 0.99 2.43 < 0.001
Liver 0.2591.01 0.97
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Figure 3.1.21 AFP levels (MOM) in placental tissue and fetal liver from Down’s
syndrome, Trisomy 18 and Trisomy 13 pregnancies.
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Table 3.1.10 Median MOM levels of intact hCG, FphCG, PAPP-A, SP-1 and PALP in
placental tissue from unaffected control and Down’s syndrome pregnancies and
results of significance testing.
Marker Median MOM 
Unaffected Down’s syndrome 
controls
Mann-Whitney
p-value
intact hCG 1.19 4.06 <0.001
FphCG 1.05 3.40 <0.001
PAPP-A 0.84 0.96 0.304
SP-1 0.91 1.79 <0.001
Placental ALP 1.10 0.91 0.318
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Figure 3.1.22 Levels of intact hCG, FphCG, PAPP-A, SP-1 and placental ALP (MOM)
in placental tissue from Down’s syndrome, Trisomy 18 and Trisomy 13 pregnancies.
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Table 3.1.11 Median levels of GGT (MOM) in placental tissue, fetal liver and fetal
Ileum from unaffected control and Down’s syndrome pregnancies, and results of
significance testing.
Tissue Median MOM Mann-Whitney
Unaffected
controls
Down’s syndrome p-value
Placenta 0.93 1.29 0.009
Liver 0.90 2.01 <0.001
Ileum 1.02 0.43 <0.001
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Figure 3.1.23 GGT levels (MOM) in placenta! tissue, fetal liver and fetal ileum from
Down’s syndrome, Trisomy 18 and Trisomy 13 pregnancies.
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Table 3.1.12 Marker levels (MOM) in fetal and placental tissues from one Trisomy 13 
and four Trisomy 18 pregnancies. No placental tissue was available from the Trisomy 
18 case T18/4.
Marker level (MOM)
Trisomy 13 Trisomy 18
1 1 2 3 4
Plac. AFP 3.25 1.18 3.18 2.01 -
Plac.
hCG
4.20 0.59 2.97 0.31 -
Plac.
PphCG
0.95 ND 1.66 0.40 -
Plac.
PAPP-A
0.55 0.39 0.39 0.45 -
Plac. SP1 7.44 1.41 1.30 1.85 -
Plac.
PALP
1.43 0.70 1.07 2.11 -
Plac. GGT 2.68 1.20 4.18 2.75
Liver AFP 1.24 1.88 1.22 1.83 0.92
Liver GGT 7.58 6.39 3.97 3.15 1.06
Ileum
GGT
0.35 0.30 0.81 0.52 0.33
ND - not detectable
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3.2 MARKER LEVELS IN MATERNAL SERUM.
3.2.1 ALPHAFETOPROTEIN.
3.2.1.1 Down’s syndrome.
Maternal serum AFP levels analysed prospectively and expressed as MOM, were 
available for 62 Down’s syndrome pregnancies identified by maternal serum screening 
and are illustrated in Figure 3.2.1. The median AFP level (MOM) in maternal serum 
from this series of Down’s syndrome pregnancies was 0.69 MOM.
3.2.1.2 Trisomy 18.
The concentrations of AFP in maternal serum were available for two Trisomy 18 
pregnancies (cases T18/3 and T18/4). These were 0.55 MOM at 16 weeks gestation 
(T18/3) and 0.34 MOM at 15 weeks gestation (T18/4) (Figure 3.2.1).
3.2.2 HUMAN CHORIONIC GONADOTROPIN.
3.2.2.1 Down’s syndrome.
HCG levels analysed prospectively and expressed as MOM, were available for the 
same series of 62 Down’s syndrome pregnancies and are illustrated in Figure 3.2.2. 
Maternal serum hCG levels were above 1.00 MOM in all but two of the Down’s 
syndrome pregnancies. The overall median serum intact hCG level in this series of 
affected pregnancies was 2.72 MOM.
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Figure 3.2.1 Levels of AFP (MOM) in maternal serum from 62 Down’s syndrome
pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18 pregnancies.
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Figure 3.2.2 Levels of intact hCG (MOM) in maternai serum from 62 Down’s
syndrome pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18
pregnancies.
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3.2.2.2 Trisomy 18.
The concentrations of intact hCG in maternal serum from two Trisomy 18 pregnancies 
(cases T18/3 and T18/4) were 0.16 MOM at 16 weeks gestation (T18/3) and 0.17 
MOM at 15 weeks gestation (T18/4) (Figure 3.2.2).
3.2.3 FREE BETA HUMAN CHORIONIC GONADOTROPIN.
3.2.3.1 Normal Ranges.
Median FphCG levels in maternal serum from unaffected pregnancies from 15 to 20 
weeks gestation have been established in this Department using the FphCG assay 
described in this study (Berry et al 1997). FphCG medians are given in Table 3.2.1. In 
unaffected pregnancies FphCG levels decrease from 15 to 20 weeks gestation.
3.2.3.2 Down’s Syndrome.
FphCG levels, expressed as MOM, in maternal serum from 58 Down’s syndrome 
pregnancies at 15 to 20 weeks gestation are shown in Figure 3.2.3. Twenty-two of of 
these samples have been investigated as part of another study (Berry et al 1997). In 
the majority of the Down’s syndrome pregnancies FphCG levels were above 1.00 
MOM. The median serum FphCG level in the Down’s syndrome pregnancies was 3.06 
MOM.
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Table 3.2.1 Median levels of FphCG (ng/ml) in maternal serum from unaffected
control pregnancies at each week of gestation from 15 to 20 weeks (from Berry et al
1997).
Gestation Median FphCG level 
(ng/ml)
15 11.5
16 9.6
17 8.0
18 6.7
19 5.5
20 4.6
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Figure 3.2.3 Levels of FphCG (MOM) in maternal serum from 58 Down’s syndrome
pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18 pregnancies.
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3.23.3 Trisomy 18.
The concentrations of FphCG in maternal serum from two Trisomy 18 pregnancies
(cases T18/3 and T18/4) were 0.13 MOM at 16 weeks gestation (T18/3) and 0.12
MOM at 15 weeks gestation (T18/4) (Figure 3.2.3).
3.2.4 PREGNANCY ASSOCIATED PLASMA PROTEIN A.
3.2.4.1 Normal Ranges.
Median PAPP-A levels in maternal serum from unaffected pregnancies from 15 to 20 
weeks gestation were established as part of another study in this Department (Berry et 
al 1997) and are presented in Table 3.2.2. In unaffected pregnancies, PAPP-A levels 
increase with advancing gestation from 15 to 20 weeks gestation.
3.2.4.2 Down's Syndrome.
PAPP-A levels, expressed as MOM, in maternal serum from 58 Down’s syndrome 
pregnancied at 15 to 20 weeks gestation are shown in Figure 3.2.4. Twenty-three of 
these samples were also investigated as part of another study (Berry et al 1997). 
Serum PAPP-A levels in the Down’s syndrome pregnancies were fairly evenly 
distributed above and below 1.00 MOM with an overall median PAPP-A level of 0.92 
MOM.
178
-'4
3
Table 3.2.2 Median levels of PAPP-A (lU/l) in maternal serum from unaffected
control pregnancies at each week of gestation from 15 to 20 weeks (from Berry et al
1997).
Gestation Median PAPP-A level 
(lU/i)
15 6.66
16 8.62
17 10.9
18 13.4
19 16.1
20 19.2
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Figure 3.2.4 Levels of PAPP-A (MOM) in maternal serum from 58 Down’s syndrome
pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18 pregnancies.
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3.2.43 Trisomy 18.
The concentrations of PAPP-A in maternal serum from two Trisomy 18 pregnancies
(cases T18/3 and T18/4) were 0.06 MOM at 16 weeks gestation (T18/3) and 0.07
MOM at 15 weeks gestation (T18/4) (Figure 3.2.4).
3.2.5 PREGNANCY SPECIFIC BETA 1 GLYCOPROTEIN.
3.2.5.1 Unaffected Controls.
The concentration of SP1 in maternal serum from 114 unaffected pregnancies at 15 to 
20 weeks gestation is shown in Figure 3.2.5. Median and regressed median SP1 
levels at each week of gestation are presented in Table 3.2.3. Regressed medians 
were calculated using the equation: SP1 median = Q(o 867+0.0344 x gestation) the
unaffected pregnancies median SP1 levels increased with advancing gestation from 
15 to 20 weeks. The overall median serum SP1 level in the unaffected control 
pregnancies was 1.00 MOM.
3.2.5 2 Down’s Syndrome.
SP-1 levels, expressed as MOM, in maternal serum from 58 Down’s syndrome 
pregnancies at 15 to 20 weeks gestation are illustrated in Figure 3.2.6. Maternal serum 
SP-1 levels in the Down’s syndrome pregnancies were significantly higher than in the 
unaffected pregnancies (Mann-Whitney, p<0.001), with an overall median level of 1.33 
MOM in the Down’s syndrome pregnancies.
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Figure 3.2.5 Median and regressed median levels of SP1 (lU/l) in maternal serum
from 114 unaffected pregnancies at 15 to 20 weeks gestation.
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Gestation No, of 
samples
Median Regressed median
15 20 24,5 24.1
16 20 25,1 26.1
17 20 29.8 28.3
18 20 29.9 30.6
19 16 32.0 33.1
20 18 36.8 35.9
Table 3.2.3 Median and regressed median levels of SP1 (lU/l) in maternal serum
from 114 unaffected pregnancies at each week of gestation from 15 to 20 weeks.
'I
183
2SP1
MOM
14
o
008o
cP
oo
%o
o
o
o
cP
83
o
o
o
o
o
GO
%
oo
on o
cP
OO
9" oo o■ 0
O
o
15 16 17
Down's syndrome 
Trisomy 18 
Control median
O
O
O
18 19
Gestation (completed weeks)
o
o
20 21
Figure 3.2.6 Levels of SP1 (MOM) in maternal serum from 58 Down’s syndrome
pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18 pregnancies.
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3.2.S.3 Trisomy 18.
The concentrations of SP1 in maternal serum from two Trisomy 18 pregnancies (cases
T18/3 and T18/4) were 0.90 MOM at 16 weeks gestation (T18/3) and 0.81 MOM at 15
weeks gestation (T18/4) (Figure 3.2.6).
3.2.6 ALKALINE PHOSPHATASE.
3.2.6.1 Unaffected Controls.
Total and placental ALP activity in maternal serum from 114 unaffected pregnancies at 
15 to 20 weeks gestation are shown in Figure 3.2.7 and Figure 3.2.8 respectively. 
Median total and placental ALP levels at each week of gestation are presented in 
Table 3.2.4, along with the percentage contribution of the placenta! isoenzyme to the 
total ALP activity at each week of gestation. Total and placental ALP regressed 
medians were calculated using the following equations: total ALP median = 
.,^ (2 .8 2 + 0 .0 0 7 3  X gestation)^ placental ALP median = io (o ^ o 6 + o .o 8 5 9  X gestation) Rgg^essed
medians are presented in Table 3.2.5. Both total and placental ALP activity was found 
to increase with advancing gestation. The contribution of the placental isoenzyme to 
the total ALP activity was less than 5%, increasing gradually as gestation advanced. 
The median levels of total and placental ALP activity in the unaffected pregnancies 
were 0.97 MOM and 0.99 MOM respectively.
3.2.6.2 Down’s Syndrome.
Total and placental ALP activity, expressed as MOM, in maternal serum from 54
Down’s syndrome pregnancies at 15 to 20 weeks gestation are shown in Figure 3.2.9
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Figure 3.2.7 Median and regressed median levels of total ALP (nmoles/hr/ml) in 
maternal serum from 114 unaffected pregnancies at 15 to 20 weeks gestation.
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Figure 3.2.8 Median and regressed median levels of placental ALP (nmoles/hr/ml) in 
maternal serum from 114 unaffected pregnancies at 15 to 20 weeks gestation.
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Table 3.2.4 Median total and placental ALP levels (nmoles/hr/ml) in maternal serum 
from 114 unaffected pregnancies at each week of gestation from 15 to 20 weeks, 
along with the percentage contribution of the placental isoenzyme to the total ALP 
activity.
Gestation No. of samples Medians 
Total ALP Plac ALP
% placental 
ALP
15 20 873 15.7 1.80
16 20 781 14.0 1.79
17 20 988 28.3 2.86
18 20 810 34.3 4.23
19 16 911 27.9 3.06
20 18 934 38.8 4.15
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Table 3.2.5 Regressed median total and placental ALP levels (nmoles/hr/ml) in 
maternal serum from 114 unaffected pregnancies at each week of gestation from 15 to 
20 weeks, along with the percentage contribution of the placental isoenzyme to the 
total ALP activity.
Gestation No. of 
samples
Regressed medians 
Total ALP Plac ALP
% placental 
ALP
15 20 844 15.2 1.8
16 20 858 18.6 2.17
17 20 873 22.6 2.59
18 20 887 27.6 3.11
19 16 903 33.6 3.72
20 18 918 41.0 4.47
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Figure 3.2.9 Levels of total ALP (MOM) in maternal serum from 54 Down's syndrome
pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18 pregnancies.
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and Figure 3.2.10 respectively. Total ALP activity was lower in maternal serum from 
Down’s syndrome pregnancies with a median level of 0.83 MOM. The reduction was 
found to be statistically significant using the Mann-Whitney Test (p=0.002). Placental 
ALP activity in maternal serum from the Down’s syndrome pregnancies was not 
significantly different from normal (Mann-Whitney, p=0.50), with a median level of 1.04 
MOM.
3.2.63 Trisomy 18.
Marker levels in maternal serum from two Trisomy 18 pregnancies are summarised in 
Table 3.2.7.
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Total and placental ALP activity in maternal serum from two Trisomy 18 pregnancies 
(cases T18/3 and T18/4) were 1.05 MOM and 0.64 MOM respectively at 16 weeks 
gestation (T18/3) and 0.74 MOM and 0.34 MOM respectively at 15 weeks gestation 
(T18/4) (Figure 3.2.9 and Figure 3.2.10).
3.2.7 SUMMARY OF MARKER LEVELS IN MATERNAL SERUM.
A summary of marker levels in maternal serum from Down’s syndrome and unaffected 
pregnancies is presented in Table 3.2.6. Levels of AFP and total ALP were found to 
be lower in Down’s syndrome pregnancies than in normal pregnanies. Intact hCG, 
FphCG and SP-1 levels were elevated in maternal serum from Down’s syndrome 
pregnancies, while PAPP-A and placental ALP levels were unchanged (Figure 3.2.11).
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Figure 3.2.10 Levels of placental ALP (MOM) in maternal serum from 54 Down’s
syndrome pregnancies at 15 to 20 weeks gestation, and in two Trisomy 18
pregnancies.
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Table 3.2.6 Summary of marker levels (median MOM) in maternal serum from
.-Ç:
Down’s syndrome and unaffected pregnancies.
I
'1
Marker Median MOM Mann-Whitney
Unaffected Down’s syndrome p-value
controls
'Î:AFP 0.69 - ■v
intact hCG 2.72 i:
FphCG 3.06
PAPP-A •R 0.92 -
:|SP-1 1.00 1.33 <0.001
Total ALP 0.97 0.83 0.002
Plac ALP 0.99 1.04 0.505 I f
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Figure 3.2.11 Levels of AFP. intact hOG, FphCG, PAPP-A, SP1, total ALP and
placental ALP (MOM) in maternal serum from Down’s syndrome and Trisomy 18
pregancies.
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Table 3.2.7 Summary of marker levels (MOM) in maternal serum from two Trisomy
18 pregnancies.
Case
no.
Gest. AFP intact
hCG
FphCG PAPP-A SP1 Total
ALP
Placental
ALP
T18/3 16 0.55 0.16 0.13 0.06 0.90 1.05 0.64
T18/4 15 0.34 0.17 0.12 0.07 0.81 0.74 0.34
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3.3 MARKER LEVELS IN AMNIOTIC FLUID.
3.3.1 ALPHAFETOPROTEIN.
3.3.1.1 Normal Ranges.
Median AFP levels in amniotic fluid from unaffected pregnancies established as part of 
the routine analysis of several hundred amniotic fluid specimens are presented In 
Table 3.3.1. Median amniotic fluid AFP levels decrease from 15 to 21 weeks gestation.
3.3.1.2 Down’s Syndrome.
Amniotic fluid AFP levels were measured prospectively in 34 of the Down’s syndrome 
pregnancies as part of the routine analysis of AFP and acetylcholinesterase in all 
amniotic fluids. AFP levels, expressed as MOM, in amniotic fluid from 34 Down’s 
syndrome pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.1. The 
overall median level of AFP in amniotic fluid Down’s syndrome pregnancies was 0.87 
MOM.
3.3.1.3 Trisomy 18.
The level of AFP in amniotic fluid from one Trisomy 18 pregnancy (case T18/4) at 17 
weeks gestation was 1.07 MOM (Figure 3.3.1).
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Table 3.3.1 Median levels of AFP (MU/I) in amniotic fluid from unaffected
pregnancies.
Gestation Median
(MU/I)
15 13.0
16 11.2
17 9.36
18 7.62
19 5.82
20 4.08
21 2.40
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Figure 3.3,1 Levels of AFP (MOM) in amniotic fluid from 34 Down’s syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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3.3.2 HUMAN CHORIONIC GONADOTROPIN.
3.3.2.1 Unaffected Controls.
The concentration profile of intact hCG in amniotic fluid from 132 unaffected 
pregnancies at 15 to 21 weeks gestation is shown in Figure 3.3.2. Median and 
regressed median hCG levels at each week of gestation are presented in Table 3.3.2. 
Regressed intact hCG medians were calculated using the equation; Intact hCG 
median = -jQ(2-i3-o.o897 x gestation) / ^ p ^ p jo t ic  fluid hCG levels decreased with advancing
gestation. The overall median level of intact hCG in amniotic fluid from the unaffected 
control pregnancies was 0.92 MOM.
3.3.2.2 Down’s Syndrome.
Intact hCG levels, expressed as MOM, in amniotic fluid from 33 Down’s syndrome 
pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.3. Amniotic fluid hOG 
levels were elevated in the Down’s syndrome pregnancies with a median level of 1.38 
MOM. This elevation was found to be statistically significant (p=0.028) using the Mann- 
Whitney Test.
3.3.23 Trisomy 18.
The level of intact hCG in amniotic fluid from one Trisomy 18 pregnancy (case T18/4) 
at 17 weeks gestation was 0.58 MOM (Figure 3.3.3).
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Figure 3.3.2 Median and regressed median levels of intact hOG (lU/ml) in amniotic
fluid from 132 unaffected pregnancies at 15 to 21 weeks gestation.
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Table 3.3.2 Median and regressed median levels of intact hCG (lU/ml) in amniotic
fluid from 132 unaffected pregnancies at each week of gestation from 15 to 21 weeks.
Gestation No. of samples Median Regressed median
15 20 6.10 6.41
16 20 5.15 5.24
17 20 3.95 4.28
18 18 2.95 3.49
19 20 2.55 2.85
20 20 2.25 2.33
21 14 1.80 1.90
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Figure 3.3.3 Levais of intact hCG (MOM) in amniotic fluid from 33 Down’s syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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3.3.3 FREE BETA HUMAN CHORIONIC GONADOTROPIN.
3.3.3.1 Unaffected Controls.
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The concentration profile of FphCG in amniotic fluid from 132 unaffected pregnancies 
at 15 to 21 weeks gestation is shown in Figure 3.3.4 Median and regressed median 
FphCG levels at each week of gestation are presented in Table 3.3.3. Regressed 
amniotic fluid FphCG medians were calculated using the equation: FphCG median = 
^q(3.7o-o.io2 X gestation) pphCG levsls follow a pattern similar to that in
maternal serum, decreasing with advancing gestation from 15 to 21 weeks but are 
approximately 10 times higher than in maternal serum at equivalent gestations. The 
median level of FphCG in amniotic fluid from the unaffected control pregnancies was 
1.00 MOM.
■'J:
3.3 3.2 Down’s Syndrome.
FphCG levels, expressed as MOM, in amniotic fluid from 33 Down's syndrome 
pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.5. Amniotic fluid 
FphCG levels were elevated in the Down’s syndrome pregnancies with a median level 
of 1.33 MOM. This elevation was found to be statistically significant (p=0.002) using 
the Mann-Whitney Test.
33.3.3 Trisomy 18.
The level of FphCG in amniotic fluid from one Trisomy 18 pregnancy (case T18/4) at 
17 weeks gestation was 0.97 MOM (Figure 3.3.5).
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Figure 3.3.4 Median and regressed median levels of FphCG (ng/ml) in amniotic fluid 
from 132 unaffected pregnancies at 15 to 21 weeks gestation.
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Table 3.3.3 Median and regressed median levels of FphCG (ng/ml) in amniotic fluid
from 132 unaffected pregnancies at each week of gestation from 15 to 21 weeks.
Gestation No. of samples Median Regressed median
15 20 144 145
16 20 101 114
17 20 95.1 90.3
18 18 84.5 71.3
19 20 51.6 56.4
20 20 50.5 44.5
21 14 29.4 35.2
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Figure 3.3.5 Levels of FphCG (MOM) in amniotic fluid from 33 Down's syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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3.3.4 PREGNANCY ASSOCIATED PLASMA A.
3.3.4.1 Unaffected Controls.
The concentration profile of PAPP-A in amniotic fluid from 132 unaffected pregnancies 
at 15 to 21 weeks gestation is shown in Figure 3.3.6. Median and regressed median 
PAPP-A levels at each week of gestation are presented in Table 3.3.4. Regressed 
median PAPP-A levels were calculated using the equation: PAPP-A median = 
^ q ( - o .662+ o .o o 32 X g es ta tio n ) ^niniotic fluld PAPP-A levsIs increased gradually with advancing
gestation, similar to the rate of increase noted in placental tissues but more slowly 
than the rise observed in maternal serum at 15 to 21 weeks. The overall median level 
of PAPP-A in amniotic fluid from the unaffected control pregnancies was 1.04 MOM.
3.3 4.2 Down’s Syndrome.
PAPP-A levels, expressed as MOM, in amniotic fluid from 33 Down’s syndrome 
pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.7. PAPP-A levels in 
amniotic fluid from Down’s syndrome pregnancies was not significantly different from 
normal (Mann-Whitney, p=0.126), with a median level of 0.95 MOM in the Down’s 
syndrome pregnancies.
33.4.3 Trisomy 18.
The level of PAPP-A in amniotic fluid from one Trisomy 18 pregnancy (case T18/4) at 
17 weeks gestation was 0.52 MOM (Figure 3.3.7).
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Figure 3.3.6 Median and regressed median levels of PAPP-A (lU/l) in amniotic fluid
from 132 unaffected pregnancies at 15 to 21 weeks gestation.
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Table 3.3.4 Median and regressed median levels of PAPP-A (lU/i) in amniotic fluid
from 132 unaffected pregnancies at each week of gestation from 15 to 21 weeks.
Gestation No. of samples Median Regressed median
15 20 0.233 0.243
16 20 0.265 0.245
17 20 0.260 0.247
18 18 0.252 0.249
19 20 0.204 0.251
20 20 0.275 0.253
21 14 0.286 0.254
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Figure 3.3.7 Levels of PAPP-A (MOM) in amniotic fluid from 33 Down’s syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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3.3.5 PREGNANCY SPECIFIC BETA 1 GLYCOPROTEIN.
3.3.5.1 Unaffected Controls.
The concentration profile of SRI In amniotic fluid from 132 unaffected pregnancies at 
15 to 21 weeks gestation is shown in Figure 3.3.8. Median and regressed median SP1 
levels at each week of gestation are presented in Table 3.3.5. Regressed amniotic 
fluid SP1 medians were calculated using the equation: SP1 median = -{o(^ 4^+o.o28o x 
gestation) f|ujd SP1 levels wore found to increase with advancing gestation
between 15 and 21 weeks. The overall median level of SP1 in amniotic fluid from the 
unaffected control pregnancies was 0.97 MOM.
3.3.5.2 Down’s Syndrome.
SP1 levels, expressed as MOM, in amniotic fluid from 32 Down’s syndrome
pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.9. Amniotic fluid SP1
levels in the Down’s syndrome pregnancies were not significantly different from the 
controls Mann-Whitney, p=0.749). The overall median level of SP1 in amniotic fluid 
from the Down’s syndrome pregnancies was 0.91 MOM.
3.35.3 Trisomy 18.
The level of SP1 in amniotic fluid from one Trisomy 18 pregnancy (case T18/4) at 17 
weeks gestation was 0.80 MOM (Figure 3.3.9).
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Figure 3.3.8 Median and regressed median levels of SP1 (mlU/1) in amniotic fluid
from 132 unaffected pregnancies at 15 to 21 weeks gestation.
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Table 3.3.5 Median and regressed median levels of SP1 (mlU/l) in amniotic fluid
from 132 unaffected pregnancies at each week of gestation from 15 to 21 weeks.
Gestation No. of samples Median Regressed median
15 20 539 581
16 20 689 620
17 20 784 661
18 18 513 705
19 20 809 752
20 20 751 802
21 14 948 855
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Figure 3.3.9 Levels of SP-1 (MOM) in amniotic fluid from 32 Down’s syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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3.3.6 ALKALINE PHOSPHATASE.
3.3.6.1 Unaffected Controls.
The activity profiles of total and placental ALP in amniotic fluid from 132 unaffected 
pregnancies at 15 to 21 weeks gestation are illustrated in Figure 3.3.10 and Figure 
3.3.11 respectively. Median levels of total and placental ALP activity are presented in 
Table 3.3.6, along with the percentage contributions of the placental isoenzyme to the 
total ALP activity at each week of gestation. Regressed medians are presented in 
Table 3.3.7. Median total and placental ALP activities were calculated using the 
following equations: Total ALP median = placental ALP median =
.^q (o.863+o .oo72 X gestation) total ALP activity was found to decrease with advancing
gestation, placental ALP activity increased from 15 to 21 weeks gestation. Median 
levels of total and placental ALP in amniotic fluid from unaffected pregnancies were 
0.92 MOM and 1.00 MOM respectively.
3.3 6.2 Down’s Syndrome.
Total and placental ALP activity, expressed as MOM, in amniotic fluid from 33 Down’s 
syndrome pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.12 and 
Figure 3.3.13 respectively. Total ALP levels were significantly reduced in Down’s 
syndrome pregnancies (Mann-Whitney, p<0.001), with a median level of 0.39 MOM. 
There was also a significant reduction in placental ALP levels in amniotic fluid from 
Down's syndrome pregnancies (Mann-Whitney, p=0.008), but to a lesser extent than 
for total ALP (placental ALP median MOM = 0.75).
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Figure 3.3.10 Median and regressed median levels of total ALP (nmoles/hr/ml) in
amniotic fluid from 132 unaffected pregnancies at 15 to 21 weeks gestation.
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Figure 3.3.11 Median and regressed median levels of placental ALP (nmoles/hr/ml) in
amniotic fluid from 132 unaffected pregnancies at 15 to 21 weeks gestation.
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Table 3.3.6 Median total and placental ALP levels (nmoles/hr/ml) in amniotic fluid 
from 132 unaffected pregnancies at each week of gestation from 15 to 21 weeks, 
along with the percentage contribution of the placental isoenzyme to the total ALP 
activity.
Gestation No of 
samples
Total ALP
Medians
Plac ALP
% placental 
ALP
15 20 216 9.73 4.5
16 20 214 8.72 4.07
17 20 333 10.4 3.12
18 18 230 9.92 4.31
19 20 181 9.21 5.09
20 20 187 10.5 5.61
21 14 181 10.5 5.80
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Table 3.3.7 Regressed median total and placental ALP levels (nmoles/hr/ml) in 
amniotic fluid from 132 unaffected pregnancies at each week of gestation from 15 to 
21 weeks, along with the percentage contribution of the placenta! isoenzyme to the 
total ALP activity.
Gestation No.of samples Regressed 
Total ALP
medians 
Plac ALP
% placental 
ALP
15 20 250 9.35 3.80
16 20 238 9.51 4.00
17 20 227 9.67 4.26
18 18 216 9.83 4 55
19 20 205 10.0 4.88
20 20 195 10.2 5.23
21 14 186 10.3 5.54
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Figure 3.3.12 Levels of total ALP (MOM) in amniotic fluid from 33 Down’s syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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Figure 3.3.13 Levels of placental ALP (MOM) In amniotic fluid from 33 Down’s
syndrome pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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3.3.63 Trisomy 18.
The levels of total and placental ALP in amniotic fluid from one Trisomy 18 (case
T 18/4) pregnancy at 17 weeks gestation were 1.09 MOM and 0.52 MOM respectively
(Figure 3.3.12 and Figure 3.3.13 respectively).
3.3.7 GAMMA GLUTAMYL TRANSFERASE.
3.3.7.1 Unaffected Controls.
The activity profile of GOT in amniotic fluid from 132 unaffected pregnancies at 15 to 
21 weeks gestation is shown in Figure 3.3.14. Median and regressed median GGT 
levels at each week of gestation are presented in Table 3.3.8. Regressed GGT 
medians were calculated using the equation: GGT median = Q^(3.89 o.o732 x gestation) ^
Amniotic fluid GGT activity decreased with advancing gestation. The overall median 
level of GGT activity in the unaffected pregnancies was 0.99 MOM.
3.3.7 2 Down’s Syndrome.
GGT activity, expressed as MOM, in amniotic fluid from 33 Down’s syndrome 
pregnancies at 15 to 21 weeks gestation are shown in Figure 3.3.15. Amniotic fluid 
GGT activity was significantly lower in Down’s syndrome pregnancies than In 
unaffected pregnancies (Mann-Whitney, p<0.001). The overall median level of GGT 
activity in amniotic fluid from the affected pregnanies was 0.48 MOM.
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Figure 3.3.14 Median and regressed median levels of GOT (U/I) in amniotic fluid from
132 unaffected pregnancies at 15 to 21 weeks gestation.
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Table 3.3.8 Median and regressed median levels of GGT (U/I) in amniotic fluid from
132 unaffected pregnancies at each week of gestation from 15 to 21 weeks.
Gestation No. of samples Median Regressed median
15 20 542 616
16 20 566 521
17 20 487 440
18 18 438 372
19 20 257 314
20 20 250 265
21 14 247 224
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Figure 3.3.15 Levels of GGT (MOM) in amniotic fluid from 33 Down's syndrome
pregnancies at 15 to 21 weeks gestation, and in one Trisomy 18 pregnancy.
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33.7.3 Trisomy 18.
The level of GGT in amniotic fluid from one Trisomy 18 pregnancy (case T18/4) at 17
weeks gestation was 0.11 MOM (Figure 3.3.15).
3.3.8 SUMMARY OF MARKER LEVELS IN AMNIOTIC FLUID.
AFP. intact hCG, FphCG, PAPP-A, SP1, total ALP, placental ALP and GGT levels 
(MOM) in amniotic fluid from Down s syndrome pregnancies are shown in Figure
3.3.16. A summary of marker levels in amniotic fluid from Down’s syndrome and
unaffected pregnancies is presented in Table 3.3.9. Levels of AFP, total ALP, 
placental ALP and GGT in amniotic fluid from Down’s syndrome pregnancies were 
lower than in unaffected pregnancies, while intact hCG and FphCG levels were 
elevated. PAPP-A and SP1 levels in amniotic fluid from Down’s syndrome pregnancies 
were not significantly different from normal.
Marker levels in amniotic fluid from one Trisomy 18 pregnancy are summarised in 
Table 3.3.10.
3.4 CORRELATION ANALYSIS.
A summary of marker levels (median MOM) in fetal tissues and in corresponding 
maternal serum and amniotic fluid samples from Down’s syndrome pregnancies is 
presented in Table 3.4.1. The relationships between marker levels in fetal tissue, 
maternal serum and amniotic fluid from the Down’s syndrome pregnancies was 
examined using correlation analysis.
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Figure 3.3.16 Levels of AFP, Intact hCG, FphCG. PAPP-A SP1, total ALP, placental
ALP and GGT levels (MOM) in amniotic fluid from Down’s syndrome and Trisomy 18
pregnancies.
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Table 3.3.9 Summary of marker levels (median MOM) in amniotic fluid from Down’s
syndrome and unaffected pregnancies.
Marker Median MOM 
Unaffected Down’s syndrome 
controls
Mann-Whitney
p-value
AFP - 0.87 -
intact hCG 0.92 1.39 0.017
PphCG 1.00 1.33 0.002
PAPP-A 1.04 0.95 0.126
SP-1 0.97 0.91 0.749
Total ALP 0.92 0.39 <0.001
Plac ALP 1.01 0.75 0.005
GGT 0.99 0.48 <0.001
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Table 3.3.10 Summary of marker levels (MOM) in amniotic fluid from one Trisomy 18
pregnancy.
Case
no.
AFP intact
hCG
FpfiCG PAPP-A SP1 Total
ALP
Placental
ALP
GGT
T18/4 1.07 0.58 0.97 0.52 0.80 1.09 0.52 0.11
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Table 3.4.1 Summary of marker levels (median MOM) in fetal tissues and in
corresponding maternal serum and amniotic fluid samples from Down’s syndrome
pregnancies.
Marker
Ileum Liver
Median MOM 
Placenta Maternal
serum
Amniotic
fluid
AFP - 0.97 2.43 0.69 0.87
intact hCG - - 4.06 2.72 1.39
FphCG - - 3.40 3.06 1.33
PAPP-A - - 0.96 0.92 0.95
SP-1 “ - 1.79 1.33 0.91
Total ALP - - 0.83 0.39
Plac ALP - - 0.91 1.04 0.75
GGT 0.43 2.01 1.29 - 0.48
I
I
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The results of correlation analysis on AFP levels (logarithmically transformed MOMs) in 
the Down’s syndrome pregnancies are presented in Table 3.4.2. There was no 
significant correlation between AFP levels in fetal tissues and in maternal serum or 
amniotic fluid from Down’s syndrome pregnancies. No significant correlation was 
found between AFP levels in amniotic fluid and maternal serum from Down’s 
syndrome pregnancies.
The results of correlation analysis on each of the placental markers (intact hCG, 
FphCG, PAPP-A, SP-1 and placental ALP) in placenta! tissue and in corresponding 
maternal serum and amniotic fluid samples from Down’s syndrome pregnancies are 
presented in Table 3.4.3. There were significant correlations between the levels of 
intact hCG in placental tissue and maternal serum (Figure 3.4.1), placental tissue and 
amniotic fluid (Figure 3.4.2) and in amniotic fluid and maternal serum (Figure 3.4.3) 
from the Down’s syndrome pregnancies. A significant correlation was also found 
between the levels of FphCG in placenta! tissue and maternal serum (Figure 3.4.4), 
and in maternal serum and amniotic fluid (Figure 3.4.5) from the Down’s syndrome 
pregnancies. However, no such association was found between placental and 
amniotic fluid levels of FphCG.
Despite the similarities between the median MOM levels of PAPP-A, SP-1 and 
placental ALP in placental tissue and maternal serum from the Down’s syndrome 
pregnancies, no significant correlation was found. Neither was there a correlation 
between the levels PAPP-A or placental ALP in amniotic fluid and maternal serum. 
There was a significant correlation between maternal serum and amniotic fluid levels 
of SP1 in the Down’s syndrome pregnancies (Table 3.4.3).
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Table 3.4.2 Correlation between levels of AFP in fetal liver, placenta (plac), 
maternal serum (ms) and amniotic fluid (af) from corresponding Down’s syndrome 
pregnancies.
n Correlation
co-efficient
p-value
AFP plac. AFP/ ms AFP 48 0.02 0.903
plac. AFP/ af AFP 28 -0.09 0.650
af AFP/ ms AFP 34 -0.002 0.993
liver AFP/ ms AFP 50 0.08 0.583
liver AFP/af AFP 25 -0.08 0.698
plac. AFP/ liver AFP 38 0.07 0.680
232
Table 3.4.3 Correlation between levels of intact hCG, FphCG, PAPP-A, SP-1 and
placental ALP in placental tissue (plac). maternal serum (ms) and amniotic fluid (af)
from corresponding Down’s syndrome pregnancies.
n Correlation
co-efficient
p-value
Intact hCG plac. hCG/ ms hCG 48 0.44 0.002
plac. hCG/ af hCG 27 0.46 0.016
af hCG/ ms hCG 33 0.49 0.004
FphCG plac. FphCG/ ms FphCG 44 0.63 <0.001
plac. FphCG/ af FphCG 27 0.12 0.581
af FphCG/ ms FphCG 32 0.53 0.002
PAPPA plac. PAPPA/ ms PAPPA 44 0.27 0.079
plac. PAPPA/ af PAPPA 27 -0.19 0.337
af PAPPA/ ms PAPPA 32 -0.02 0.936
SP-1 plac. SP-1/ ms SP-1 44 0.06 0.677
plac. SP-1/ af SP-1 26 0.08 0.687
af SP-1/ ms SP-1 31 0.66 <0.001
Plac ALP plac. PALP/ ms PALP 42 0.30 0.056
plac. PALP/ af PALP 27 0.38 0.053
af PALP/ ms PALP 29 0.22 0.251
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Figure 3.4.1 Correlation between the levels of intact hOG in placental tissue and
maternal serum from 48 Down’s syndrome pregnancies.
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Figure 3.4.2 Correlation between the levels of intact hCG in placental tissue and
amniotic fluid from 27 Down’s syndrome pregnancies.
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Figure 3.4.3 Correlation between the levels of intact hCG in amniotic fluid and
maternal serum from 33 Down’s syndrome pregnancies.
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Figure 3.4.4 Correlation between the levels of FphCG in placental tissue and
maternal serum from 48 Down’s syndrome pregnancies.
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Figure 3.4.5 Correlation between the levels of FphCG in amniotic fluid and maternal 
serum from 33 Down’s syndrome pregnancies.
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îNo significant correlation was found between the levels of GGT in amniotic fluid from 
Down’s symdrome pregnancies and the levels of GGT in placenta, fetal liver or fetal 
ileum from corresponding Down's syndrome pregnancies (Table 3.4.4).
3.5 EFFECT OF FETAL SEX ON HCG LEVELS.
It has been reported that the level of intact hCG in the maternal circulation is 
influenced by the sex of the fetus. Maternal serum levels of hCG are reported to be 
significantly lower in pregnancies with male fetuses after 18 weeks gestation (Brody 
and Garlstrom 1965, Boroditsky et al 1975, Obiekwe and Chard 1982, Leporrier et al 
1992, Muller et ai 1993a).
The effect of fetal sex on the concentration of intact hCG and FphCG in placental 
homogenates, maternal serum and amniotic fluid from Down’s symdrome pregnancies 
in this study was examined. Median MOM levels of intact hCG and FphCG in placental 
homogenates, maternal serum and amniotic fluid from Down’s syndrome pregnancies 
with respect to fetal sex are presented in Table 3.5.1. There was no significant 
difference in the levels of intact hCG or FphCG in either placental tissue, maternal 
serum or amniotic fluid from Down’s syndrome pregnancies with a male fetus
compared to Down’s syndrome preganncies with a female fetus. In unaffected
■,,.rJ;pregnancies, placenta! intact hCG levels were higher in pregnancies with a male fetus 
(1.34 MOM) than in pregnancies with a female fetus (0.94 MOM), although the 
difference was not statistically significant (Mann-Whitney, p=0.110). Likewise, 
placental levels of FphCG in unaffected pregnancies with a female fetus (median MOM 
= 1.01) were not significantly different (P = 0.222) from those with a male fetus 
(median MOM = 1,04).
=ÿ
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Table 3.4.4 Correlation between levels of GGT in fetal liver, fetal ileum, placental
tissue (plac) and amniotic fluid (af) from corresponding Down’s syndrome pregnancies.
n Correlation
co-efficient
p-value
GGT plac. GGT/ af GGT 26 -0.02 0.940
liver GGT/ af GGT 23 -0.21 0.329
ileum GGT/ af GGT 19 -0.07 0.766
plac. GGT/ liver GGT 36 -0.02 0.909
plac. GGT/ ileum GGT 29 0.09 0.630
liver GGT/ ileum GGT 45 0.24 0.112
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Table 3.5.1 Intact hCG and FphCG levels (MOM) in placental tissue, maternal
serum and amniotic fluid from Down’s syndrome pregnancies with respect to fetal sex.
Fetal
Male
sex
Female
Mann-
Whitney
p-value
Intact Placenta 4.60 (n=30) 3.38 (n=21) 0.193
hCG Maternal serum 2.81 (n=37) 2.67 (n=25) 0.736
Amniotic fluid 1.36 (n=22) 1.45 (n=11) 0.909
FBhCG Placenta 4.19 (n=30) 2.95 (n=21) 0.553
Maternal serum 2.97 (n=34) 3.17 (n=24) 0.912
Amniotic fluid 1.27 (n=22) 2.12 (n=11) 0.244
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3.6 IMMUNOHISTOCHEMISTRY.
3.6.1 Placental Localisation of Markers.
The localisations of AFP, hCG, PAPP-A, SP-1 and PALP in placental tissue from 
unaffected control and Down’s syndrome pregnancies are shown in Figures 3.6.1- 
3.6.5 respectively. For each of the markers staining was localised to the 
syncytiotrophoblast in both unaffected and Down’s syndrome placental sections. The 
syncytiotrophoblast is a continuous layer around the circumference of the villi, beneath 
which is a barely visible discontinuous layer of cytotrophoblast cells. This is 
characteristic of placental morphology at this stage of pregnancy when the 
cytotrophoblast layer is less prominent than at earlier gestations. Within the 
trophoblast of the villi is the connective tissue core (stroma) which is derived from the 
extraembryonic mesoderm. Fetal blood vessels are visible in only a few of the 
placental sections. A detailed investigation of the morphology of the placental sections 
was not carried out due to poor structural integrity which is an inherent disadvantage 
of using frozen sections.
3.6.2 Semiquantitative Analysis of Stained Placental Sections,
After an initial examination of the placental sections, it appeared that the degree of 
staining intensity for each of the markers in placental sections from Down’s syndrome 
and unaffected pregnancies may reflect the biochemical results e.g. stronger staining 
for hCG in the Down’s syndrome sections than in the unaffected sections 
corresponding to the increased levels of hCG levels in the placental extracts from 
Down’s syndrome pregnancies. To investigate this further the slides were scored as 
described in Chapter 2.4.4 and the scores analysed using the Sign test. The results of
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Figure 3.6.1. Immunohistochemical localisation of AFP in placental tissue from
unaffected control (top) and Down’s syndrome (bottom) pregnancies at 19 weeks
gestation.
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Figure 3.6.2. Immunohistochemical localisation of hCG in placental tissue from
unaffected control (top) and Down’s syndrome (bottom) pregnancies at 17 weeks
gestation.
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Figure 3.6.3. Immunohistochemical localisation of PAPP-A in placental tissue from
unaffected control (top) and Down’s syndrome (bottom) pregnancies at 14 weeks
gestation.
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Figure 3.6.4. Immunohistochemical localisation of SP1 in placental tissue from
unaffected control (top) and Down’s syndrome (bottom) pregnancies at 14 weeks
gestation.
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Figure 3.6.5 Immunohistochemical localisation of placental ALP in placental tissue
from unaffected control (top) and Down’s syndrome (bottom) pregnancies at 16 weeks
gestation.
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the Sign test for each of the markers are presented in Table 3.6.1. No significant 
difference was found in the staining intensities for any of the markers in unaffected 
control and Down’s syndrome placental sections.
3.7 SUMMARY OF POST MORTEM REPORTS.
3.7.1 Down’s Syndrome.
Post mortem reports were available for 55 of the 67 Down’s syndrome fetuses from 
which fetal tissues were collected. The majority of the fetuses exhibited external 
pathology characteristic of Down’s syndrome (e.g rounded head, protruding tongue, 
flat features, broad nasal bridge, small low-set ears). Nuchal thickening was observed 
in 36 of the Down’s syndrome fetuses and a cystic hygroma was observed on one 
case. Internal developmental abnormalities were found in 25 of the Down’s syndrome 
fetuses and included 22 cases with heart defects, 6 cases with Meckel’s diverticulum, 
one with duodenal stenosis/atresia, one with lung abnormalities and one hydropic 
fetus. Placental pathology was recorded for 31 of the Down’s syndrome cases and 
included varying degrees of fibrinoid degeneration, villous oedema, calcification and 
villous haemorrhage.
3.7.2 Other Abnormalities.
Post mortem reports were available for 2 of the Trisomy 18 fetuses. Both cases had 
developmental heart defects and widespread chorionic haemorrhage was evident on 
examination of the placenta.
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Table 3.6.1 The number of positive and negative difference in the staining 
intensities of AFP, hCG, PAPP-A, SP-1 and placental ALP in placental sections from 
Down’s syndrome and unaffected pregnancies, and the results of the significance test 
(Sign test).
Marker No. of +ve 
differences
No. of -ve 
differences
Ties p-value
AFP 6 4 6 0.754
hCG 6 2 8 0.289
PAPP-A 7 2 7 0.179
SP-1 3 8 5 0.227
PALP 5 7 4 0.774
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CHAPTER 4.
DISCUSSION
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4.1 MARKER ANALYSIS IN FETAL TISSUES.
4.1.1 THE USE OF REGRESSION ANALYSIS TO ESTIMATE WEEKLY 
MEDIANS.
During pregnancy, the maternal serum concentration of most feto-placental markers 
changes with advancing gestation. Conversion of marker levels into MOM eliminates 
the gestational effect and facilitates comparison of marker levels between 
pregnancies. To convert marker levels in individual pregnancies to MOM, median 
marker levels in unaffected pregnancies must be estimated, usually by analysis of 
several hundred samples distributed across appropriate gestations. In the absence of 
sufficient samples at each gestation, reasonable estimates of gestational medians can 
be obtained by regression. The aim of the present study was to compare the levels of 
certain biochemical markers in fetal tissues from Down’s syndrome and apparently 
unaffected control pregnancies. Fetal tissues were obtained from Down’s syndrome 
pregnancies following therapeutic termination at 10 to 24 weeks gestation, the majority 
of cases being of 20 weeks gestation and over. Control fetal tissues were obtained 
from 75 putatively normal pregnancies terminated for psycho-social reasons at 12 to 
22 weeks gestation. Because of the nature of the control samples, most were 
terminated before 20 weeks gestation and few tissues were available at later 
gestations. An alternative source of fetal material from spontaneous abortions was not 
used in this study due to the possibility of pathophysiological differences in fetal 
tissues between spontaneous and induced abortion. In the present study all fetal 
tissues were obtained following induction of labour by administration of Gemeprost 
(Cervigem) vaginal pessaries either alone or in combination with Mifepristone (RU 
486). Chard et ai (1990) reported an increase in maternal serum AFP levels following 
administration of Mifepristone for termination of pregnancy in the first trimester. RU
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486 has also been shown to decrease hCG synthesis and secretion by placental 
cultures (Das and Catt 1987), although Olajide et al (1989) found that circulating levels 
if hCG in vivo were unchanged until after abortion was complete. Furthermore, 
spontaneous abortion itself may be associated with pathological changes in the levels 
of biochemical markers.
In view of the small number of control samples available at each gestation and the 
incomplete overlap of the gestational range of the affected and unaffected 
pregnancies, regression analysis was used to estimate weekly medians. Median 
values obtained by regression analysis will be most accurate within the gestational 
range of the pregnancies from which the regression equations are derived. However, 
in this study a significant proportion of the Down s syndrome tissue samples were 
obtained at gestations beyond the upper limit of the gestational range of the controls. 
Marker medians for gestational weeks outside the control range were therefore 
obtained by extrapolation of the regression curve. The validity of this approach was 
suggested from two pieces of evidence; (1) it was observed that the trends in the 
regression curves in placental tissues for the markers intact hCG, FphCG, PAPP-A 
and placental ALP were similar to the changes in median levels of these markers in 
maternal serum and (2) from analysis of the tissue data using only the subset of cases 
(placenta - n = 34, liver - n = 51, ileum - n = 45) which were within the gestational 
range of the controls. The results of this analysis are presented in Table 4.1.1. 
Although there are some differences in the median MOM levels of the markers in the 
subset of Down’s syndrome pregnancies compared to the entire series, the trends in 
marker variation are identical to those described in Section 3.1.11. One exception is 
that the increase in placental levels of GGT in Down’s syndrome pregnancies is not 
statistically significant based on the analysis of only the Down’s syndrome cases within 
the gestational range of the controls.
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Table 4.1.1 Analysis of marker levels in fetal tissues using the subset of Down’s 
syndrome cases which were within the gestational range of the controls.
Tissue Marker Controls
No. of Median 
cases MOM
Down’s syndrome
No. of Median 
cases MOM
Mann-
Whitney
p-value
Placenta Intact hCG 52 1.19 34 3.98 <0.001
PphCG 52 1.05 34 3.32 <0.001
PAPP-A 52 0.84 34 1.16 0.069
SP1 52 0.91 34 1.50 <0.001
Placental ALP 52 1.10 34 1.13 0.474
AFP 52 0.99 34 2.40 <0.001
GGT 52 0.93 34 1.16 0.118
Liver AFP 68 1.01 51 0.92 0.155
GGT 65 0.90 50 2.03 <0.001
Ileum GGT 63 1.02 45 0.48 0.001
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By expressing marker levels in Down’s syndrome pregnancies as an overall median 
MOM it is being assumed that the change in marker MOM in Down’s syndrome 
pregnancies is of a constant magnitude at all gestations. However, this may not be the 
case as some studies have shown that MOM levels of certain markers in maternal 
serum (e.g. inhibin, PAPP-A, SP1) change with gestation in Down’s syndrome 
pregnancies (Aitken et a! 1996b, Qin et al 1996, Berry et al 1997, Qin et al 1997). The 
change with gestation of marker levels in fetal tissues from the Down’s syndrome 
pregnancies was not investigated in this study due to insufficient numbers of cases, 
particularly at the earlier and later gestations.
4.2 ALPHAFETOPROTEIN.
4.2.1 AFP IN NORMAL PREGNANCY.
During pregnancy AFP is synthesised primarily by the yolk sac and by the fetal liver 
(Gitlin et al 1972). As pregnancy advances the fetal liver grows and becomes the 
principle source of AFP. In the fetal circulation, AFP levels increase to a peak of 
approximately 3mg/ml at 10 to 13 weeks gestation, after which levels decrease until 
term (Gitlin and Boesman 1966). The increase in the level of AFP in the fetal 
circulation is probably due to an increase in the synthesis of AFP by the fetal liver 
(Gitlin 1975). The yolk sac begins to decrease in size towards the end of the first 
trimester and has usually disappeared by 20 weeks gestation (Jauniaux and Moscoso 
1992). Wathen et a! (1992) found no correlation between yolk sac size and AFP 
concentration in maternal serum, amniotic fluid or extra-embryonic coelomic fluid 
(EECF) at 8 to 12 weeks gestation. AFP synthesis by the yolk sac has decreased 
substantially by approximately 9 to 11 weeks gestation (Gitlin et al 1972, Gitlin 1975) 
so that by the second trimester of pregnancy, AFP in the feto-maternal compartment is
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almost exclusively of fetal hepatic origin. Gitlin and Boesman (1966) estimated the 
relative amount of AFP produced by the fetus at different stages of development by 
multiplying the plasma concentration of AFP by the weight of the fetus at a given 
gestation. They reported that while the fetal plasma concentration of AFP decreased 
from 14 to 20 weeks gestation, the relative amount of AFP synthesised by the fetus 
increased rapidly during this period and then remained constant until 30 to 32 weeks 
of gestation. Thus it was proposed that the decrease in the plasma concentration of 
AFP from 14 to 32 weeks was due to a greater increase in the weight of the fetus 
compared to the relative increase in the total AFP produced by the fetus.
In the present study, AFP was measured in extracts of fetal liver from 68 control 
pregnancies at 12 to 22 weeks gestation. Fetal hepatic AFP levels were found to 
decrease with advancing gestation. This is consistent with the results of Kronquist et ai 
(1990a) who also found a reduction in hepatic AFP levels with advancing gestation. 
Brizot et al (1996b) reported that in normal fetuses at 12 to 15 weeks gestation the 
highest level of hepatic AFP mRNA expression was at 13 weeks, corresponding to the 
peak in fetal serum AFP levels at 13 weeks of gestation. These results suggest that 
the decrease in the concentration of AFP after 13 weeks of gestation is due to a 
decrease in synthesis of AFP by the fetal liver.
Amniotic fluid AFP is derived from the fetal circulation through the unkeratinised skin 
of the fetus in early pregnancy and from fetal urine once the fetal kidney starts to 
function around the end of the first trimester (Gitlin and Boesman 1966, Seppala and 
RouslahtI 1972, Aitken and Crossley 1995). In the present study, the concentration of 
AFP in the amniotic fluid was found to decrease from 15 weeks to 21 weeks of 
gestation. This is consistent with previous studies which show that the concentration of 
AFP in the amniotic fluid increases from 11 weeks gestation to a peak at 13 weeks 
gestation, followed by a gradual decrease to term (Seppala and Rouslahti 1972,
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Crandall et al 1989, Palomaki et al 1993). Wathen et al (1991, 1993) found that high 
levels of AFP in amniotic fluid at 8 weeks gestation decreased rapidly until 11 weeks 
followed by a increase to a peak at 13 weeks and subsequent decline thereafter. The 
authors propose that high amniotic fluid AFP levels in early pregnancy may be due to 
excessive leakage of AFP into the amniotic fluid and reduced clearance by fetal 
swallowing prior to the development of the fetal renal and digestive systems. The 
concentration of the Con-A non-reactive form of AFP (yolk sac) decreases with 
advancing gestation corresponding to the decline of the yolk sac towards the end of 
the first trimester (Roushlati et al 1979, Toftager-Larsen et al 1980, Machlewicz et al 
1984, Jauniaux and Moscoso 1992).
In the maternal circulation AFP levels increase to a peak of approximately 450ng/l at 
32 weeks of gestation and then decline to term (Gitlin 1975, Rouslahti and Hirai 1978). 
Using data from the present study it is estimated that the concentration of AFP in the 
maternal circulation at 16 weeks gestation is approximately 0.3% of that in the 
amniotic fluid. Thus, a concentration gradient exists between AFP levels in the 
amniotic fluid and the maternal circulation. However, there is little correlation between 
amniotic fluid and maternal serum AFP levels in the second trimester and it is thought 
that only a small percentage of AFP in the maternal circulation is derived from the 
amniotic fluid across the fetal membranes (Gitlin 1975, UK Collaborative Study II 1979, 
Wald and Guckle 1980, Los et al 1985). In the first trimester, before the fusion of the 
decidua capsularis and the decidua parietalis at 12 to 16 weeks gestation, AFP 
transfer across the fetal membranes is limited. Maternal serum AFP is derived primarily 
from the fetal circulation by means of diffusion through the placenta (Gitlin 1975, Los 
et al 1985, Brumfield et al 1990). The concentration of AFP in the maternal circulation 
at any stage of gestation is related to the concentration of AFP in the fetal circulation 
and the size of the placenta (Gitlin 1975, Rouslahti and Hirai 1978). In the present 
study, it was found that AFP levels in homogenates of placental tissue from 52
256
unaffected control pregnancies decreased from 12 to 20 weeks gestation. This 
corresponds to the decrease in AFP levels in the fetal circulation during this period. 
The concentration of AFP in placental homogenates was approximately 10% of that in 
the fetal liver and Is presumed to be endogenous as the result of transfer from the 
fetal serum.
The mechanisms involved in the transfer of AFP from the fetal circulation to the 
maternal circulation are not known. There are regions on the surface of placental villi 
where the syncytiotrophoblast layer is very thin and is in direct contact with the 
underlying fetal capillaries. It is at these regions where feto-maternal transport 
presumably occurs (Chard 1986, Jauniaux et al 1992). In the present study, AFP was 
found to be localised to the syncytiotrophoblast layer of placental villi. No specific 
staining for AFP was found in the villous core. It is possible that AFP is transferred 
from the fetal circulation into the maternal circulation across the syncytiotrophoblast 
layer at sites where the syncytiotrophoblast is in direct contact with the fetal capillaries.
Brownbill et al (1995) investigated the mechanisms of AFP transport in perfused term 
placental cotyledons. Immunohistochemical analysis showed that AFP was localised to 
cytotrophoblast cells associated with fibrinoid deposits at regions where there was a 
break in the syncytiotrophoblast and the authors proposed that AFP transport from the 
fetal circulation to the maternal circulation occurs at these sites. AFP was also found to 
be present in the syncytiotrophoblast and in trophoblast cells in the decidua. A second 
route of AFP transport was proposed by which AFP in the decidua enters the maternal 
circulation via vessels which cross the basal plate.
Brownbill et al (1995) also reported that In perfused placental cotyledons the rate of 
transfer of AFP from the fetal circulation to the maternal circulation was faster than 
from the maternal circulation to the fetal circulation. This suggests that the mechanism
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of AFP transfer across the placenta is more complex than passive diffusion. Cellular 
uptake of AFP by various tumour and embryonic tissues occurs via specific AFP cell- 
surface receptors (Moro et al 1993, Mizejewski 1995). Thus, if AFP receptors are 
present in the placenta, cellular uptake and transport of AFP may occur via a receptor- 
mediated mechanism.
The presence of AFP in the syncytiotrophoblast and cytotrophoblast of the placenta 
and in trophoblast cells in the decidua may simply reflect uptake by these cells but 
may also be an indication of AFP synthesis. Trace amounts of AFP have been 
detected in culture media from placental cultures (Van Firth and Adinolf 1969, Gitlin et 
al 1972, Hustin et al 1980). However, this was not common to all cultures studied and 
may reflect assay non-specificity or release of endogenous AFP from the cultures 
rather than synthesis of AFP. Preliminary results of a study on placental AFP mRNA 
levels suggest that AFP gene expression in the placenta is of little functional 
significance (Kronquist et al 1990b).
4.2.2 AFP IN DOWN’S SYNDROME PREGNANCIES.
Numerous studies have shown that second trimester maternal serum AFP levels are 
significantly lower in Down’s syndrome pregnancies than in unaffected pregnancies 
(Table 4.2.1). Maternal serum AFP levels are also reduced in the first trimester of 
Down’s syndrome pregnancies (Table 4.2.2). In the present study, maternal serum 
samples were available from 62 of the Down’s syndrome pregnancies from which fetal 
tissues were obtained and serum AFP levels were reduced to a median of 0.69 MOM.
In this study, it was also found that AFP levels were reduced to 0.87 MOM in amniotic 
fluid obtained from 34 of the Down’s syndrome pregnancies prior to termination. This 
is consistent with, although less markedly reduced than the levels reported in previous
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Table 4.2.1 Summary of 33 published studies on maternal serum levels of AFP in
the second trimester of Down’s syndrome pregnancies.
Reference No. of cases Gestation AFP
median
MOM
Seller (1984) 8 15-20 0.80
Guibald et al (1984) 13 14-20 0.76
Fuhrmann et al (1984) 43 16-20 0.80
Cowchock & Ruch (1984) 40 14-20 1.00
Hershey et al (1985) 28 16-24 0.87
Spencer & Carpenter (1985) 27 16-20 0.82
Murday & Slack (1985) 45 15-19 0.63
Voigtlander & Vogel (1985) 29 NS 0.78
Doran et al (1986) 46 15-19 0.79
Ashwood et al (1987) 26 14-20 0.69
Cuckle et al (1987) 68® 14-20 0.72
Tabor et al (1987) 86^ 14-20 0.64
Di Maio et al (1987) 18 14-22 0.76
Del Junco et al (1989) 22 NS 0.64
Osanthanondh et al (1989) 26 16-22 0.84
Heyl et al (1990) 16 15-19 0.82
Kronquist et al (1990a) 18 18-22 0.72
Norgaard-Pedersen et al (1990) 42 14-18 0.70
Suchy & Yeager (1990) 16 15-22 0.70
Waller et al (1990) 113 15-20 0.77
MacDonald et al (1991) 54 14-21 0.90
Mancini et al (1991) 9 15-18 0.62
Miller et al (1991) 8 14-20 0.75
Spencer (1991a) 29 16-18 0.73
Zeitune et al (1991) 114 16-20 0.72
Haddow et al (1992) 20 NS 0.77
Phillips et al (1992) 7 15-19 0.89
Ryall et al (1992) 57 15-21 0.74
Spencer and Macri (1992) 23 16-17 0.76
Spencer et al (1992a) 90 14-21 0.72
Stone et al (1993) 21 15-17 0.68
Norgaard-Pedersen et al (1994) 72 14-18 0.70
Berry et al (1997) 47 15-21 0.72
Total 1281 0.75*
NS
weighted geometric mean, 
not stated.
includes cases previously reported by Cuckle et al (1984). 
includes cases previously reported by Tabor et al (1984).
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Table 4.2.2 Summary of 15 published studies on maternal serum levels of AFP in
Down’s syndrome pregnancies In the first trimester.
Reference No. of 
cases
Gestation AFP median MOM
Scioscia et al (1987) 8 6-14 1.06
Cuckle et al (1988) 22® 7-12 0.72
Brock et al (1990) 21 7-14 0.71
Crandall et al (1991) 10 9-12 0.59
Johnson et al (1991) 11 8-12 0.70
Aitken et al (1993a) 16 6-14 0.65
Crandall et al (1993) 11 11-15 0.74
Fuhrmann et al (1993) 19^ 8-12 0.97
Kellner et al (1994) 5 5-14 0.90
Biagiotti et al (1995) 41 8-12 0.74
Brizot et al (1995c) 35 10-13 0.84
Casais et al (1996) 19 10-13 0.78
Wald et al (1996b) 77 8-14 0.87
Zimmerman et al (1996) 4 10-13 0.62
Berry et al (1997) 53 7-14 0.80
Total 352 0.80*
%
■4
1
%
l l
weighted geometric mean.
includes cases reported by Brambati et al (1986), Barkai et al (1987), Milunsky 
et al (1988) and Neibolo et al (1990).
includes cases previously reported by Wenger et al (1990) and some cases 
included Cuckle et al (1984).
260
studies (Table 4.2.3). There was no correlation between the levels of AFP in
corresponding amniotic fluid and maternal serum samples from the Down’s syndrome
pregnancies.
Although the association between low AFP levels and Down’s syndrome is well 
established, the mechanisms behind this reduction are not known. It was proposed 
initially that immaturity of the Down’s syndrome fetus was the reason behind reduced 
maternal serum AFP levels in the second trimester of Down’s syndrome pregnancies, 
with AFP levels being characteristic of those at an earlier gestation (Canick et a! 1988, 
Wald et al 1988). Waller et al (1992) investigated the association between reduced 
maternal serum AFP levels and fetal growth retardation in 54 pregnancies which 
resulted in the birth of a Down’s syndrome child. There was no association between 
maternal serum AFP levels and birth weight. In a study of the prenatal growth of 563 
Down’s syndrome fetuses at 29 weeks gestation to term, Kucera (1971) found no 
evidence of abnormal growth of the Down’s syndrome fetuses compared to normal 
between 29 weeks gestation and term. Librach et al (1988) reported that there was no 
significant difference in the weights of Down’s syndrome fetuses (n=50) compared with 
the weights of unaffected control fetuses during the second trimester. Thus, there is 
no evidence to support slow fetal growth as the underlying cause of reduced AFP 
levels in Down’s syndrome pregnancies.
Several authors have proposed that low maternal serum and amniotic fluid levels in 
Down’s syndrome pregnancies may be caused by reduced synthesis of AFP by the 
fetal liver (Cuckle et al 1984, Davis et al 1985, Cuckle and Wald 1986, Crandall et al 
1988). Cuckle and Wald (1986) investigated this possibility by measuring AFP levels in 
cord blood from 22 Down’s syndrome babies and from 66 unaffected control babies. 
AFP levels in cord blood from the Down’s syndrome babies were significantly lower 
(0.45 MOM) than in cord blood from the unaffected babies. These results provide
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Table 4.2.3 Summary of 19 published studies on amniotic fluid levels of AFP in
Down’s syndrome pregnancies.
* weighted geometric mean.
NS not stated.
® mean MOM.
■ ::
''x
Reference No. of cases Gestation AFP median
Cowchock and Ruch (1984) 52 14-20 0.80 'î
Tabor et al (1984) 25 NS 0.64
Baumgarten et al (1985) 27 NS 0.71
Cuckle et al (1985) 48 13-20 0.64
Davis et al (1985) 18 15-18 0.70® %
Hershey et al (1985) 28 16-24 0.72 4
Hullin et al (1985) 37 15-21 0.58 .1
Voitlander & Vogel (1985) 44 16-21 0.78 ïî
Doran et al (1986) 46 15-19 0.62®
Jones et al (1986) 78 15-20 0.73 "ÿ
Ashwood et al (1987) 6 14-20 0.71 ?■
Crandall et al (1988) 111 15-24 0.73
Jones et al (1988) 15 15-17 0.76® 1
Kaffe et al (1988) 90 15-21 0.72
Giddy et al (1989) 26 16 0.74 i
Zeitune et al (1989) 52 16-22 0.60 44
Kronquist et al (1990a) 12 17-22 0.72 S
Spencer et al (1993a) 14 16-20 0.77 .4.:Jî
Spencer et al (1997a) 91 17-22 0.72 "ï
Total 890 0.67* 1
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indirect support for the theory that AFP synthesis by the fetal liver is reduced in 
Down’s syndrome at term. However, Scioscia et al (1988) reported that AFP levels in 
fetal serum from 11 Down’s syndrome fetuses at 17 to 25 weeks gestation were not 
significantly different from normal. Likewise, Nicolini et al (1988) found that the median 
multiple of the mean level of AFP in fetal serum from 6 Down’s syndrome fetuses was 
1.08. Seller (1990) measured fetal serum AFP levels in 21 fetuses with Down’s 
syndrome at 19 to 27 weeks gestation. Fetal serum levels were not significantly 
different from normal at 19 and 20 weeks of gestation, but after 20 weeks, serum AFP 
levels in the Down’s syndrome fetuses declined more rapidly than in the normal 
fetuses. Scioscia et al (1988) also found that the concentration of AFP in fetal serum 
from four Down’s syndrome fetuses at 21 weeks of gestation and over were below 
normal median levels. These results and the findings of Cuckle and Wald (1986) 
suggest that Down’s syndrome fetuses may synthesise lower amounts of AFP than 
unaffected fetuses during the second half of pregnancy. However, normal levels of 
AFP in fetal serum prior to 21 weeks gestation are not consistent with the theory that 
reduced synthesis of AFP is the cause of low maternal serum and amniotic fluid AFP 
levels in Down’s syndrome pregnancies in the second trimester.
Jones et al (1988) reported that despite an overall reduction in the levels of AFP in 
amniotic fluid from 15 Down’s syndrome pregnancies, there was no difference in the 
percentage contribution of Con-A non-reactive AFP (yolk sac origin) to total AFP levels 
between the Down’s syndrome and unaffected pregnancies. This suggests that AFP 
derived from the fetal liver and the yolk sac are affected in a similar manner in Down’s 
syndrome pregnancies. Los et al (1995) measured AFP levels in homogenised fetal 
material (fetal limbs, trunk, thorax and skull) from six first trimester Down’s syndrome 
fetuses and from 12 fetuses with Mendalian disorders but with normal karyotypes. AFP 
levels were significantly lower in the Down’s syndrome fetuses compared to the 
fetuses with the normal karyotypes but there was no difference in the percentage of
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Con-A non-reactive AFP between the two groups. The authors propose that AFP 
synthesis by the fetal liver and yolk sac is reduced in Down’s syndrome pregnancies. 
However, only a small number of cases was included in this study and the 
experimental design was far from ideal.
Kronquist et al (1990a) measured AFP levels in homogenates of fetal liver from 28 
Down’s syndrome fetuses at 17 to 22 weeks gestation. AFP levels were significantly 
reduced in fetal liver homogenates from the Down’s syndrome pregnancies despite 
apparently normal levels of total protein and total mRNA production. The reduction of 
AFP levels was most evident at 17 to 19 weeks of gestation. Kronquist et a! (1994) 
later confirmed these findings in a larger series of 50 Down’s syndrome cases, 
including some at 12 to 15 weeks gestation. The reduction in AFP levels was found to 
be significant only at 17 to 19 weeks gestation. In the present study, AFP was 
measured in homogenates of fetal liver from 54 Down’s syndrome fetuses and 68 
unaffected control fetuses at 12 to 24 weeks gestation. AFP levels in homogenates of 
fetal liver from the Down’s syndrome fetuses (0.97 MOM) were not significantly 
different from those of the unaffected control fetuses (1.01 MOM). There was no 
correlation between fetal hepatic levels of AFP and AFP levels in the maternal serum 
or amniotic fluid. In a recent study, Brizot et al (1996b) examined fetal hepatic AFP 
mRNA levels in 13 Down’s syndrome and 24 unaffected control pregnancies at 12 to 
15 weeks gestation. Hepatic AFP mRNA levels in the Down’s syndrome pregnancies 
were not significantly different from normal and the authors proposed that reduced 
AFP levels in Down’s syndrome pregnancies may be caused by post-transcriptional 
alterations such as increased degradation of AFP mRNA, modified stability of AFP or 
increased degradation of AFP in the maternal circulation or amniotic fluid. However, 
Kronquist et al (1990a) found no evidence of alteration in AFP mRNA processing or in 
the post-translational modification of the AFP polypeptide in Down’s syndrome 
pregnancies.
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Thus, considering the results of the present study and of published studies of AFP 
levels in fetal serum (Scioscia et al 1988, Nicolini et al 1988, Seller 1990) and in fetal 
liver (Kronquist et al 1990a, Brizot et al 1996b) from Down’s syndrome fetuses, it 
seems that reduced synthesis of AFP by the fetal liver is not the reason for low 
maternai serum and amniotic fluid AFP levels in Down’s syndrome pregnancies in the 
second trimester.
As noted above (Section 4.2.1), the principle source of AFP in second trimester 
amniotic fluid is fetal urine, while maternal serum AFP is derived primarily directly from 
the fetal circulation across the placenta and indirectly from the amniotic fluid across 
the maternal decidua. In the absence of reduced hepatic synthesis in Down’s 
syndrome fetuses, the reduction in maternal serum and amniotic fluid AFP levels in 
Down’s syndrome pregnancies may be caused by disruption of these routes of 
transfer. It has been proposed that reduced AFP levels in Down’s syndrome 
pregnancies are caused by impaired or delayed fetal kidney function and/ or impaired 
membrane or placental passage of AFP (Scioscia et al 1988, Seller 1990, van Lith et 
al 1991a). In the present study, placental AFP levels were significantly higher (2.43 
MOM) in the Down’s syndrome pregnancies than in the unaffected pregnancies. The 
median maternal serum level of AFP from 62 of the Down’s syndrome pregnancies 
included in this study was 0.69 MOM. There was no correlation between the levels of 
AFP in placental tissue and in corresponding maternal serum from the Down’s 
syndrome pregnancies. Immunohistochemical studies demonstrated that AFP was 
localised to the syncytiotrophoblast in placental tissue from both the Down’s syndrome 
and unaffected control pregnancies. In normal pregnancy, the concentration gradient 
of AFP from high levels in fetal blood to low levels in maternal blood promotes transfer 
of AFP from the fetal circulation to the maternal circulation. The endogenous level of 
AFP in the placenta is presumably a balance between the rate of uptake of AFP by the 
syncytiotrophoblast from the fetal circulation and the rate of its secretion into the
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maternal circulation. Any reduction in the rate of release of AFP at the feto-maternal 
interface will result in the accumulation of AFP in the syncytiotrophoblast. It is possible 
that in Down’s syndrome pregnancies AFP is synthesised in normal amounts, at least 
during the first half of pregnancy, but that there is a defect in the placental transport of 
AFP resulting in elevated placental and reduced maternal serum levels of AFP.
The concentration of AFP in amniotic fluid from the Down’s syndrome pregnancies at 
15 to 21 weeks gestation was reduced to 0.87 MOM, despite apparently normal 
hepatic AFP levels. This may indicate that the excretion of AFP by the fetal kidneys is 
affected in Down’s syndrome pregnancies. There was no evidence of renal 
abnormalities in any of the Down’s syndrome cases for which port-mortem reports 
were available. Fetal urine does not become the major source of amniotic fluid until 
around 16-20 weeks gestation (Whittle 1995). if impaired fetal kidney function is the 
cause of reduced amniotic fluid AFP In the second trimester, it would be expected that 
AFP levels would be normal in the first trimester as AFP reaches the amniotic fluid by 
a different route, for example by exudation from fetal capillaries through unkeratinised 
fetal skin. However, due to the difficulty of obtaining amniotic fluid samples at these 
early gestations there are no published data on amniotic fluid AFP levels in the first 
trimester of Down’s syndrome pregnancies.
4.2.3 AFP IN TRISOMY 13 AND TRISOMY 18 PREGNANCIES.
AFP levels in fetal liver, placenta, maternal serum and amniotic fluid from one Trisomy 
13 and four Trisomy 18 pregnancies included in this study are summarised in Table 
4.2.4.
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Table 4.2.4 AFP levels (MOM) In fetal liver, placental tissue, maternal serum and
amniotic fluid from Trisomy 13 and Trisomy 18 pregnancies.
Case
No.
Fetal liver
AFP MOM (gestation) 
Placenta Maternal serum Amniotic fluid
T13/1 1.24 (23) 3.25 (23) - -
T18/1 1.88 (23) 1.18(23) - -
T18/2 1.22 (22) 3.18(22) - -
T18/3 1.83 (21) 2.01 (21) 0.55 (16) “
T18/4 0.92 (19) - 0.34 (15) 1.07 (17)
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A summary of published studies on maternal serum levels of AFP in Trisomy 18 
pregnancies in the first and second trimesters is given in Table 4.2.5. A meta-analysis 
of the results shown in Table 4,2.5, weighted for the number of Trisomy 18 cases in 
each study, reveals an overall maternal serum AFP level of 0.90 MOM in the first 
trimester (total of 40 cases) and 0.64 MOM in the second trimester (total of 296 
cases). In the present study, second trimester maternal serum was available from two 
Trisomy 18 pregnancies. Serum AFP levels were substantially reduced in both cases, 
consistent with previous studies. Median maternal serum AFP levels of 1.19 MOM 
(n=5), 0.5 MOM (n=5) and 0.74 MOM (n=9) have been reported in Trisomy 13 
pregnancies in the second trimester (Doran et al 1986, Johnson et al 1991, Zeitune et 
al 1991).
Amniotic fluid from one Trisomy 18 pregnancy was found to have an AFP level of 1.07 
MOM. This is comparable with published studies which show that amniotic fluid AFP 
levels appear to be normal in association with Trisomy 13 and Trisomy 18 (Davis et al 
1985, Doran et al 1986, Ashwood et al 1987, Lindenbaum et al 1987, Kaffe et al 1988, 
Crandall et al 1988, Zeitune et al 1989).
Nicolini et al (1988) reported that the concentration of AFP in fetal serum from six 
Trisomy 18 pregnancies at 16 to 33 weeks gestation was reduced to 0.78 MOM. 
Therefore, reduced synthesis of AFP by the fetal liver may be the cause of low 
maternal serum AFP levels in the second trimester of Trisomy 18 pregnancies. Zeitune 
et al (1989) proposed that if AFP synthesis was reduced in Trisomy 18 pregnancies, 
amniotic fluid AFP levels may be restored to normal by the reduced turnover of AFP 
caused by lack of fetal swallowing. However, In the present study, AFP levels in fetal 
liver homogenates from the Trisomy 13 pregnancy and three of the four Trisomy 18 
pregnancies were higher than in the normal pregnancies. Placental levels of AFP were 
also elevated in the trisomie pregnancies suggesting that reduced maternal serum
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Table 4.2.5 Summary of published studies on maternal serum AFP levels in Trisomy
18 pregnancies in the first and second trimesters.
Reference No. of cases 1st/2nd
trimester
AFP
median
MOM
Crandall et al (1991) 7 1st 0.99
Johnson et al (1991) 7 1st 1.3
Aitken et al (1993a) 5 1st 0.71
Fuhrman et al (1993) 17 1st 0.80
Van Lith et al (1994) 8 1st 1.26
Zimmermann et al (1996) 3 1st 0.62
Doran et al (1986) 10 2nd 0.64
Ashwood et al (1987) 10 2nd 0.72
Lindenbaum et al (1987) 38 2nd 0.60
Canick et al (1990a) 10 2nd 0.57
Nebiolo et al (1990) 6 2nd 0.73
Norgaard-Pedersen et al (1990) 7 2nd 0.49
Miller et al (1991) 9 2nd 0.49
Zeitune et al (1991) 19 2nd 0.68
Barkai et al (1993) 14 2nd 0.66
Spencer et al (1993b) 52 2nd 0.71
Palomaki et al (1995) 89 2nd 0.65
Aitken et al (1996b) 32® 2nd 0.53
includes four cases at 8-12 weeks which were previously reported by Aitken et 
al (1993a).
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AFP levels may be caused by the abnormal placental transport of AFP. Reduced 
placental size associated with Trisomy 13 and Trisomy 18 pregnancies may also affect 
the transfer of AFP from the fetal circulation to the maternal circulation.
4.3 HUMAN CHORIONIC GONADOTROPHIN.
4.3.1 HCG LEVELS IN NORMAL PREGNANCIES.
It is generally accepted that the syncytiotrophoblast of the placenta Is the principle 
source of dimeric hCG during pregnancy (Gosseye and Fox 1984, Kurmann et al 
1984, Hay et al 1988). The syncytiotrophoblast is in direct contact with the maternal 
blood. Once formed, dimeric hCG is secreted continuously from the 
syncytiotrophoblast into the maternal circulation with very little being stored within the 
cells (Sideri et al 1980, Billingsley and Wooding 1990). The concentration of Intact 
hCG in the maternal circulation at any stage of pregnancy should therefore reflect the 
rate of synthesis of hCG by the placenta. The concentration of intact hCG in the 
maternal circulation increases to a peak at 8 to 12 weeks gestation, followed by a 
decline to a plateau at around 18 weeks after which the concentration remains 
relatively constant to term (Braunstein et al 1976, Kietzy et al 1985, Ozturk et al 1987).
In the present study, intact hCG levels were measured in homogenates of placental 
tissue from 52 control pregnancies at 12 to 20 weeks gestation. Median hCG levels 
decreased with advancing gestation, in parallel with the changing concentration of 
hCG in the maternal circulation at this stage of pregnancy. This is consistent with the 
results of Vaitukaitls (1974) who found that hOG levels in placental tissue was highest 
in the first trimester and decreased thereafter. These results indicate that the changing
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concentration of hCG in the maternal circulation with advancing gestation reflects the 
changing rate of synthesis and/ or secretion of hCG by the placenta.
Intact hCG was also measured in amniotic fluid from 132 control pregnancies at 15 to 
21 weeks gestation. Amniotic fluid hCG levels were found to decrease with advancing 
gestation. This is consistent with previous studies which show that amniotic fluid hCG 
levels increase to a peak at 11 to 14 weeks gestation, followed by a marked decline to 
low levels which are maintained to term (Clements et al 1976, Belisle and Tulchinsky 
1980, Ozturk et al 1988). It was also found that the concentration of intact hCG in the 
amniotic fluid was approximately 15% of the maternal serum concentration at 15 to 20 
weeks gestation. This is consistent with previous studies which have shown that 
amniotic fluid hCG levels are less than 20% of maternal serum levels in both the first 
and second trimesters of pregnancy (Ozturk et al 1988, lies et al 1992). HCG is 
present in the fetal circulation at a lower concentration than in amniotic fluid and 
maternal serum (Crosignani et al 1972, Clements et al 1976). Thus it appears that 
intact hCG is preferentially secreted into the maternal circulation with a slower transfer 
into the amniotic fluid through the chorionic and amniotic membranes.
HCG is also present in the maternal serum and amniotic fluid in the form of its free 
subunits. In the maternal circulation, free ahCG increases from very low levels in early 
pregnancy to 30-40% of total hCG levels at term (Cole et al 1984, Ozturk et al 1987, 
Ozturk et al 1988). A small proportion (<5%) of the total hCG concentration in the 
maternal circulation is accounted for by FphCG, the concentration of which increases 
to a peak at around nine weeks gestation and declines thereafter (Cole et al 1984, 
Ozturk et al 1987, Berry et al 1995). In the present study maternal serum levels of 
FphCG were found to decrease with advancing gestation from 15 to 20 weeks. In 
placental tissue samples obtained from 52 control pregnancies at 10 to 20 weeks
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gestation in this study, FphCG levels were found to decrease with advancing 
gestation. Thus, maternal serum FphCG levels appear to reflect the change in 
placental concentrations of FphCG at this stage of pregnancy.
In contrast to intact hCG, the levels of FahCG and FphCG in the amniotic fluid are 
greater than in the maternal circulation (Ozturk et al 1988, Iles et al 1992, Spencer et 
al 1997). In the present study, amniotic fluid levels of FphCG were up to 10 times 
higher than in maternal serum at 15 to 20 weeks gestation. Amniotic fluid FphCG 
levels were found to decrease with advancing gestation. The highest concentration of 
FahCG in the amniotic fluid occurs around 15 to 16 weeks gestation with levels 
decreasing rapidly to 21 weeks when levels are lower than in maternal serum (Ozturk 
et al 1988). Amniotic fluid FphCG levels are lower than FahCG levels but the 
concentration profile is similar to that of FahCG (Ozturk et al 1988).
The mechanisms leading to the varying proportions of hCG and its subunits in 
maternal serum and amniotic fluid are not yet understood. HCG is present in maternal 
urine in the form of the intact molecule, free hCG subunits and the p-core fragment. 
Maternal serum and urine also contain hCG molecules that are ‘nicked’ between 
residues 47 and 48 or 45 and 46 on the p-subunit (Cole et al 1993, Cole 1994). The p- 
core fragment may be of placental origin or may be a degradation product of hCG and 
FphCG (Cole and Birkin 1984, Wehmann et al 1984, Wehmann et al 1990). Nicked 
hCG rapidly dissociates into FahCG, and nicked FphCG and Cole et al (1993) 
proposed a pathway by which there is increased nicking and dissociation of hCG as 
pregnancy advances, contributing to the decline in maternal serum hCG levels at the 
end of the first trimester and resulting in increased urinary hCG subunit and p-core 
levels. The metabolic clearance rate of free hCG subunits from the maternal circulation 
is more rapid than for intact hCG (Wehman and Nisula 1979). The different
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concentrations of hCG and its subunits in maternal serum and amniotic fluid may be a 
reflection of different rates of dissociation and clearance from the two compartments. 
However, there is no evidence of increased dissociation of hCG in the amniotic fluid 
(Ozturk et al 1988, Iles et al 1992). Ozturk et al (1988) proposed that the high 
concentration of intact hCG in maternal serum compared to amniotic fluid is due to the 
preferential secretion of intact hCG into the maternal circulation and that lower hCG 
subunit levels are a result of a low rate of placental secretion and more rapid metabolic 
clearance of subunits from the circulation.
Another possible explanation is that there are alternative sites of hCG and hCG 
subunit synthesis. In the first trimester of pregnancy, the concentration of hCG and its 
subunits is higher in extraembryonic coelomic fluid (EECF) than in maternal serum or 
amniotic fluid indicating that the extra-placental chorionic trophoblast, as opposed to 
the placental trophoblast, may be the principle site of hCG synthesis in the first 
trimester (lies et al 1992, Chard et al 1995). Furthermore, Chard et al (1995) proposed 
that the peak in maternal serum hCG concentrations at the end of the first trimester 
may be due to secretion of hCG by the extra-placental chorion which is reduced 
following fusion with the amnion.
Immunohistochemical studies have demonstrated the presence of hCG in the 
epithelial cells of the amniotic membrane from early pregnancy (six weeks) to term (de 
Ikonicoff and Cedard 1973, Ho et al 1982). Plouzek et al (1993) found that at term, 
phCG mRNA is expressed at lower levels in the amnion and chorion than in the 
placenta, while ahCG mRNA was expressed in the amnion but not in the chorion. HCG 
synthesis has also been reported in the fetal liver and kidneys (McGregor et al 1981, 
McGregor et al 1983). Low levels of hCG have been detected in a number of adult
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tissues (testis, ovary, liver, kidney, pituitary and lung) and in non-pregnant adult serum 
(Braunstein et al 1979, Odell and Griffin 1987).
Inhibins (inhibin-A and inhibin-B) are products of the placenta which may have a 
physiological role in the regulation of hCG synthesis. Inhibin suppresses in-vitro 
secretion of hCG by trophoblast cell cultures, while hCG itself stimulates inhibin 
secretion (Petraglia et al 1987, Petraglia et al 1989). The concentration profile of 
inhibin-A in the maternal circulation in early pregnancy is similar to that of intact hCG. 
Maternal serum inhibin-A levels increase to a peak at 8-10 weeks gestation, decline to 
a plateau at around 16 weeks with a subsequent rise in the third trimester so that 
highest levels are reached at term (Muttukrishna et al 1995, Aitken et al 1996b, 
Wallace et al 1996a). The trophoblast of the placenta is believed to be the principle 
source of circulating inhibin-A during pregnancy (Petraglia et al 1987, Wallace and 
Healy 1996, Petraglia 1997). Inhibin-A is also present in second trimester amniotic 
fluid and levels increase with advancing gestation (Wallace et al 1996a). In contrast to 
intact hCG but similar to FahCG and FphCG, the concentration of inhibin-A in amniotic 
fluid is significantly higher than in maternal serum indicating that there may be an 
alternative source of inhibin-A in amniotic fluid (Wallace et al 1996a). The decidua, 
fetal tissues, amnion and chorion are potential sites of synthesis of inhibin subunits 
(Petraglia et al 1990, Petraglia et al 1993, Jaffe et al 1993). Riley et al (1996) reported 
that in the first trimester, inhibin-A is present in maternal serum and EECF but is 
absent from amniotic fluid. This suggests that in the first trimester of pregnancy, the 
chorionic trophoblast synthesises inhibin-A as well as intact hCG and free hCG 
subunits.
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4.3.2 HCG IN DOWN’S SYNDROME PREGNANCIES.
In the present study, intact hCG levels were measured in homogenates of placental 
tissue from 61 Down’s syndrome pregnancies at 10 to 24 weeks gestation. The 
majority of the pregnancies were terminated during the second trimester. Intact hCG 
levels were significantly higher in placental tissue from the Down’s syndrome 
pregnancies (4.06 MOM) than in placental tissue from the controls. The median level 
of intact hCG in second trimester maternal serum samples from 62 Down’s syndrome 
pregnancies from which fetal tissues were collected was 2.72 MOM. This is slightly 
higher than the results of previous studies on maternal serum hCG levels in the 
second trimester of Down’s syndrome pregnancies (Table 4.3.1) and may reflect the 
bias In selection of study cases through prenatal screening. Maternal serum intact 
hCG levels are also elevated in the first trimester of Down’s syndrome pregnancies 
(Table 4.3.2), but the elevation is less than in the second trimester and appears to 
occur towards the end of the first trimester. Intact hCG levels in amniotic fluid from 33 
of the Down’s syndrome pregnancies in this study were also found to be significantly 
higher (1.39 MOM) than normal, but the magnitude of elevation was less than in 
maternal serum. This confirms previous studies which show that intact hCG levels are 
elevated in amniotic fluid from Down’s syndrome pregnancies (Cuckle et al 1991, Wolf 
et al 1992, Spencer et al 1993a, Spencer et al 1997a).
In the present study, there was significant correlation between the levels of intact hCG 
in placental tissue and in corresponding maternal serum and amniotic fluid samples 
from the Down’s syndrome pregnancies. Elevated amniotic fluid intact hCG levels in 
Down’s syndrome pregnancies may therefore be a reflection of elevated maternal 
serum hCG levels. Furthermore, the increase in maternal serum intact hCG levels in
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Table 4.3.1 Summary of 25 published studies on maternal serum levels of intact
hCG in Down’s syndrome pregnancies in the second trimester.
Reference No. of Gestation hCG median
cases MOM
Arab et al (1988) 77 NS 1.61
Wald et al (1988) 77 13-28 2.04
Del Junco et al (1989) 22 NS 2.10
Knight et al (1989) 24 NS 2.70
Osathanondh et al (1989) 26 16-22 2.59
Petrocik et al (1989) 38 15-19 2.50
Bartels et al (1990) 43^ 14-24 2.18
Heyl et al (1990) 16 15-19 1.89
Muller & Boue (1990) 50 14-19 2.39
Norgaard Pedersen et al (1990) 42 14-18 1.57
Suchy & Yeager (1990) 16 15-22 2.40
Bogart et al (1991) 6 15-20 2.14
Crossley et al (1991b) 49 15-20 2.18
MacDonald et al (1991) 54 14-21 1.79
Mancini et al (1991) 9 15-18 2.33
Miller et al (1991) 8 14-20 2.11
Spencer (1991a) 29 16-18 1.88
Haddow et al (1992) 35 NS 2.50
Herrou et al (1992) 24 15-19 2.96
Phillips et al (1992) 7 15-19 2.77
Ryall e ta l (1992) 57 15-21 2.12
Spencer et al (1992a) 90 14-21 2.03
Stone et al (1993) 21 15-17 2.00
Bartels et al (1994) 50 14-21 2.19
Norgaard-Pedersen et al (1994) 72 15-17 2.11
Total 942 2.12*
* weighted geometric mean.
NS not stated.
 ^ includes cases previously reported by Bogart et al (1987,1989).
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Table 4.3.2 Summary of 13 published studies on maternal serum levels of intact
hCG in Down’s syndrome pregnancies in the first trimester.
Reference No. of 
cases
Gestation hCG median MOM
Cuckle et al (1988) 22 7-12 1.10
Bogart et al (1989) 6 9-11 1.14®
Brock et al (1990) 21 7-14 1.43
Johnson et al (1991) 11 8-12 0.91
Kratzeretal (1991) 17 9-12 1.23
Van Lith et al (1992) 24 9-11 1.19
Aitken et al (1993a) 16 6-14 0.97
Crandall et al (1993) 11 11-14 1.73
Kellner et al (1994) 5 5-14 0.90
Macintosh et al (1994) 23 8-14 1.40
Biagiotti et al (1995) 41 8-12 1.50
Brizot et al (1995c) 41 10-13 1.50
Wald et al (1996b) 77 8-14 1.23
Total 315 125*
weighted geometric mean, 
estimated from publication.
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the second trimester of Down’s syndrome pregnancies appears to be caused by an 
increase In the synthesis of hCG by the placenta.
The concentration of FphCG was also higher in placental tissue from Down’s 
syndrome pregnancies (3.40 MOM) compared to normal. The median level of FphCG 
in second trimester maternal serum from 62 Down’s syndrome pregnancies was 3.06 
MOM. This is consistent with, although slightly higher than, the results of previous 
studies (Table 4.3.3) and again reflects the selection of Down’s syndrome pregnancies 
through abnormal maternal serum biochemistry. Maternal serum FphCG levels are 
also elevated in the first trimester of Down’s syndrome pregnancies (Table 4.3.4). 
There was a significant correlation between the levels of FphCG in placental tissue 
and in corresponding maternal serum from the Down’s syndrome pregnancies. This 
suggests that the secretion of FphCG into the maternal circulation in Down’s syndrome 
pregnancies is not altered and that elevated second trimester maternal serum levels 
may be caused by increased placental synthesis of the FphCG subunit.
Abbas et al (1995) measured hCG concentrations in fetal and maternal serum from 41 
aneuploid pregnancies at 17-32 weeks, including eight with Down’s syndrome and 41 
gestationally matched controls samples. Fetal serum and maternal serum hCG levels 
were not significantly different from the controls, although there was a slight increase 
in maternal serum hCG levels. There was a significant association between fetal 
serum and maternal serum hCG levels in the normal and aneuploid groups combined 
and the authors proposed that the route of secretion of hCG into the fetal and 
maternal circulation is the same in normal and aneuploid pregnancies. However, there 
were too few cases included in the study to give a clear picture of the changes in fetal 
serum and maternal serum hCG concentrations in Down’s syndrome pregnancies.
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Table 4.3.3 Summary of eight published studies on maternal serum FphCG levels in
Down’s syndrome pregnancies in the second trimester.
Reference No. of
cases
Gestation FphCG median 
MOM
Crossley et al (1991a) 81 NS 2.30
Ryall 0t al (1992) 57 15-21 2.36
Spencer and Carpenter (1993) 11 15-19 2.62
Stone et al (1993) 21 15-17 2.50
Wald et al (1993) 75 14-24 2.22
Maori et al (1994) 480® 14-22 2.64
Norgaard Pederson at al (1994) 72 14-18 2.31
Berry et al (1997) 47 15-21 2.79
Total 844 2.53*
NS
weighted geometric mean, 
not stated.
includes cases previously reported by Maori et al (1990, 1992), Spencer 
(1991a), Larsen e ta l (1992), Spencer and Carpenter (1992), Spencer and 
Maori (1992) and Spencer et ai (1992a).
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Table 4.3.4 Summary of 14 published studies on maternal serum FphCG levels in
Down’s syndrome pregnancies in the first trimester.
Reference No. of 
cases
Gestation FphCG median 
MOM
Ozturk et al (1990) 9 8-12 1.62®
Macri et al (1993a) 38^ 9-13 2.20
Macintosh et al (1994) 23^ 8-14 2.10
Brambati et al (1994b) 13 8-12 1.13
Kellner et al (1994) 5 5-14 2.20
Biagiotti et al (1995) 41 8-12 2.00
Brizot et al (1995c) 41 10-13 2.00
Brizot et al (1995b) 9 12-15 1.43
Noble et al (1995) 61 10-14 2.13
Casals et al (1996) 19 10-13 1.35
Krantz et al (1996) 22 10-13 2.09
Wald et al (1996b) 77 8-14 1.79
Zimmermann et al (1996) 4 10-13 1.50
Berry et ai (1997) 54 7-14 1.99
Total 416 1.93*
* weighted geometric mean.
® estimated from publication.
^ includes cases previously reported by Spencer et al (1992b) and Aitken et al
(1993a).
seven cases also included in Macri et al (1993a).
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Significantly elevated levels of FphCG in the amniotic fluid from Down’s syndrome 
pregnancies have previously been reported (Wolf et al 1992, Spencer et al 1997a). In 
the present study, FphCG levels in amniotic fluid from Down’s syndrome pregnancies 
were significantly higher (1.33 MOM) than in normal control pregnancies. There was 
no correlation between the levels of FphCG in placental tissue and amniotic fluid from 
the Down’s syndrome pregnancies and the magnitude of elevation of FphCG levels 
was much greater in placental tissue than in the amniotic fluid. This suggests that the 
placenta may not be the main source of FphCG in the amniotic fluid. Although the 
magnitude of elevation of FphCG in the amniotic fluid is less than in the maternal 
circulation, the concentration of FphCG in the amniotic fluid is still greater than in the 
maternal circulation. In amniotic fluid from Down’s syndrome pregnancies, intact hCG 
and FphCG levels are elevated to a similar extent. This indicates that increased 
dissociation of intact hCG into its subunits is unlikely to be the cause of increased 
FphCG levels in amniotic fluid.
In the present study, intact hCG and FphCG levels were found to be substantially 
elevated in placental tissue from Down’s syndrome pregnancies. This suggests that 
increased maternal serum concentrations of intact hCG and FphCG in Down’s 
syndrome pregnancies may be caused by increased synthesis of hCG subunits by the 
placenta. Evidence to support this theory is provided in a study by Eldar-Geva et al 
(1995). These investigators found that trophoblast cultures from second trimester (17- 
23 weeks gestation) Down’s syndrome pregnancies secreted 10 times more hCG than 
trophoblast cultures from control placentae at the same gestation. This increase 
appeared to be due to a marked increase in the levels of phCG mRNA and a smaller 
increase in the levels of ahCG mRNA.
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Brizot et al (1995b) measured ahCG and phCG mRNA in homogenates of placenta! 
tissue from nine Down’s syndrome and 30 unaffected control pregnancies at 11 to 15 
weeks gestation. ahCG and phCG mRNA levels were higher in the Down’s syndrome 
cases than in the controls but the increase was not statistically significant. The 
concentration of FphCG in corresponding maternal serum samples from the Down’s 
syndrome pregnancies was significantly higher than in the controls. There was no 
correlation between the levels of phCG mRNA in placental tissue levels from the 
control and Down’s syndrome pregnancies. The authors propose that placental 
expression of ahCG and phCG subunits is not altered in Down’s syndrome 
pregnancies but that there may be alterations in the post-transchptional processing of 
the hCG molecule. However, the number of cases included in this study is small and 
the samples were obtained mainly from first trimester pregnancies, at which stage the
HCG is a glycoprotein which contains up to 30% carbohydrate. The biological activity 
of hCG, interaction of ahCG and phCG subunits, receptor binding and metabolic 
clearance rate of hCG are all affected by alterations in the carbohydrate moiety. For 
example, removal of sialic acid residues results in decreased activity due to the 
increased metabolic clearance of asiaio-hCG from the circulation (Merz 1994). Kratzer 
et al (1991a) reported that there was no difference in the bioactivity of hCG in maternal 
serum from Down’s syndrome and control pregnancies. This suggests that the post- 
transcriptional processing of hCG is not altered in Down’s syndrome pregnancies.
In second trimester maternal serum from Down’s syndrome pregnancies, the 
proportion of FphCG which is nicked is 5 times greater than in normal pregnancies
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f
increase in maternal serum intact hCG levels is less marked than in the second 
trimester.
(Cole 1994). The concentration of the p-core fragment in second trimester maternal
urine from Down’s syndrome pregnancies has been reported to be approximately five 
times higher than normal (Cuckle et al 1994b, Cuckle et al 1995b, Canick et al 1995), 
although some studies found a less marked increase (Hayashi and Kozu 1995, 
Spencer et al 1996a). Cuckle et al (1996a) reported that maternal urinary p-core 
concentrations in 10 Down’s syndrome pregnancies in the first trimester were not 
significantly different from normal (range: 0.36-3.57 MOM). However, in a larger series 
of 22 Down’s syndrome pregnancies at 10 to 12 weeks gestation, Spencer et al 
(1997b) reported that the concentrations of FphCG and p-core in maternal urine were 
significantly increased to 1.87 MOM (range: 0.15-27.64) and 2.91 MOM (range: 0.01- 
20.33) respectively. This suggests that there may be an increase in the production of 
nicked hCG molecules and/ or increased degradation of hCG molecules in Down’s 
syndrome pregnancies.
4 . 3 . 2 . 1  E f f e c t  o f  f e t a l  s e x  o n  h C G  l e v e l s .
Previous studies have shown that the concentration of hCG in the maternal circulation, 
from approximately 18 weeks gestation to term, is significantly higher in women 
carrying a female fetus than in women carrying a male fetus (Crosignani et al 1972, 
Boroditsky et al 1975, Obiewick and Chard 1982, Leporrier et al 1992, Muller et al 
1993a). In contrast, Crosignani et al (1972) found that the concentration of hCG in 
amniotic fluid at term was significantly higher in women carrying male fetuses. The 
concentration of hCG in cord blood from male and female fetuses at term was not 
significantly different. Clements et al (1976) reported that there was no difference in 
fetal serum and amniotic fluid hCG levels in relation to fetal sex.
Placental levels of hCG do not appear to be affected by fetal sex during the second 
trimester of pregnancy, however, at term placental hCG levels are higher in
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pregnancies with female fetuses than with male fetuses (Hobson and Wide 1974, 
Wide and Hobson 1974). In the present study, there was no significant difference in 
placenta! levels of hCG between pregnancies with female fetuses and those with male 
fetuses.
Wolf et al (1992) investigated the effect of fetal sex on amniotic fluid concentrations of 
total hCG and FphCG in Down’s syndrome and unaffected pregnancies. In the 
unaffected control pregnancies there was no significant difference between the sexes 
but in Down’s syndrome pregnancies, amniotic fluid total hCG and FphCG 
concentrations were higher when the fetus was female. In contrast, Spencer et al 
(1997a) reported that amniotic fluid total hCG and FphCG concentrations were higher 
in unaffected pregnancies with female fetuses than those with male fetuses but that 
there was no fetal sex difference in hCG concentration in amniotic fluid from Down’s 
syndrome pregnancies.
In the present study, there was no significant difference in the concentration of total 
hCG and FphCG in placental tissue, maternal serum and amniotic fluid from Down’s 
syndrome pregnancies with female fetuses compared to those with male fetuses.
4.3.2.2 Factors Affecting the Regulation of hCG Synthesis in Normal and
Down’s syndrome Pregnancies.
Extensive studies on the regulation of hCG synthesis have shown that the 
mechanisms involved in the control of hCG synthesis and secretion throughout 
pregnancy are complex (Jameson and Hollenberg 1993, Cole 1994, Merz 1994).
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The relative amounts of ahCG and phCG subunits produced by the placenta varies at 
different stages of pregnancy, suggesting that there may be independent regulation of 
hCG subunits. Levels of both ahCG and phCG mRNA decrease towards term with 
phCG mRNA levels barely detectable in placenta at term. However the ratio of ahCG 
mRNA to phCG mRNA increases from 2:1 In the first trimester to 12:1 in term placenta 
(Boothby et al 1983, Kelly et al 1991). The relative excess of the ahCG subunit 
throughout pregnancy implies that synthesis of the phCG subunit is the rate limiting 
step in the formation of dimeric hCG. The mechanisms involved in the regulation of 
hCG subunit gene expression have been studied extensively and are reviewed by 
Jameson and Hollenberg (1993). Elevated levels of intact hCG and FphCG in Down’s 
syndrome pregnancies connot be the result of a gene dosage effect as the genes 
encoding the ahCG and phCG subunits are not located on chromosome 21. The 
ahCG subunit is coded by a single gene on chromosome 6 (Fiddes and Goodman 
1981) and the phCG subunit by a cluster of six genes on chromosome 19 (Graham et 
al 1987). However, an increase in the level of chromosome 21 encoded regulatory 
proteins may indirectly affect the regulation of synthesis of other proteins, including 
hCG.
A number of substances have been shown to regulate the synthesis and/ or secretion 
of hCG by placental cultures or trophoblast tumour cell lines (Table 4.3.5). However, 
the mechanisms by which these modulators exert their effects, or whether they have a 
role in the in vivo production of hCG has still to be determined. Furthermore, many of 
these studies were carried out on term or on first trimester placentae, therefore the 
physiological effects of these substances on placental function throughout pregnancy 
are not known.
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Table 4.3.5 Factors affecting the synthesis or secretion of hCG by placental cultures 
or trophoblast tumour cell lines.
Modulator Effect Reference
GnRH 1 Barneau and Kaplan (1988) 
Merz et al (1991)
Epidermal growth factor 1 Morrish et al (1987)
y-amino butyric acid 1 Licht et al (1992)
Fibroblast growth factor I Oberbauer et al (1988)
Macrophage colony stimulating factor 1 Saito e ta l (1991)
Glucocortcoids 1 Wilson and Jawad (1982)
Retinoic acid 1 Kato and Braunstein (1991)
Insulin 1 Ren and Braunstein (1991)
Cyclic AMP 1 Jameson and Hollenberg (1993)
Activin 1 Petraglia et al (1989)
Norepinephrine 1 Shi and Zuang (1993)
Fetal neural tissue D/F Shurtz-Swirski et al (1991)
Transforming growth factor p D Morrish et al (1991)
NE Petraglia et al (1989)
Ium our necrosis factor-a D Ohashi et al (1992)
Progesterone D Wilson et al (1980)
1 Ahmed et al (1988)
Prolactin D Yuen et al (1986)
Inhibin D Petraglia et al (1989)
D/NE* Mersol-Barg et al (1990)
Testosterone D/NE" Ahmed et al (1988)
Estradiol NE Ahmed et al (1988)
I
§■
-a:
a
-
I - increased, D - decreased, NE - no effect. 
 ^ - gestation dependent
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Gonadotropin-releasing hormone (GnRH) stimulates the release of hCG from placental 
cultures in a dose-dependent manner (Barneau and Kaplan 1989, Merz et al 1991). 
GnRH gene expression has been demonstrated in the stroma of the placenta and in 
both the cytotrophoblast and syncytiotrophoblast (Kelly et al 1991) and receptors for 
GnRH have been identified in the placenta (Iwashita et al 1986). Thus GnRH may be a 
possible regulator of hCG synthesis in vivo, although its precise physiological role is 
not clear (Sller-Khodr et al 1991).
Activin and inhibin have also been shown to modulate the secretion of hCG by 
placental cells in vitro. Petraglia et al (1987) reported that hCG secretion by 
trophoblast cultures was increased in the presence of antibody to inhibin, while hCG 
itself increased trophoblast secretion of inhibin. Petraglia et al (1989) reported that 
activin stimulated the production of GnRH and potentiated the GnRH induced 
secretion of hCG. Steele et al (1993) reported that recombinant activin increased hCG 
secretion by trophoblast cells independently of GnRH. Both studies demonstrated that 
inhibin alone did not affect hCG secretion but was capable of reversing activin induced 
changes. Activin also increases the production of progesterone by cultured placental 
cells (Petraglia et al 1989), while progesterone itself has been shown to affect the 
production of hCG (Wilson et al 1980, Wilson and Jawad 1982, Ahmed et al 1988). 
The effects of inhibin and progesterone on hCG synthesis are of interest as both 
inhibin and progesterone have been shown to be elevated in the second trimester of 
Down’s syndrome pregnancies (Knight et al 1989, Van Lith et al 1992, Spencer et al 
1993c, Cuckle et al 1994a). Maternal serum inhibin levels are not significantly different 
from normal in the first trimester of Down’s syndrome pregnancies (Van Lith et al 
1994, Wallace et al 1994). Studies using assays specific for dimeric inhibin-A have 
shown that inhibin-A is elevated in both the first and second trimesters of Down’s 
syndrome pregnancies (Cuckle et al 1995a, Wallace et al 1995, Aitken et al 1996b, 
Wald et al 1996a, Wallace et al 1996b). However, in contrast to Intact hCG, inhibin-A
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levels are significantly lower in amniotic fluid from Down’s syndrome pregnancies than 
in normal pregnancies suggesting that there may be differential expression of inhibin-A 
by the chorionic trophoblast and the placental trophoblast in Down’s syndrome 
pregnancies (Wallace et al 1997).
Interferons (a, p, y) were originally identified for their ability to protect cells from viral 
infection but are now known to have a wide range of regulatory functions particularly in 
association with cell growth and differentiation and the immune response (Balkwill 
1985, Taylor-Papadimitriou and Rozengurt 1985, Tamm et al 1987). Interferon-a 
(IFNa) is produced by the placenta and fetal tissues during pregnancy (Chard 1989, 
Loke and King 1990). lies and Chard (1989) reported that IFNa increased the 
secretion of the phCG subunit by bladder tumour cells in vitro. This is of particular 
interest as the gene encoding IFNa/p receptors are located on the pathological section 
of chromosome 21. The expression of IFN receptors has been shown to be increased 
in a dose-dependent manner in Down’s syndrome and the biological response to IFNa 
is increased 3-14 fold (Cooper and Hall 1988). This may have important implications in 
the mechanisms which give rise to elevated hCG in Down’s syndrome pregnancies.
Receptors for hCG (hCG/LH receptors) have been demonstrated in both the 
cytotrophoblast and syncytiotrophoblast of the mid-trimester and term placenta, 
indicating possible autocrine and paracrine roles in the placenta (Reshef et al 1990, 
Lei and Rao 1992). Licht et al (1993) proposed a mechanism by which hCG down- 
regulates its own synthesis in the term placenta via 80kDa hCG/LH receptors. HCG 
was unable to regulate its own synthesis in first trimester placental cultures and in 
human gestational trophoblastic neoplasms, both of which secrete high levels of hCG 
(Licht et al 1993, Licht et al 1994). A 50kDa receptor, which is a truncated form of the 
80kDa receptor found in term placenta, was found to be expressed in first trimester
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placenta and in trophoblastic neoplasms. The concentration profile of hCG in maternal 
serum may be a reflection of the differential expression of hCG/LH receptors and the 
ability of hCG to regulate its own synthesis in term but not first trimester placenta. If so, 
it may be that in Down’s syndrome hCG lacks the ability to down regulate its own 
synthesis, possibly due to the abnormal expression or function of hCG/LH receptors.
The trophoblast of the placenta is made up of mononucleated cytotrophoblast cells, 
multinucleated syncytiotrophoblast cells and intermediate trophoblast cells. The 
syncytiotrophoblast is derived from the cytotrophoblast cells through a process of 
aggregation and differentiation. The intermediate cells may represent an intermediate 
stage of cytotrophoblast differentiation (Kurman et al 1984). Hoshina et al (1982,1983) 
demonstrated that ahCG and phCG subunit mRNA was localised primarily to the 
syncytiotrophoblast, but was also present in some cytotrophoblast cells. Subsequent 
studies have localised the ahCG subunit primarily to the cytotrophoblast, while phCG 
is localised almost exclusively to the syncytiotrophoblast (Hay 1988, Kelly et al 1991). 
Synthesis of dimeric hCG is linked predominantly to the syncytiotrophoblast and 
intermediate trophoblast cells (Gosseye and Fox 1984, Kurman et al 1984, Hay 1988). 
Marou et al (1992) reported that hCG was localised primarily to the cytotrophoblast in 
4-5 week placentae and exclusively to the syncytiotrophoblast in placentae at 6-12 
weeks. The morphology of the placenta and the ratio of cytotrophoblast to 
syncytiotrophoblast changes with advancing gestation. Although the concentration of 
hCG in the maternal circulation throughout pregnancy does not reflect the increase in 
trophoblastic mass (Braunstein et al 1980), synthesis and secretion of dimeric hCG 
may be directly related to the pattern of differentiation of the trophoblast (Hoshina et al 
1985, Hay 1988, Boime 1991).
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Hay (1988) reported that the increase in maternal serum levels of hCG between 3 and 
9 weeks gestation coincided with the presence of an extensive layer of 
syncytiotrophoblast in the placenta. The decline in serum hCG levels after 10 weeks 
gestation coincided with declining numbers of cytotrophoblast cells resulting in a 
reduction of the syncytial layer and the reduced capacity of the placenta to synthesise 
hCG subunits and secrete dimeric hCG. Thus, the authors proposed that hCG 
synthesis depends on the rate of differentiation of cytotrophoblasts into 
syncytiotrophoblasts. Another possibility is that expression of ahCG and phCG subunit 
genes depends on the stage of differentiation of the trophoblast (Hoshina et al 1985, 
Boime 1991). Expression of the ahCG and then phCG subunit genes is initiated In the 
cytotrophoblast cells following commitment to differentiation into syncytiotrophoblast. 
The presence of numerous cytotrophoblast ceils in the placenta in early pregnancy, 
when hCG levels are high, may serve to maintain a pool of intermediate trophoblast 
cells which are capable of expressing both ahCG and phCG subunits and dimeric 
hCG. Declining levels of hCG are associated with the formation of fully differentiated 
syncytiotrophoblast cells and reduced numbers of cytotrophoblasts. Both of these 
theories are based on the reduction of the number of cytotrophoblast cells with 
advancing gestation. However, Mayhew and Simpson (1994) reported that the 
absolute number of cytotrophoblast cells does not decrease as gestation advances, 
but suggested that the cytotrophoblast cells become more thinly distributed as the 
villous surface expands. Shi et al (1993) proposed that hCG regulated its own 
synthesis by promoting the differentiation of cytotrophoblast into syncytiotrophoblast. 
Low to moderate concentrations of exogenous hCG were found to promote 
trophoblast differentiation in the term placenta, while high concentrations inhibited 
differentiation. It is possible that in Down’s syndrome pregnancies there are 
morphological changes to the placenta, such as abnormal differentiation of
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cytotrophoblast into syncytiotrophoblast, that affect the synthesis of hCG subunits and 
the formation of dimeric hCG.
4.3.3 HCG LEVELS IN TRISOMY 13 AND TRISOMY 18 PREGNANCIES.
Intact hCG levels in placental tissue, maternal serum and amniotic fluid from the 
Trisomy 13 and Trisomy 18 pregnancies included in this study are presented in Table 
4.3.6. Intact hCG concentrations were extremely low in second trimester maternal 
serum samples from two of the Trisomy 18 pregnancies. These results are consistent 
with previous studies (Table 4.3.7). Combining data from six published studies, totaling 
159 Trisomy 18 cases, gives an overall second trimester maternal serum intact hCG 
level of 0.33 MOM. Analysis of data from four published studies on first trimester 
maternal serum intact hCG levels in Trisomy 18 pregnancies, including a total of 37 
affected cases, reveals an overall level of 0.43 MOM. The concentration of intact hCG 
in amniotic fluid from one Trisomy 18 pregnancy was also found to be reduced. Abbas 
et al (1995) reported that hCG levels in fetal serum and maternal serum from 18 
Trisomy 18 pregnancies at 17-32 weeks gestation were significantly lower than in 
unaffected pregnancies.
FphCG levels in placental tissue, maternal serum and amniotic fluid from the Trisomy 
13 and Trisomy 18 pregnancies included in this study are presented in Table 4.3.8. As 
with intact hOG, FphCG levels were also extremely low in second trimester maternal 
serum from two Trisomy 18 pregnancies. This is consistent with previous studies which 
show that maternal serum FphCG levels are reduced in both the first and second 
trimesters of Trisomy 18 pregnancies (Ozturk et al 1990, Spencer et al 1993b, Aitken 
et al 1993a, Macri et al 1993a, Brizot et al 1995c, Aitken et al 1996b, Zimmerman et al 
1996). The reduction in maternal serum FphCG concentrations from one of the
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Table 4.3.6 Intact hCG levels (MOM) in placental tissue, maternal serum and
amniotic fluid from Trisomy 13 and Trisomy 18 pregnancies.
Case No.
Placental
Intact hCG MOM (gestation) 
Maternal serum Amniotic fluid
T13/1 4.20 (23) - -
T18/1 0.59 (23) -
T18/2 2.97 (22) - -
T18/3 0.31 (21) 0.16(16) -
T18/4 - 0.17(15) 0.58 (17)
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Table 4.3.7 Summary of published studies on maternal serum intact hCG levels in
Trisomy 18 pregnancies in the first and second trimesters.
Reference No. of 
cases
1 st/2nd 
trimester
Intact hCG 
median MOM
Johnson et al (1991) 7 1st 0.32
Van Lith et al (1992) 6 1st 0.80
Aitken et al (1993a) 5 1st 0.27
Brizot et al (1995c) 19 1st 0.40
Arab et al (1988) 5 2nd 0.34®
Canick et al (1990a) 10 2nd 0.27
Crossley et al (1991b) 4^ 2nd <0.40
Miller et al (1991) 9 2nd 0.36
Barkai et al (1993) 14 2nd 0.23
Palomaki et al (1995) 89 2nd 0.36
Aitken et al (1996b) 32^ 2nd 0 30
estimated from publication, 
not included in meta-analysis.
includes four cases at 8-12 weeks which were previously reported by Aitken et 
al (1993a).
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Table 4.3.8 FphCG levels (MOM) in placental tissue, maternal serum and amniotic
fluid from Trisomy 13 and Trisomy 18 pregnancies.
Case No.
Placenta
FphCG MOM (gestation) 
Maternal serum Amniotic fluid
T13/1 0.95 (23) “ -
T18/1 ND (23) -
T18/2 1.66 (22) - -
T18/3 0.04 (21) 0.13(16) -
T18/4 - 0.12 (15) 0.97 (17)
ND not detectable.
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Trisomy 18 pregnancies did not appear to be reflected in amniotic fluid from the same
pregnancy.
Studies on small numbers of Trisomy 13 pregnancies suggest that maternal serum 
intact hCG and FphCG levels are low in the first trimester (Kratzer et ai 1991b, Brizot 
et ai 1995b). In the second trimester of Trisomy 13 pregnancies, maternal serum intact 
hCG levels have been reported to be normal (Crossley et al 1991a), elevated (Muller 
et al 1993a) and reduced (Suchy and Yeager 1990, Johnson etal 1991)
Clearly, the underlying reasons for abnormal maternal serum hCG concentrations in 
Trisomy 18 and Down’s syndrome pregnancies are different. Placental insufficiency 
may be a contributory factor in the reduction of intact hCG and FphCG levels in 
Trisomy 18 pregnancies. Low maternal serum intact hCG and FphCG levels may be 
attributed to reduced placental synthesis in one of the Trisomy 18 cases, however it is 
not possible to identify a trend in placental intact hCG and FphCG levels in Trisomy 18 
pregnancies as the results from the other cases are variable.
4.4 PREGNANCY ASSOCIATED PLASMA PROTEIN A.
4.4.1 PAPP A LEVELS IN NORMAL PREGNANCIES.
PAPP A was measured in homogenates of placental tissue from 52 unaffected control 
pregnancies at 12 to 20 weeks gestation. Logarithmic regression was used to provide 
the regression equation which best fitted the control data. However, the overall median 
PAPP-A level in the controls was slightly lower (0.86 MOM) than would be expected for
an accurate regression model. Median placental PAPP-A levels were found to
increase between 12 and 20 weeks gestation, corresponding to the increase In
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materna! serum PAPP-A levels with advancing gestation in normal pregnancies 
(Folkersen et al 1981, Bischof et al 1982a, Berry et al 1997). Immunohistochemical 
studies demonstrated that PAPP-A was localised to the syncytiotrophoblast of the 
placenta. This is consistent with previous studies and confirms that the 
syncytiotrophoblast is the likely source of PAPP-A in the maternal circulation 
(Wahlstrom et al 1981, Gosseye and Fox 1984, Tornhave et al 1984). It has been 
proposed that the synthesis and secretion of placental proteins is directly related to the 
total mass of the placental trophoblast, the rate of blood flow into the intervillous space 
and the concentration of the product in the intervillous space (Gordon and Chard 
1979, Chard 1986, Chard 1993). However, Sorensen et al (1995) reported that the 
production rate of PAPP-A, estimated from median maternal serum PAPP-A 
concentrations at 7-20 weeks gestation, was higher than the estimated growth rate of 
the placenta. This suggests that other factors may be involved in the regulation of 
PAPP-A synthesis and secretion.
PAPP-A levels were also measured in amniotic fluid from 132 control pregnancies at 
15 to 21 weeks gestation. PAPP-A is present in the amniotic fluid at approximately 2% 
of maternal serum levels. Amniotic fluid PAPP-A levels increased gradually with 
advancing gestation, similar to the change in concentration of PAPP-A in the maternal 
circulation during the same gestational period (Bischof et al 1982a). This indicates that 
amniotic fluid PAPP-A may be derived directly from the maternal circulation. However, 
PAPP-A is not detectable in amniotic fluid until 13 weeks gestation (Bischof et al 
1982a, lies et al 1994). lies et al (1994) reported that in corresponding samples of 
maternal serum, EECF and amniotic fluid from normal pregnancies at 8-14 weeks 
gestation, the concentration of PAPP-A was highest in maternal serum, low in EECF 
and absent from amniotic fluid prior to 13 weeks gestation. This is similar to the pattern 
seen for inhibin-A (Riley et al 1996), but is in contrast to hCG (total phCG, intact hCG
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and FahCG), the concentration of which is highest in the EECF in the first trimester 
(lies et al 1992). One possible explanation for the absence of PAPP-A from first 
trimester amniotic fluid is that PAPP-A is a large protein (750kDa) and consequently 
may have a slow rate of transfer from the maternal circulation into the amniotic fluid. 
Alternatively, the EECF and amnion may act as a barrier to the transfer of proteins 
from the maternal circulation into the amniotic fluid in the first trimester of pregnancy 
(Gulbis et al 1992, lies et al 1994).
4.4.2 PAPP-A LEVELS IN DOWN’S SYNDROME PREGNANCIES.
Maternal serum PAPP-A levels are significantly reduced in the first trimester of 
pregnancies where the fetus has Down’s syndrome. A summary of the studies on first 
trimester maternal serum PAPP-A levels in Down’s syndrome pregnancies is given in 
Table 4.4.1. However, in the second trimester of Down’s syndrome pregnancies, 
maternal serum PAPP-A levels are not significantly different from normal (Table 4.4.2). 
Berry et al (1997) reported that the median level of PAPP-A in maternal serum from 
Down’s syndrome pregnancies in the first trimester was 0.50 MOM. However, the 
magnitude of the reduction in median PAPP-A levels decreased with advancing 
gestation until normal levels were reached in the second trimester (0.94 MOM). As 
PAPP-A levels are lower at earlier gestations, the overall median MOM reported in 
individual studies will be affected by the distribution of samples according to gestation.
In the present study, PAPP-A was measured in maternal serum from 58 Down’s 
syndrome pregnancies at 15 to 20 weeks gestation. The overall median level of PAPP- 
A in maternal serum from the Down’s syndrome pregnancies was 0.92 MOM, 
consistent with previous studies (Table 4.4.2). PAPP-A levels were also measured in 
amniotic fluid from 32 of these Down’s syndrome pregnancies at 15 to 21 weeks
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Table 4.4.1 Summary of 13 published studies on maternal serum PAPP-A levels in
Down’s syndrome pregnancies in the first trimester.
Reference No. of 
cases
Gestation PAPP-A median 
MOM
Wald et al (1992b) 19 9-12 0.23
Muller et al (1993b) 17 9-14 0.42
Bersinger et al (1994) 29 10-13 0.59
Brambati et al (1994a) 29® 6-11 0.31
Brizot et al (1994) 45 10-13 0.50
Macintosh et al (1994) 23^ 8-14 0.39
Spencer et al (1994) 2 f 7-14 0.62
Casais et al (1996) 19 10-13 0.42
Krantz et al (1996) 22 10-13 0.41
Qin et al (1996) 39 5-12 0.87
Wald et al (1996b) 77 8-14 0.43
Zimmermann et al (1996) 4 10-13 0.51
Berry et al (1997) 52 7-14 0.50
Total 396 0.50*
weighted geometric mean.
includes cases previously reported by Brambati et ai (1993). 
includes cases previously reported by Hurley et al (1993). 
includes cases previously reported by Aitken et al (1994).
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Table 4.4.2 Summary of five published studies on maternal serum PAPP-A levels in
Down’s syndrome pregnancies in the second trimester.
Reference No. of 
cases
Gestation PAPP-A median 
MOM
Cuckle et al (1992) 18 15-20 0.87
Wald & Voiler (1992) 16 15-20 1.02
Knight et al (1993) 30 15-19 1.01
Aitken et al (1994) 48 15-20 1.00
Berry et al (1997) 47 15-21 0.94
Total 159 0.97*
weighted geometric mean.
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gestation. Amniotic fluid PAPP-A levels In the Down’s syndrome pregnancies were not 
significantly different from normal (median MOM=0.95). There are no published 
studies on amniotic fluid PAPP-A levels in Down’s syndrome pregnancies.
In this study, the majority of Down’s syndrome and control pregnancies from which 
fetal tissues were collected were terminated during the second trimester. Placental 
levels of PAPP-A in the Down’s syndrome pregnancies (0.96 MOM) were not 
significantly different than in the controls (0.86 MOM). Despite the similarity between 
the overall median MOM levels of PAPP-A in placental tissue, maternal serum and 
amniotic fluid from the Down’s syndrome pregnancies, the correlation between PAPP- 
A levels in the different fetal-maternal compartments was not statistically significant. 
The results of the present study suggest that in the second trimester of Down’s 
syndrome pregnancies the mechanisms involved in the synthesis, secretion and 
transport of PAPP-A are not disturbed.
The question still remains as to the cause or causes of reduced maternal serum 
PAPP-A levels in the first trimester and their apparent normalisation in the second 
trimester of Down’s syndrome pregnancies. Brizot et al (1996a) investigated placental 
expression of PAPP-A. placental PAPP-A protein levels and maternal serum levels of 
PAPP-A in 8 pregnancies affected by Down’s syndrome and in 15 normal control 
pregnancies at 12 to 15 weeks gestation. Maternal serum levels of PAPP-A were 
significantly lower in the Down’s syndrome pregnancies than in the controls. Although 
the levels of placental PAPP-A mRNA and placental PAPP-A protein were also lower 
in the Down’s syndrome pregnancies than in the controls, the reduction was not 
statistically significant. However, this may be due to the small number of cases and 
controls studied. Brizot et al (1996a) proposed that the reduction in maternal serum 
levels of PAPP-A in the first trimester of Down’s syndrome pregnancies was not due to 
a reduction in PAPP-A synthesis by the placenta, but was caused by post-translational
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alterations such as impaired placental transport of PAPP-A or changes affecting 
alternative sources of PAPP-A. However, as the magnitude of the reduction in 
maternal serum PAPP-A levels in Down’s syndrome pregnancies decreases with 
advancing gestation (Berry et al 1997), a less marked difference in placental PAPP-A 
levels might be expected at 12 to 15 weeks gestation than at an earlier stage in the 
first trimester.
4.4.3 PAPP-A LEVELS IN TRISOMY 13 AND TRISOMY 18 PREGNANCIES.
PAPP-A levels in placental tissue, maternal serum and amniotic fluid from the Trisomy 
13 and Trisomy 18 pregnancies included in this study are presented in Table 4.4.3. 
Very low levels of PAPP-A were detected in second trimester maternal serum from two 
cases of Trisomy 18 and in amniotic fluid from one Trisomy 18 case. PAPP-A levels 
were also substantially reduced in placental tissue from the Trisomy 13 and Trisomy 
18 pregnancies. These results suggest that in the second trimester of Trisomy 13 and 
Trisomy 18 pregnancies, circulating PAPP-A levels are lower than normal due to 
reduced placental synthesis of PAPP-A. Very low levels of PAPP-A in Trisomy 18 
pregnancies may be a response to imminent abortion as there is a high rate of fetal 
loss In Trisomy 18 pregnancies (Connor and Ferguson-Smith 1991).
Previous studies have shown that PAPP-A levels in maternal serum from Trisomy 18 
pregnancies in the first trimester are lower than normal (Brambati et ai 1993, Spencer 
et al 1994, Brizot et al 1996a, Zimmermann et al 1996). Hurley et al (1993) reported 
that one Trisomy 13 pregnancy had a maternal serum PAPP-A level of 0.41 MOM in 
the first trimester.
Brizot et al (1996a) measured placental levels of PAPP-A mRNA, placental PAPP-A 
protein and maternal serum levels of PAPP-A In seven Trisomy 18 pregnancies at 12
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Table 4.4.3 PAPP-A levels (MOM) in placental tissue, maternal serum and amniotic
fluid from Trisomy 13 and Trisomy 18 pregnancies.
Case No.
Placental
PAPP-A MOM (gestation) 
Maternal serum Amniotic fluid
T13/1 0.39 (23) - -
T18/1 0.39 (23) - -
T18/2 0.39 (22) - -
T18/3 0.45(21) 0.06 (16) -
T18/4 - 0.07(15) 0.52 (17)
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to 15 weeks gestation. Maternal serum PAPP-A levels in the Trisomy 18 pregnancies 
were lower than normal, but there was no statistically significant difference in placental 
levels of PAPP-A mRNA or PAPP-A protein. The authors propose that abnormal 
serum PAPP-A levels may be caused by post-translational alterations.
4.5 PREGNANCY SPECIFIC pi GLYCOPROTEIN.
4.5.3 SP1 LEVELS IN NORMAL PREGNANCIES.
SP1 was measured in placental tissue from 52 control pregnancies at 12 to 20 weeks 
gestation. SP1 could not be detected in a small number of the placental homogenates. 
Placental levels of SP1 decreased with advancing gestation. These results are 
contrary to those of Grudzinskas et al (1980) who found an apparent increase in the 
concentration of SP-1 in placental tissue with advancing gestation. However, this was 
based on the analysis of SP1 concentration in homogenates of placental tissue from 
only five pregnancies terminated in the first trimester and five term deliveries.
In maternal serum from 114 control pregnancies at 15 to 20 weeks gestation, median 
SP1 levels were found to increase with advancing gestation. This is consistent with 
previous studies (Wald et al 1989, Graham et al 1992, Sorensen et al 1995, Qin et al 
1997). Unlike the other placental products (intact hCG, FphCG and PAPP-A), the 
concentration profile of SP1 in the maternal circulation does not appear to reflect the 
change in placental SP1 levels with gestation. This may be due to the possible 
differences in the mechanisms which regulate the synthesis and secretion of placental 
proteins. As discussed previously, it has been proposed that the production rate of 
placental proteins is related to the mass of the trophoblast, the blood flow into the 
intervillous space and the concentration of the placental product in the intervillous
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space (Gordon and Chard 1979, Chard 1986, Chard 1993). Sorensen et al (1995) 
demonstrated that the rates of change in the levels of hCG, PAPP-A, SP1 and hPL in 
maternal serum were different, suggesting that the synthesis of these proteins may be 
regulated by independent mechanisms. The rates of increase of SP-1 and hPL in the 
maternal circulation were similar to the rate of growth of the placenta, confirming the 
results of Braunstein et al (1980) who found that the concentrations of SP1 and hPL in 
maternal serum were correlated with the estimated growth of the trophoblast. Thus, 
increasing concentrations of SP1 in the maternal circulation with advancing gestation 
may closely reflect the increase in trophoblastic mass. However, the decrease with 
advancing gestation in the placental concentration of SP1 in normal pregnancies is 
difficult to reconcile with this theory.
In the present study, immunohistochemical analysis demonstrated that SP1 was 
localised to the syncytiotrophoblast of the placenta. This is in agreement with previous 
studies which suggest that SP1 is a product of the syncytiotrophoblast (Lin and 
Halbert 1976, Gosseye and Fox 1984). However, it is possible that there may be other 
sources of SP1 in the maternal circulation. Some studies have shown that SP1 is 
present at extremely low concentrations in tissue extracts and serum from non­
pregnant healthy adults, while other studies have not been able to confirm this 
(Sorensen 1984), and the evidence for a maternal source of SP1 during pregnancy is 
weak. Ho et al (1982) demonstrated the presence of SP1 in the trophoblast cells and 
amniotic epithelium of the amniochorionic membrane in early and late pregnancy. In a 
more recent study, Plouzek et al (1993) found that the amniotic and chorionic 
membranes expressed low levels of SP1 and that there was tissue-specific expression 
of different SP1 subgroups by the amnion, chorion and placental trophoblast.
The concentration of SP1 in the amniotic fluid at 15 to 20 weeks gestation is 
approximately 2% of maternal serum levels at the same gestation and a sensitive
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immunofluorometric assay was required for amniotic fluid SP1 determination (Qin et al 
1997). If the amnion and chorion were major sites of SP1 synthesis, a higher 
concentration of SP1 in the amniotic fluid might be expected. Amniotic fluid SRI levels 
increased with advancing gestation, similar to the concentration profile of SP1 in the 
maternal circulation. These results are in agreement with previous studies 
(Grudzinskas et al 1978, Kelly et al 1994). The concentration of SP1 in the fetal 
circulation is approximately 0.1% of that in the maternal circulation (Grudzinskas et al 
1978). Thus the pattern of SP1 concentrations in the different fetal-maternal 
compartments appears to be similar to that of other placental products (e.g. intact 
hCG, PAPP-A), suggesting that SP1 is secreted from the placenta into the maternal 
circulation and is then transported from the maternal decidua across the fetal 
membranes into the amniotic fluid.
4.5.2 SP1 LEVELS IN DOWN’S SYNDROME PREGNANCIES.
Published studies on SP1 levels in maternal serum from Down’s syndrome 
pregnancies in the first and second trimesters are presented in Table 4.5.1 and Table
4.5.2 respectively. As with PAPP-A, the change in maternal serum SP1 levels in 
Down’s syndrome pregnancies varies with gestation (Qin et a! 1997). In the second 
trimester, maternal serum SP1 levels are elevated in association with fetal Down’s 
syndrome, although reports vary with regard to the magnitude of variation. Qin et al 
(1997) investigated maternal serum SP1 levels in both the first and second trimesters 
of Down’s syndrome pregnancies. Maternal serum SP1 levels were significantly 
reduced to 0.29 MOM at 5-9 weeks gestation. At 10-12 weeks gestation maternal 
serum SP1 levels were not significantly different from normal (0.89 MOM), while at 14- 
20 weeks maternal serum SP1 levels in the Down’s syndrome pregnancies were 
significantly elevated (1.28 MOM). Thus, in Down’s syndrome pregnancies there is a
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Tabie 4.5.1 Summary of six published studies on maternal serum SP1 levels in
Down’s syndrome pregnancies in the first trimester.
Reference No. of 
cases
Gestation SP1 median 
MOM
Brock et al (1990) 21 7-14 0.79
Macintosh et al (1993) 14 6-12 0.40
Aitken et al (1994) 14 7-14 0.73
Bersinger et al (1994) 20 10-11 0.95
9 12-13 0.68
Brizot et al (1995a) 45® 10-13 0.96
Qin et al (1997) 25 5-9 0.27
14 10-12 0.89
I
'a
includes cases previously published by Bersinger et al (1994).
î
■?i
-i.
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Table 4.5.2 Summary of eight published studies on maternal serum SP1 levels in
Down’s syndrome pregnancies in the second trimester.
Reference No. of 
cases
Gestation SP1 median 
MOM
Bartels & Lindemann (1988) 24 16-19 2.10
Wald et al (1989) 77 13-27 1.20
Knight et al (1989) 24 NS 1.53
Petrocik et al (1990) 46 15-20 1.98®
Bartels et al (1990) 43 14-24 1.54
Graham et al (1992) 48 15-20 1.17
Bartels et al (1994) 50 14-21 1.28
Qin et al (1997) 117 14-20 1.28
Total 429 1.41*
weighted geometric mean, 
estimated from publication.
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SP1 levels were also measured in amniotic fluid from 32 Down’s syndrome and 132 
control pregnancies at 15 to 21 weeks gestation. Amniotic fluid SP1 levels were 
slightly lower in the Down’s syndrome pregnancies than in the normal pregnancies, 
however the difference was not statistically significant. These results are consistent 
those of Kelly et al (1994) who reported that the overall MOM level of SP1 (0.83 MOM) 
in amniotic fluid from 46 Down’s syndrome pregnancies at 12 to 20 weeks gestation 
was not significantly different from the controls (n = 106). However, Kelly et al (1994) 
noted that at earlier gestations (less than 16 weeks) amniotic fluid SP1 levels In the 
Down's syndrome pregnancies were significantly lower (0.51 MOM) than in the 
controls, the effect being less marked if all cases of less than 19 weeks gestation were 
included. Thus, in amniotic fluid from Down’s syndrome pregnancies, SP1 may follow 
a pattern of increasing MOM levels with advancing gestation similar to that seen in 
maternal serum (Aitken et al 1994, Qin et al 1997). No such association was found in
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trend of increasing maternal serum SP1 MOM levels with advancing gestation, similar 
to that described for PAPP-A (Berry et al 1997). In the present study, SP1 levels were 
found to be significantly elevated to 1.33 MOM in maternal serum from Down’s 
syndrome pregnancies at 15 to 20 weeks gestation.
In placental tissue from the series of Down’s syndrome pregnancies in this study, the 
majority of which were terminated during the second trimester, SP1 levels were 
significantly higher (1.77 MOM) than in placental tissue from the control pregnancies 
(0.91 MOM). Examination of placental SP1 MOM levels in relation to gestation (Figure 
3.1.12) revealed a trend of increasing placental SP1 MOM levels with advancing 
gestation in the Down’s syndrome pregnancies. This may correspond to the trend of 
increasing maternal serum SP1 MOM levels with advancing gestation in Down’s 
syndrome pregnancies (Qin et al 1997). However, there are insufficient data on 
placental SP1 levels at the early and late gestations to investigate this further.
the present study, although there was a significant correlation between the 
concentration of SP1 in maternal serum and corresponding amniotic fluid samples. 
Results from earlier studies also suggest that amniotic fluid SP1 levels in trisomie 
pregnancies are normal or slightly reduced (Heiklnheimo et al 1984, Wurz et al 1981). 
Bartels and Lindemann (1988) reported that amniotic fluid SP1 levels were elevated in 
Down’s syndrome pregnancies at 16 and 17 weeks gestation, but were not 
significantly different from normal at 18 and 19 weeks gestation. However, these 
results were obtained from the analysis of SP1 In amniotic fluid from 44 Down’s 
syndrome pregnancies and only 39 control pregnancies. The small number of controls 
in this study (Bartels and Lindemann 1988) may account for the different results.
The elevation in placental levels of SP1 in Down’s syndrome pregnancies suggests 
that there is increased synthesis of SP1 by Down’s syndrome placentae in the second 
trimester. This increased synthesis is not a direct result of increased gene dosage as 
SP1 is encoded by a family of genes on chromosome 19 (Streydio et al 1990). It is 
possible that increased placental synthesis of SP1 is the underlying cause of 
increased maternal serum SP1 levels in the second trimester of Down’s syndrome 
pregnancies. However, there was no correlation between placental and maternal 
serum levels of SP1 in the Down’s syndrome pregnancies. This is in marked contrast 
to the other placental markers (intact hCG, FphCG, PAPP-A, placental ALP) which all 
show some degree of association between placental and maternal serum levels. This 
may suggest that the placenta is not the principle source of SP1 in the maternal 
circulation and that other sources may contribute to the increase in maternal serum 
levels in Down’s syndrome pregnancies in the second trimester. As noted above, the 
amnion and chorion are possible sites of SP1 synthesis. However, if synthesis of SP1 
by the amnion and chorion was increased in Down’s syndrome pregnancies, amniotic 
fluid SP1 levels would most likely be elevated as opposed to the normal or slightly 
reduced levels found in the present study and in the study by Kelly et al (1994).
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In contrast to other placental markers, the change in maternal serum SP1 
concentrations in Down’s syndrome pregnancies is not mirrored in amniotic fluid. 
However, this is similar to inhibin-A, the concentration of which is increased in 
maternal serum but reduced in amniotic fluid from Down’s syndrome pregnancies 
(Aitken et al 1996b, Wallace et al 1997). Thus, it is possible that the source of SP1 
and inhibin-A in amniotic fluid is different from the source of these markers in the 
maternal circulation (Wallace et al 1997). Furthermore, in Down’s syndrome 
pregnancies there may be tissue-specific changes in the expression of these proteins. 
Other possible explanations for the difference in maternal serum and amniotic fluid 
SP1 concentrations in Down’s syndrome pregnancies include increased degradation 
or clearance of SP1 from the amniotic fluid or defective transport of SP1 from the 
maternal circulation into the amniotic fluid. However, the latter suggestion is unlikely 
because of the correlation between maternal serum and amniotic fluid SP1 levels in 
Down’s syndrome pregnancies.
Chard (1991) proposed that the changes in marker levels in maternal serum from 
Down’s syndrome pregnancies were the result of a generalised decrease in products 
of fetal origin and a generalised increase in products of placental origin. However, the 
demonstration of reduced PAPP-A and SP1 levels in the first trimester of Down’s 
syndrome pregnancies and normal PAPP-A levels in the second trimester contradicts 
this theory. The reasons for the reduced maternal serum SP1 levels in the first 
trimester of Down’s syndrome pregnancies remain obscure.
4.5.3 SP1 LEVELS IN TRISOMY 13 AND TRISOMY 18 PREGNANCIES.
SP1 levels in placental tissue, maternal serum and amniotic fluid from the Trisomy 13 
and Trisomy 18 pregnancies included in this study are presented in Table 4.5.3. 
Placental levels of SP1 are elevated in all of the cases, while in maternal serum from
310
Table 4.5.3 SP1 levels (MOM) in placental tissue, maternal serum and amniotic fluid
from Trisomy 13 and Trisomy 18 pregnancies.
Case No.
Placental
SP1 MOM (gestation) 
Maternal serum Amniotic fluid
T13/1 7.44 (23) - -
T18/1 1.41 (23) - -
T18/2 1.30 (22) -
T18/3 1.85(21) 0.90(16) -
T18/4 - 0.81 (15) 0.80 (17)
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two Trisomy 18 pregnancies and in amniotic fluid from one Trisomy 18 pregnancy SP1 
levels do not appear to be substantially different from normal.
Bartels and Lindemann (1988) reported that three out of four cases of Trisomy 18 had 
maternal serum SP1 levels above the control median. However, the results of 
subsequent studies on small numbers of affected cases indicate that maternal serum 
SP1 levels are normal in both the first and second trimesters of Trisomy 18 
pregnancies (Bartels et al 1990, Graham et al 1992, Macintosh et al 1993). Graham et 
al (1992) reported that maternal serum levels of SP1 were not significantly different 
from normal in four Trisomy 13 pregnancies and Bartels et al (1990) found SP1 levels 
of 1.07 MOM and 0.36 MOM in maternal serum from two Trisomy 13 pregnancies.
4.6 ALKALINE PHOSPHATASE.
4.6.1 ALP LEVELS IN NORMAL PREGNANCY.
Total and placental ALP activity was measured in homogenates of placental tissue 
from 52 controi pregnancies at 12 to 20 weeks gestation. Total ALP activity may 
include contributions from the bone, liver, kidney, intestinal and placental Isoenzymes. 
However, there was no difference between total ALP and placenta! ALP activities in 
the placental samples indicating that only the placental isoenzyme is expressed in 
placental tissue, immunohistochemical analysis using an antibody specific to the 
placental ALP isoenzyme demonstrated that ALP was localized to the 
syncytiotrophoblast of the placenta. Placental ALP is synthesised in the 
syncytiotrophoblast from around 7 weeks of gestation (Okamoto et al 1990).
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The alkaline phosphatase isoenzymes are microvillar enzymes which are bound to the 
microvillar membrane of cells in a variety of tissues (liver, Intestine, kidney, placenta) 
by means of a phosphatidylinositol-glycan anchor (Pl-G). During post-translational 
processing of the ALP protein, Pl-G is attached to the peptide with the concomitant 
cleavage of a GOOH-terminal signal peptide (Low et al 1988, Amthauer et al 1992, 
DeBroe and Moss 1992). In the placenta, ALP is attached to the external surface of 
the apical border of the syncytiotrophoblast which is in contact with the maternal blood. 
Placental ALP probably enters the maternal circulation by dissociation from the 
trophoblast microvillar membrane.
In the present study, total and placental ALP activities in maternal serum from control 
pregnancies were found to increase with advancing gestation from 15 to 20 weeks. 
The contribution of the placental isoenzyme to total ALP activity increased with 
gestation from 1.8% at 15 weeks to 4.5% at 20 weeks. These results are consistent 
with previous studies (Brock and Barron 1988, Ind et al 1994a, Aitken et al 1996a).
In amniotic fluid, total ALP activity was found to decrease with gestation from 15 to 21 
weeks. Total ALP activity in amniotic fluid is extremely low until 13 weeks gestation, at 
which stage ALP activity increases to a peak at around 18 weeks gestation, followed 
by a decline to a plateau with a further increase after 28 weeks gestation (Seelen 
1978, Mulivor et al 1979, Muller et al 1988, Campbell et al 1992b). In contrast, levels of 
the placental isoenzyme in amniotic fluid from the series of control pregnancies in this 
study were found to increase with advancing gestation from 15 to 20 weeks gestation, 
consistent with the results of Mulivor et al (1979). Ind et al (1993, 1994b) reported that 
amniotic fluid levels of placental ALP increased from 12 weeks to a peak at around 18 
weeks, followed by a decline to 21 weeks. In the present study, it was found that the 
contribution of the placental isoenzyme to totai amniotic fluid ALP activity increased
313
from 4.5% at 15 weeks gestation to 5.8% at 20 weeks gestation. The rate of increase 
of placental ALP activity in the amniotic fluid is less than in the maternal circulation, 
with amniotic fluid placental ALP levels being two thirds of maternal serum levels at 15 
weeks but less than one third of maternal serum levels at 20 weeks.
In amniotic fluid in the first half of pregnancy, total ALP is a combination of the 
placental isoenzyme (4%), the tissue non-specific bone/liver/ kidney isoenzyme (15%) 
and the intestinal isoenzyme (81%) (Mulivor et al 1979). The initial increase in total 
ALP activity in amniotic fluid at around 13 weeks gestation appears to be due to the 
presence of the intestinal isoenzyme, presumably of fetal intestinal origin following the 
disappearance of the anal membrane (Mulivor et al 1979, Jalanko et al 1985, Potier et 
al 1985, Muller et al 1988). The proportion of intestinal ALP activity decreases rapidly 
after 22 weeks gestation coinciding with the time at which Innervation of the anal 
sphincter occurs (Mulivor et al 1979). The subsequent increase in total ALP activity is 
probably due to an increase in the levels of fetal-derived tissue non-specific ALP and 
placental ALP (Mulivor et al 1979). The increase in amniotic fluid placental ALP levels 
with gestation is probably a reflection of the increased contribution of the placental 
isoenzyme from the maternal circulation. However, the relative concentration of 
placental ALP in the amniotic fluid compared to the maternal circulation at 15 weeks 
gestation is greater than for other trophoblast derived proteins. For example, amniotic 
fluid intact hCG levels are 1/10 of maternal serum levels and amniotic fluid PAPP-A 
and SP1 levels are 1/50 of maternal serum levels at 15 to 20 weeks gestation. 
Placental ALP levels in the amniotic fluid are two thirds of maternal serum levels at 15 
weeks of gestation decreasing to less than one third of maternal serum levels at 20 
weeks gestation. This suggests that in early pregnancy placental ALP may enter the 
amniotic fluid by an alternative route or that there may be an another source of 
placental ALP in the amniotic fluid. Like certain other placental proteins (e.g. hCG
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subunits, SP1, inhibin-A), there is evidence to suggest that placental ALP is expressed 
in the amniotic and chorionic membranes (Plouzek et al 1993, Wallace et al 1996a).
4.6.2 ALP LEVELS IN DOWN’S SYNDROME PREGNANCIES.
Brock et al (1990) investigated placental ALP activity in maternal serum from 21 
Down’s syndrome pregnancies in the first trimester using a specific immunoassay. 
Placental ALP levels in the Down’s syndrome pregnancies (0.93 MOM) were not 
significantly different from normal. However, all but two of the Down’s syndrome 
samples were obtained at 7 to 12 weeks gestation, a stage at which maternal serum 
placental ALP levels are very low (Okamoto et al 1990). Ind et al (1994a) also 
investigated maternal serum levels of placental ALP in 33 cases of Down’s syndrome 
and 300 controls at 14 to 21 weeks gestation using an immunoradiometric assay. They 
found a small but significant increase (1.2 MOM) in placental ALP levels in the Down’s 
syndrome pregnancies, an increase which was more marked at later gestations. Aitken 
et al (1996a) measured both heat stable and immunoreactive ALP in maternal serum 
from 37 Down’s syndrome pregnancies at 15 to 20 weeks gestation. There was no 
significant difference in the levels of total or placental ALP in the Down’s syndrome 
pregnancies compared to normal. The overall median levei of total ALP activity in the 
Down’s syndrome pregnancies was 0.93 MOM. The median placental ALP activity was 
found to be 1.09 MOM by the heat inactivation assay and 0.96 MOM by immunoassay.
In the present study, total and placental ALP activity was measured in second 
trimester maternal serum from 54 Down’s syndrome pregnancies using a fluorometric 
end point assay similar to that used by Aitken et al (1996a). There was a small but 
significant reduction in total ALP activity to 0.83 MOM in the Down’s syndrome 
pregnancies. However, placentai ALP activity (1.04 MOM) was not significantly
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different from normal. These results are consistent with those of Aitken et al (1996a) in 
that they show that maternal serum placental ALP levels are unchanged in the second 
trimester of Down’s syndrome pregnancies. There was no evidence to support a trend 
of increasing maternal serum placental ALP levels in Down’s syndrome pregnancies in 
either the present study or in the study by Aitken et al (1996a). Six of the Down’s 
syndrome cases investigated in this study were also included in the study by Aitken et 
al (1996a).
It is possible that the difference in the maternal serum levels of placental ALP reported 
for Down’s syndrome pregnancies may arise from the use of different types of assays 
i.e. specific immunoassays compared to biochemical assays measuring enzyme 
activity. However, Mulivor et al (1985) measured ALP isoenzyme activities in maternal 
serum and amniotic fluid samples using a heat denaturation-chemical inhibition 
method and an immunoprécipitation assay that uses monoclonal antibodies specific 
for the different ALP isoenzymes. They found a close correlation between the values 
obtained by both methods. Aitken et a! (1996a) also demonstrated a high correlation 
between the leveis of placental ALP in maternal serum estimated using the heat- 
inactivation fluorometric end-point assay with those obtained using the specific 
immunoassay. This confirms that the ALP activity measured following heat inactivation 
is the placental isoenzyme.
In the present study, placental ALP activity was measured in homogenates of 
placental tissue from 51 Down’s syndrome pregnancies. Placental tissue levels of 
placental ALP in the Down’s syndrome pregnancies were not significantly different 
from the controls. The median levels of placental ALP in placental tissue (0.91 MOM) 
and maternal serum (1.04 MOM) from the Down’s syndrome pregnancies were similar, 
although the correlation was not significant. Ind et al (1994a) proposed increased 
synthesis by the placenta or increased dissociation from the trophoblast as possible
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mechanisms for the increased maternal serum placental ALP activity in Down’s 
syndrome pregnancies noted in their study. However, the results of the present study 
together with those of Aitken et al (1996a) suggest that placental synthesis and 
transport of placental ALP into the maternal circulation is unchanged in Down’s 
syndrome pregnancies.
The results of the present study confirm previous reports of substantially reduced total 
ALP activity In amniotic fluid from Down’s syndrome pregnancies (Jalanko et al 1983a, 
Morin et al 1987). The median total ALP activity in amniotic fluid from 33 Down’s 
syndrome pregnancies was 0.39 MOM. Amniotic fluid placental ALP activity was also 
significantly reduced in the Down’s syndrome pregnancies compared to normal, 
although the reduction (0.75 MOM) was less than for total ALP activity. This is 
consistent with the results of Ind et al (1993, 1994b). In a larger series of amniotic fluid 
samples from 63 Down’s syndrome pregnancies and 756 normal pregnancies, 
including cases from a previous study (Ind et al 1993), Ind et al (1994b) found that 
amniotic fluid placental ALP levels were significantly reduced to 0.72 MOM in Down’s 
syndrome pregnancies.
The available evidence suggests that in Down’s syndrome pregnancies placental ALP 
activity is reduced in amniotic fluid but is normal, or only marginally elevated in the 
maternal circulation. In this way, placental ALP is similar to SP1 and inhibin-A as 
amniotic fiuid levels do not reflect maternal serum concentration changes. The 
reduced amniotic fluid levels in Down’s syndrome pregnancies may be due to 
defective transport of placental ALP from the maternal circulation, across the fetal 
membranes, into the amniotic fluid (Ind et al 1994a/b) but there is no evidence in the 
present study to support a similar abnormality between the placenta and maternal 
serum. There was a small degree of correlation between the levels of placental ALP in 
placental tissue and in amniotic fluid from the Down’s syndrome pregnancies.
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However, placentai synthesis of placental ALP appears to be normal, while amniotic 
fluid placental ALP levels are reduced. This may be further evidence for the existence 
of an alternative source of amniotic fluid placentai ALP activity (e.g. amnion or chorion) 
and as proposed for SP1 and inhibin-A, there may be tissue-specific differences in the 
expression of placental ALP in Down’s syndrome pregnancies.
The magnitude of the reduction of placental ALP activity in the amniotic fluid is not 
sufficient to be the cause of the overall reduction in total ALP activity, particularly since 
the placental isoenzyme accounts for about 4% of total ALP activity in the amniotic 
fluid. Mulivor et ai (1979) reported that at 14 to 22 weeks gestation the major 
component (81%) of total ALP activity in the amniotic fluid is the intestinal isoenzyme. 
Thus the reduction in total ALP activity in the amniotic fluid in Down’s syndrome 
pregnancies is likely to be due to a reduction in the fetal intestinal isoenzyme 
component. Morin et al (1987) found that 7 out of 21 amniotic fluid samples from 
Down’s syndrome pregnancies had levels of L-homoarginine-resistant ALP activity 
(placental/ intestinal) below the normal range. In these cases the fetuses had intestinal 
obstructions due to compacted meconium. Brock et al (1984) reported that amniotic 
fluid intestinal ALP activity (determined from the ratio of phenylalanine-resistant to 
homoarginine-resistant ALP activity) was reduced in only 11% of Down’s syndrome 
cases, compared to reduced GGT and APM activities in -50% of Down’s syndrome 
cases. If intestinal obstruction was the principle cause of reduced amniotic fluid 
microvillar enzyme activity in Down’s syndrome pregnancies, the intestinal isoenzyme 
of ALP would be expected to be reduced in the cases with low GGT and APM levels. 
Giddy et al (1989) reported that, despite a reduction in total ALP activity in amniotic 
fluid from Down’s syndrome pregnancies, there was no significant difference in the 
levels of phenylalanine-resistant and homoarginine-resistant ALP activity in Down’s 
syndrome pregnancies compared to control pregnancies. Measurement of individual
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isoenzyme components of amniotic fluid ALP activity using isoenzyme-specific 
antibodies would give a clearer picture of the change in ALP isoenzyme activities in 
Down’s syndrome pregnancies.
4.6.3 ALP LEVELS IN TRISOMY 13 AND TRISOMY 18 PREGNANCIES.
ALP activities in placental tissue, maternal serum and amniotic fluid from the Trisomy 
13 and Trisomy 18 pregnancies included in this study are presented in Table 4.6.1. 
There is no clear trend in placental ALP activity in placental tissue. In maternal serum 
from two Trisomy 18 pregnancies, the activity of placental ALP was low in relation to 
total ALP activity. This is comparable with the resuits of Aitken et al (1996a) who found 
that total ALP activity and placental ALP activity in maternal serum from 28 Trisomy 18 
pregnancies was 0.90 MOM ad 0.79 MOM respectively.
In the present study, the activity of placental ALP in amniotic fluid from one Trisomy 18 
pregnancy was low compared to total ALP activity which appeared to be unchanged. 
Previous studies involving larger numbers of cases have shown that amniotic fluid ALP 
activity (total) is reduced in association with Trisomy 18 (Jalanko et al 1983a, Morin et 
al 1987). Ind et al (1994b) found that there was no difference in placental ALP activity 
in amniotic fluid from Trisomy 18 pregnancies (n=15, median MOM=1.09) compared to 
normal. Brock et al (1984) reported that in 21% of Trisomy 18 cases studied the ratio 
of phenylalanine-resistant ALP to homoarginine-resistant ALP was outside normal 
limits. Ind et al (1994b) found that in Trisomy 13 pregnancies (n=8), amniotic fluid 
placental ALP activity was reduced to 0.75 MOM.
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Table 4.6.1 Total ALP (TALP) and placental ALP (PALP) levels (MOM) in placental
tissue, maternal serum and amniotic fluid from Trisomy 13 and Trisomy 18
pregnancies.
Case No.
Placenta
ALP MOM (gestation) 
Maternal serum Amniotic fiuid
PALP TALP PALP TALP PALP
T13/1 1.43 (23) - - “ -
T18/1 0.70 (23) - - - -
T18/2 1.07(22) - - -
T18/3 2.11 (21) 1.05 (16) 0.64 (16) - -
T18/4 "* 0.74 (15) 0.34 (15) 1.09 (17) 0.52 (17)
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4.7 GAMMA GLUTAMYL TRANSFERASE.
4.7.1 GGT LEVELS IN NORMAL PREGNANCIES.
GGT is an intrinsic membrane protein which is anchored to the microvillar membrane 
by a single hydrophobic sequence (-20 amino acids) located on the N-terminus of the 
larger subunit. The hydrophobic segment acts as both a signal sequence and a 
hydrophobic anchor sequence, therefore it is not cleaved and the N-terminus remains 
on the cytosolic side of the membrane. The smaller hydrophilic subunit, on which the 
enzymatically active site is located, extends from the external lumenal surface of the 
membrane (Semenza 1986). GGT is initially synthesised as a single precursor with 
approximately 2% of the activity of the mature dimeric form of GGT (Semenza 1986).
In human tissues GGT activity is present at high levels in the kidney, liver and intestine 
and at lower levels in the placenta (Rosalki 1975, Nemesansky and Lott 1985). In the 
liver, GGT is present in the canaliculi of the parenchyma and at greater concentrations 
in the lumenal border of the cells lining the fine biliary ductules (Rosalki 1975). In the 
present study, GGT activity was measured in homogenates of fetai liver from control 
fetuses at 12 to 22 weeks gestation. The specific activity of GGT in fetal liver was 
found to decrease with advancing gestation.
GGT activity can be detected along the length of the intestine but specific activity is 
highest in the jejunum, followed by the ileum and then the duodenum (Rosalki 1975, 
Semenza 1986). Jalanko et al (1983a) reported that meconium and bile from second 
trimester fetuses contained very high levels of GGT activity. In the present study GGT 
activity was measured in fetal ileum from control fetuses at 12 to 22 weeks gestation. 
The amount of meconium contained in the sections of ileum varied considerably,
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therefore the contents of the tissue section were gently squeezed out prior to 
processing of the tissues. In contrast to the fetal liver, GGT activity in the fetal intestine 
was found to increase with advancing gestation.
GGT activity was also measured in homogenates of placental tissue from 52 control 
pregnancies at 12 to 20 weeks gestation. Placental GGT activity was approximately 
2% of that in the fetal liver and activity was found to decrease slightly with advancing 
gestation. Jalanko et al (1983b) also found low levels of GGT activity in placental 
tissue from second trimester fetuses.
In amniotic fluid from unaffected control pregnancies, GGT activity was found to 
decrease from 15 to 21 weeks gestation. Previous studies have show that amniotic 
fluid GGT activity increases in early pregnancy to a peak at around 15 weeks 
gestation, followed by a progressive decrease in activity to term (Jalanko et al 1983b, 
Brock et al 1984, Moniz et al 1984, Muller et al 1988, Campbell et al 1992b).
The activity of GGT in amniotic fluid in the second trimester is approximately 10 to 100 
times greater than in the fetal circulation and maternal circulation (Jalanko et al 1983b, 
Moniz et al 1984). Furthermore, the activity of GGT in the fetal urine is extremely low 
(Moniz et al 1984, Muller et al 1988) indicating that the maternal circulation and fetal 
urine are not major sources of amniotic fluid GGT activity in the second trimester. 
Moniz et al (1984) demonstrated that the major GGT isoenzyme in amniotic fluid had 
the same electrophoretic mobility as the GGT isoenzyme in the fetal serum. The 
authors proposed that GGT activity in fetal serum and amniotic fluid was of placental 
origin, possibly originating from the cellular debris of placental and amnion tissue. 
However, Jalanko et al (1983b) found that the specific activity of GGT in the placenta! 
was much less than in the amniotic fluid and in other fetal tissues.
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The presence of high GGT activity in meconium and bile from second trimester fetuses 
suggests that these are likely sources of GGT activity in the amniotic fluid (Jalanko et 
al 1983b, Muller et al 1988). Furthermore, Jalanko et al (1983b) demonstrated that the 
electrophoretic mobilities of GGT in meconium, bile and amniotic fluid were similar. 
Jalanko et al (1985) and Potier et al (1986) reported that a high proportion of 
microvillar enzyme activity in the amniotic fluid was bound to fragments of microvillar 
membrane. Comparison of the patterns of enzyme activity and morphology of the 
microvillar fragments from amniotic fluid, meconium and homogenates of fetal tissues 
revealed that most of the microvillar fragments originated from the fetal gastrointestinal 
tract.
4.7.2 GGT ACTIVITY IN DOWN’S SYNDROME PREGNANCIES.
The association between low amniotic fluid GGT activity and fetal chromosome 
abnormalities was first reported by Jalanko and Aula (1982). They found that GGT 
activity in amniotic fluid from Down’s syndrome pregnancies was reduced on average 
to 53% of normal levels, with 84% of affected cases having GGT levels below the 
control median. Subsequent studies have confirmed these findings (Brock et al 1984, 
Baumah et al 1984, Morin et al 1987, Macek et al 1987, Jones and Evans 1988, Giddy 
et al 1989, Zeitune et al 1989, Szabo et al 1990). The results of the present study are 
consistent with previous studies, with GGT levels reduced to 0.48 MOM in amniotic 
fluid from 33 Down’s syndrome pregnancies. Ninety-one percent of affected cases had 
amniotic fluid GGT levels below the control median.
The reasons behind the reduction in amniotic fluid GGT activity in Down’s syndrome 
pregnancies are unknown. Morin et al (1987) found deficient microvillar enzyme 
activities in amniotic fluid from 7 out of 21 Down’s syndrome pregnancies. The cases
323
with abnormal microvillar enzyme activity all had intestinal obstructions and it is 
feasible that intestinal abnormalities may prevent the passage of microvillar enzymes 
into the amniotic fluid. However, Brock et al (1984) found that amniotic fluid intestinal 
ALP levels were reduced in only 11% of Down’s syndrome cases compared to reduced 
GGT and ARM activities in approximately 50% of cases. Intestinal ALP activity would 
be expected to be reduced in those cases with reduced GGT and APM activity if 
intestinal obstruction was the principle cause of reduced amniotic fluid microvillar 
enzyme activity in Down’s syndrome pregnancies. In contrast, Muller et al (1988) 
reported that in later pregnancy (> 27 weeks gestation) duodenal atresia was 
associated with very high levels of GGT activity, possibility caused by fetal 
regurgitation of bile. In a previous study, Muller at al (1986) reported that 51 out of 54 
cases of Down’s syndrome had GGT levels below the median, however, in two cases 
amniotic fluid GGT activity was greater than the control median. The authors proposed 
that the in these two cases duodenal atresia was present.
In the present study, post mortem reports were available for 25 of the Down’s 
syndrome cases from which amniotic fluid samples were collected. Only three of the 
cases with reduced amniotic fluid GGT activity were found to have intestinal 
abnormalities (Meckels diverticulum).
In an attempt to identify the origin of reduced GGT activity in amniotic fluid in 
association with fetal Down’s syndrome, GGT activity was measured in homogenates 
of fetal liver, fetal ileum and placental tissue from Down’s syndrome pregnancies. GGT 
activity was significantly higher in fetal liver (2.01 MOM) and placental tissue (1.29 
MOM) from Down’s syndrome pregnancies compared to normal. However, GGT 
activity in fetal ileum from Down’s syndrome pregnancies was significantly lower than 
in controls. Thus, GGT activity is reduced to a similar extent in fetal ileum and amniotic
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fluid from Down’s syndrome pregnancies. This is consistent with the results of G racy 
(1992) who found that there was a significant reduction in GGT activity in both the 
microvillar and supernatant fractions of amniotic fluid from 12 Down’s syndrome 
pregnancies. Amniotic fluid GGT activity is reduced in Down’s syndrome pregnancies 
despite the increase in activity in the fetal liver and placenta. These results suggest 
that the fetal intestine is a major source of GGT activity in the amniotic fluid and that in 
Down’s syndrome pregnancies GGT activity from this source is reduced.
The mechanisms behind the reduction In fetal intestinal and amniotic fluid GGT activity 
in Down’s syndrome pregnancies are not known. One possible explanation is that in 
Down’s syndrome pregnancies there is reduced synthesis of GGT by the fetal 
intestine, however this is difficult to reconcile with the increased levels of GGT activity 
observed in the fetal liver and placenta. It is thought that GGT is derived from the 
expression of a single gene with different isoenzymes arising from tissue-specific 
differences in post-translational modifications of the GGT peptide (Nemensky and Lott 
1986). However, Courtay et al (1994) reported that four GGT genes are expressed in 
humans in a tissue-specific manner. Tissue specific differences in GGT activity in 
Down’s syndrome pregnancies may be a result of alterations in the tissue-specific 
expression of GGT activity or defects in post-transcriptional processing of the enzyme 
or in membrane anchorage or release. The presence of an extra copy of chromosome 
21 would not have a direct effect on the expression of GGT as the genes encoding 
GGT are located on chromosome 22 (Bulle et al 1987). Such changes may be the 
indirect result of an increase in expression of chromosome 21 genes. The 
glycosylation of GGT is not altered in trisomie pregnancies. Jalanko et al (1983b) 
found that the electrophoretic mobility of GGT in second trimester amniotic fluid from 
trisomie pregnancies was similar to that from normal pregnancies.
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Unlike the other markers, GGT is not pregnancy-specific and there are no published 
studies on maternal serum levels of GGT in Down’s syndrome pregnancies. However, 
there are distinct fetal and adult forms of the enzyme which are distinguishable by their 
ability to bind to Concanavalin A (Kottegen et al 1976). Rosalki (1975) reported that 
GGT levels in the maternal circulation decrease with advancing gestation, while other 
studies have reported that there is no significant change in maternal serum GGT levels 
during pregnancy (Lum and Gambino 1972, Jalanko et al 1983b, Monlz et al 1984). 
This would suggest that despite the considerable concentration gradient which exists 
between the amniotic fluid and maternal circulation, GGT does not appear to cross the 
fetal membranes into the maternal circulation. This may be due to the fact that much 
of the GGT activity in the amniotic fluid is bound to microvillar fragments. If the 
maternal circulation does contain any fetal GGT, it is probably present in only small 
amounts and is most likely to be of placental origin. Identification of a fetal GGT 
component in maternal serum from Down’s syndrome and unaffected pregnancies 
may provide further information about the placental synthesis of GGT and the 
transport of GGT from the placenta to the maternal circulation
4.7.3 GGT IN TRISOMY 13 AND TRISOMY 18 PREGNANCIES.
Jalanko and Aula (1982) reported that amniotic fluid GGT levels were below the 25th 
centile in seven out of nine pregnancies with a Trisomy 18 fetus. The median value of 
GGT in the affected pregnancies was one third of that observed in the controls. Low 
GGT activity was also found in amniotic fluid from one Trisomy 13 pregnancy. 
Subsequent studies have confirmed that GGT activity is reduced in amniotic fluid from 
Trisomy 18 and Trisomy 13 pregnancies (Morin et al 1987, Macek et al 1987, Jones 
and Evans 1988, Zeitune et al 1989). In the present study, amniotic fluid from one
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Trisomy 18 pregnancy had a GGT activity of 0.11 MOM, consistent with previous 
studies.
GGT activity in fetal liver, fetal ileum, placental tissue and amniotic fluid from the 
Trisomy 13 and Trisomy 18 pregnancies included in this study are presented in Table 
4.7.1. The pattern of variation of GGT activity in fetal tissues from the Trisomy 13 and 
Trisomy 18 pregnancies is similar to that in Down’s syndrome pregnancies. GGT levels 
are elevated in placental tissue and fetal liver from all cases, except one Trisomy 18 
pregnancy which has a hepatic GGT level of 1.06 MOM. GGT activity was low in fetal 
ileum from all cases. Therefore, the mechanisms which give rise to abnormal GGT 
activity may be similar in Down’s syndrome, Trisomy 13 and Trisomy 18 pregnancies.
4.8 PLACENTAL PATHOLOGY.
Post-mortem examination of the placenta was carried out for 31 of the Down’s 
syndrome cases and one of the Trisomy 18 cases included in this study. General 
pathological findings included fibrinoid degeneration, placental calcification, villous 
oedema and placental hemorrhage. These are common pathological changes which 
do not appear to be of particular clinical importance (Fox 1986). However, it has been 
proposed that villous oedema results in the restriction of maternal blood flow (Fox 
1986).
In Down’s syndrome pregnancies, there does not appear to be any difference in 
placental weight compared to normal at equivalent gestations (Shepard et al 1989). 
However, in Trisomy 18 pregnancies placental weight is generally lower than in normal 
pregnancies (Shepard et al 1989).
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Table 4.7.1 GGT levels (MOM) in fetal liver, fetal ileum, placental tissue and
amniotic fluid from Trisomy 13 and Trisomy 18 pregnancies.
Case No. GGT MOM (gestation)
Placenta Fetal liver Fetal ileum Amniotic fluid
T13/1 2.68 (23) 7.58 (23) 0.35 (23) *
T18/1 1.20(23) 6.39 (23) 0.30 (23) "
T18/2 4.18(22) 3.97 (22) 0.81 (22)
T18/3 2.75 (21) 3.14(21) 0.52 (21) -
T18/4 - 1.06 (19) 0.33 (19) 0.11 (17)
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Honore et al (1976) investigated the association between placental morphology and 
fetal trisomy in a study of 66 trisomie placentae and 172 controls at 4-22 weeks 
gestation. On gross examination, two-thirds of the trisomie placentae were found to 
have cystic villi. On microscopical examination, the trisomie placentae were found to 
exhibit villous hypovascularity, persistence and irregular distribution of immature 
stromal cells and failure of development of Hofbaur cells (macrophages). Furthermore, 
the trisomie placentae often contained cytotrophoblast cells in the villous core, large 
numbers of syncytial sprouts and showed evidence of reduced trophoblastic growth 
activity and a lack of villous structural integrity. There did not appear'to be an 
association between placental morphology and specific types of trisomy.
Oberweis et al (1983) reported that in 60% of placentae examined at 28-40 weeks 
gestation, there was marked retardation of villous maturation with persistence of 
embryonic forms of villi. Irregular and immature villous maturation, under 
vascularisation and increased vascular resistance of third trimester trisomie placentae 
was also reported by Rochelson et al (1990).
Morphological changes of the placenta associated with abnormal maturation of 
placental villi, trophoblast differentiation and fetal villous and utero-placental blood flow 
would be expected to result in the impaired synthetic, secretory and transport capacity 
of the placenta. Thus, placental pathology may play a key role in the production of 
placental markers, notably intact hCG and FphCG which is in turn reflected in the 
concentrations of these markers in Down’s syndrome pregnancies.
Impaired maturation of placental villi appears to the characteristic of the Down’s 
syndrome placenta. Villous maturation involves a progressive change from large villi 
with centrally placed fetal capillaries to smaller villi with fetal capillaries located in close
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contact with the syncytiotrophoblast (Fox 1986). The process of trophoblast 
differentiation is an important part of villous maturation. Initially the cytotrophoblast 
cells form a continuous layer beneath the syncytiotrophoblast but as gestation 
advances the cytotrophoblast cells become less prominent. Within the 
syncytiotrophoblast there are regions which become specially adapted for specific 
functions (Chard 1986, Fox 1986). There are thin areas of syncytiotrohoblast which 
are in direct contact with the fetal capillaries and are the principle site of feto-maternal 
transfer (vasculosyncytiai membranes). Thicker areas of syncytiotrophoblast are 
specialised for protein synthesis. In Down’s syndrome placentae there is persistence 
of immature forms of villi with increased numbers of cytotrophoblast cells. In addition, 
abnormal villous maturation may prevent the formation of vasculosyncytiai 
membranes. Thus the Down’s syndrome placenta may have an increased capacity for 
protein synthesis and a decreased capacity for feto-maternal transfer.
4.9 SUMMARY AND CONCLUSIONS.
Investigation of endogenous levels of feto-placental markers in tissues involved in 
synthesis and/ or transport and in corresponding maternal serum and amniotic fluid 
from chromosomally abnormal pregnancies makes it possible to identify the stage at 
which the normal process of protein synthesis, secretion and transport is disrupted.
In this study it was shown that the concentration of AFP in fetal liver from Down’s 
syndrome pregnancies was not significantly different from that in unaffected 
pregnancies. Thus reduced synthesis of AFP by the fetal liver does not appear to be 
the cause of low maternal serum and amniotic fluid AFP levels during the first half of 
Down’s syndrome pregnancies. Elevated placental levels of AFP in Down’s syndrome 
pregnancies indicate that placental transport of AFP from the fetal circulation to the 
maternal circulation may be disturbed in Down’s syndrome pregnancies resulting in the
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accumulation of AFP in the syncytiotrophoblast and reduced maternal serum AFP 
levels. Abnormal placental morphology in trisomie pregnancies may cause a reduction 
in the capacity of the placental for feto-maternal transfer. Alternatively, in Down’s 
syndrome pregnancies there may be defects associated with the specific mechanisms 
of AFP transport across the placenta. Reduced amniotic fluid levels of AFP in Down’s 
syndrome pregnancies may be caused by abnormal fetal kidney function resulting in 
reduced transfer of AFP from the fetal circulation into the amniotic fluid.
Intact hCG and FphCG concentrations were significantly elevated in placental tissue 
from Down’s syndrome pregnancies. A significant elevation was also observed for 
SP1, although the magnitude of elevation was much less than for intact hCG and 
FphCG. Thus, there may be increased synthesis of hCG subunits and SP1 by the 
placenta in Down’s syndrome pregnancies. A gene dosage effect can be ruled out as 
a possible cause of increased hCG, FphCG and SP1 levels in Down’s syndrome 
pregnancies as the genes encoding these proteins are not located on chromosome 
21. PAPP-A and placental ALP levels in placental tissue from Down’s syndrome 
pregnancies were not significantly different from normal suggesting that placental 
synthesis of these proteins is not altered. There is evidence to suggest that there is 
abnormal maturation of placental villi in trisomie placentae. Morphological changes to 
the placenta may play a role in the altered synthesis of certain placental markers in 
Down’s syndrome pregnancies.
Similar trends for each of the markers (intact hCG, FphCG, PAPP-A, SP1 and 
placental ALP) were observed in maternal serum from the same series of Down’s 
syndrome pregnancies. This relationship between placental and maternal serum 
marker levels suggests that transport of these markers from their site of synthesis in 
the placenta to the maternal circulation in Down’s syndrome pregnancies is not
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disturbed. Unlike the other placental markers which alt show some degree of 
association between placental and maternal serum levels, there was no correlation 
between placental and maternal serum SP1 levels in Down’s syndrome pregnancies. 
This may be an indication of an alternative source of SP1 which contributes to SP1 
levels in maternal serum.
The change in concentrations of AFP, intact hCG and FphCG in amniotic fluid in 
Down’s syndrome pregnancies corresponds to the changes observed for each of 
these markers in maternal serum in the second trimester. AFP is reduced to a similar 
extent in maternal serum and amniotic fluid from Down’s syndrome pregnancies. Intact 
hCG and FphCG levels are increased in amniotic fluid from Down’s syndrome 
pregnancies, although the magnitude of elevation is less than in maternal serum. This 
may reflect differences in the rates of clearance of hCG and free hCG subunits from 
the two different compartments. In contrast, the change the concentrations of SP1 and 
placental ALP in amniotic fluid from Down’s syndrome pregnancies varies from that 
observed in maternal serum. SP1 levels are elevated in maternal serum but 
unchanged or slightly reduced in amniotic fluid, while placenta! ALP activity is 
unchanged in maternal serum and low in amniotic fluid from Down’s syndrome 
pregnancies. This suggests that the sources of amniotic fluid SP1 and placental ALP 
and maternal serum SP1 and placental ALP may be different, and that in Down’s 
syndrome pregnancies there may be tissue specific differences In the expression of 
these proteins.
GGT activity was found to be reduced to a similar extent in fetal ileum and in 
corresponding amniotic fluid from Down’s syndrome pregnancies, suggesting that 
amniotic fluid GGT activity may originate from the fetal intestine. GGT activity was 
elevated in fetal liver and placental tissue from Down’s syndrome pregnancies. Tissue
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specific changes in GGT activity in Down’s syndrome pregnancies maybe the result of 
tissue specific alterations in GGT expression or defects in post-transcriptional 
processing of the enzyme, or in membrane anchorage or release.
The pattern of marker changes in fetal tissues, maternal serum and amniotic fluid from 
Trisomy 13 and Trisomy 18 pregnancies varied from the changes seen in Down’s 
syndrome pregnancies. Therefore, the mechanisms giving rise to marker variations in 
Down’s syndrome, Trisomy 13 and Trisomy 18 pregnancies are not the same.
4.10 FUTURE WORK.
The present study has revealed significant differences in fetal tissue and placental 
marker levels between Down’s syndrome and unaffected pregnancies, but it is not 
clear how the presence of an extra copy of chromosome 21 leads to the observed 
changes. As none of the markers has a structural gene on chromosome 21, a direct 
gene dosage effect can be excluded. However, it is possible that the observed 
changes in marker concentrations are the result of altered cellular metabolism due to 
increased dosage of chromosome 21 genes.
A fuller picture of marker variation in Down’s syndrome pregnancies could be obtained 
by the investigation of other markers in fetal tissues and in corresponding maternal 
serum and amniotic fluid. UE3 levels are known to be reduced in first and second 
trimester maternal serum and in amniotic fluid from Down’s syndrome pregnancies. 
Estriol is produced by the syncytiotrophoblast from the fetal precursor 16a-hydroxy- 
dehyroepiandrosterone-sulphate and is metabolised via conjugated forms by the 
maternal liver. Reduced synthesis due to a diminished supply of fetal precursor, rather 
than altered placental secretion, has been proposed as the underlying cause of low
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UEa in Down’s syndrome pregnancies (Cuckle at al 1991). inhibins and activins are 
involved in the regulation of hCG synthesis. Maternal serum inhibin, and more 
specifically inhibin-A levels are elevated in Down’s syndrome pregnancies. With the 
development of assays specific for inhibin-A, inhibin-B, activin-A, activin-B and a- 
subunit precursors (Wallace and Healy 1996), it will be possible to investigate the 
physiology of inhibins and activins in Down’s syndrome and unaffected pregnancies. 
Further information may also be obtained from the study of other components of cell 
regulation and differentiation e.g. epidermal growth factor, fibroblast growth factor and 
transforming growth factors-a and -p. These growth factors may play a role in the 
regulation of trophoblast differentiation and hCG secretion. Certain markers have been 
identified which have a chromosome 21 gene location e.g. heat shock protein 70, 
superoxide dismutase. It would be of particular interest to examine the levels of these 
markers in fetal tissues, maternal serum and amniotic fluid from Down’s syndrome 
pregnancies.
Perhaps a clear comparison of the rate of production of placental markers could be 
obtained by measurement of mRNA levels in fetal tissues. However, this may prove to 
be unsatisfactory in post-abortion material where the lability of mRNA may lead to 
difficulties in interpretation. Such investigations would be better carried out using 
trophoblast cultures from Down’s syndrome and unaffected pregnancies, matched for 
gestational age and stage of culture (Eldar-Geva et al 1995). Systems for the isolation 
and culture of placental trophoblast have been developed (Ringler and Strauss 1990, 
Bloxam et al 1997a/b), and such an approach could also be used to further investigate 
the process of differentiation of cytotrophoblast into syncytiotrophoblast and the 
relative effects of exogenous materials (e.g. growth factors, cyclic AMP, inhibin, 
activin, IFNa) on the production of placental proteins, in particular hCG.
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Feto-maternal transfer of substances across the placenta could also be studied using 
trophoblast culture systems. Sophisticated two-sided syncytiotrophoblast cultures may 
provide the basis of an investigation into the mechanisms of placental transfer/ release 
of AFP, hCG and other markers in Down’s syndrome and unaffected pregnancies 
(Bloxam et al 1997a/b). Characterisation of cell surface receptors for AFP may also 
provide further insight into possible receptor-mediated transport mechanisms for AFP.
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